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ABSTRACT 
 
BACKGROUND 
Immunomodulators (IM), mainly thiopurines (TP) have been used in the treatment of 
inflammatory bowel disease (IBD) for over 50 years. Over the last 20 years, the number of drugs 
available to treat IBD has grown. The role of IM cannot be understated as they alone may control 
IBD in the long term, and also improve the efficacy of biological agents when given as co-therapy. 
The newer therapies come at an exceptionally high financial cost, raising issues with affordability 
and cost effectiveness. Any evaluation of drug treatment needs to take into account the long-term 
outcomes, particular their efficacy in the reduction of major long-term morbidities related to 
chronic uncontrolled inflammation. 
METHODS 
Three retrospective cohort studies were conducted using the “Sydney IBD Cohort”, updated in 
2012, evaluating the surgical outcomes in patients with Crohn’s disease (CD), Ulcerative colitis 
(UC) and elderly IBD patients.  Fourth study was a retrospective, single-centre cohort study of 
patients with moderate-to-severe CD, assessing the influence of thiopurine on efficacy of 
adalimumab. Fifth, was a case-based survey conducted worldwide assessing gastroenterologists’ 
selection of drug treatments based on patients’ comorbidity and age in the management of 
moderate-to-severe UC.  
RESULTS 
Early IM was associated with significantly lower rates of initial abdominal surgery  (hazard ratio 
[HR], 0.45; 95% confidence interval [CI], 0.35–0.69), recurrent abdominal surgery (HR, 0.44; 95% 
CI, 0.25–0.79) and perianal surgery (HR, 0.30; 95% CI, 0.16–0.56) in CD.  
Early TP maintenance significantly decreased the need for colectomy (HR: 0.10, 95%CI: 0.03- 0.43) 
and proximal progression of disease extent (HR: 0.26, 95%CI: 0.10-0.78), after propensity score 
matching in UC.  
  
Page | xvi 
TP dosed to therapeutic 6-thioguanine nucleotide levels (6-TGN) at induction were predictors of 
primary response (Odds ratio (OR): 4.32, 95% CI, 1.41–13.29) and time to failure (OR: 0.37 (0.15–
0.89), and therapeutic 6-TGN in semesters were associated with remission semesters (OR 3.71, 
95% CI, 1.87–7.34) in CD patients treated with adalimumab.  
Charlson Comorbidity Index was associated with delayed IM introduction in CD ( HR 0.863; 95% 
CI, 0.787–0.946) and UC (HR 0.807; 95% CI, 0.711–0.917) but not age. Early IM use was associated 
with reduced need for surgery in CD (HR 0.177; 95% CI, 0.089–0.351).  
Comorbidity reduced the probability of prescribing IMs for elderly- (OR: 0.25, 95%CI: 0.16-0.38) 
and for younger-patients (OR: 0.56, 95%CI: 0.39-0.82) with UC. Conversely, elderly- and younger-
patients with comorbidities were more likely to receive Vedolizumab (OR: 2.71, 95%CI: 1.98-3.71 
and OR: 1.37, 95%CI: 1.01-1.86, respectively) and colectomy (OR: 5.40, 95%CI: 2.74-10.64 and OR: 
4.46, 95%CI:2.25-8.87 respectively]. 
 
CONCLUSION 
Early and sustained IM use is associated with reduced risk of surgery in CD patients in all age 
groups, including elderly. Similarly, early sustained TP maintenance is associated with reduced risk 
of colectomy and proximal disease progression in UC. TP dosed to therapeutic levels, improves the 
primary response and duration of activity of adalimumab. Comorbidity is the main factor 
influencing the use of IM in the elderly. The results of these studies affirm the position of 
immunomodulators, particularly thiopurines, in the current day treatment paradigm of IBD.  
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1.1 INFLAMMATORY BOWEL DISEASE  
 
Inflammatory bowel disease (IBD) is an idiopathic, chronic, relapsing, inflammatory disorder of the 
intestinal tract caused by dysregulation of the immune response(1). It comprises Crohn’s Disease 
(CD) and ulcerative colitis (UC), which differ in the anatomical location of involvement, pattern of 
inflammation and the layers of gut wall affected(2). CD involves the full thickness of the bowel wall 
and can involve any part of the gastrointestinal tract, although it most commonly affects the small 
bowel and/or large bowel whereas UC only affects the mucosal layer of the colon (2,3). UC extends 
proximally in a continuous manner starting from the anus whereas CD location  may not be 
continuous (2,3). In the absence of treatment, both phenotypes cause chronic and permanent 
damage to the bowel leading to complications such as strictures, perforations, extra-intestinal 
manifestations and malignancies (4). Chronic uncontrolled inflammation in CD due to its 
transmural involvement leads to fistula and penetrating disease, which is not seen with UC (4). 
The aetiology of IBD is unclear, but involves environmental risk factors, probably acting via the 
intestinal microbiome, in a genetically susceptible individual leading to unconstrained 
immunological response against the intestinal wall (5).  
The incidence and prevalence of IBD varies across different populations around the world (6). 
Historically, IBD was considered to be a disease of the developed world with highest incidences 
being reported in North America, Europe, Australia and New Zealand. There has been an 
increasing incidence in the recently-developed and developing countries (7-9).  
Up to 80% of patients with CD present with an inflammatory phenotype and only 5% to 28% show 
a stricturing phenotype. However, around 50% develop stricturing and penetrating complications 
within 10 years of  diagnosis, driven by intestinal damage and fibrosis due to uncontrolled 
inflammation(10). Stricturing disease may require surgical resection of the narrowed segment of 
the bowel.   
Though treatment targets have changed over time, it still involves induction of remission followed 
by maintenance therapy. Clinical remission and objective markers of remission such as mucosal 
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healing are the current treatment targets (11). Chronic inflammation is associated with irreversible 
intestinal damage, increasing the risk of subsequent surgery (12).  
Medical therapy includes corticosteroids, mesalazine (5-aminosalicylates) and 
immunomodulators (IMs) such as the thiopurines and methotrexate. However, since the approval 
of Infliximab in 1998 as the first biological agent to treat IBD, the number of drugs available to 
treat IBD has grown. These newer biological therapies, however, come at an exceptionally high 
financial cost, which is increasing exponentially with time. A recent Australian study found the 
total cost for anti-tumour necrotic factor (TNF) over the 7-year period was $380 million, with 
Infliximab prescription increasing fourfold over the study period, while Adalimumab increased by 
6-fold(13). With increasing incidence of IBD in both developed and developing countries, 
affordability and cost effectiveness of biologic therapies needs to be critically evaluated, as a 
patient on biologic therapy will attract a higher treatment cost to the health care system,  
compared to a patient on IM therapy (14). However, multiple studies addressing the cost-benefit 
aspects of biologic therapies, have shown the significant savings gained by reducing disease 
complications, hospitalisations and surgery to be superior compared to the direct cost of the 
biologics (14).  Similarly, due to its very low direct cost, if IMs are shown to reduce disease 
complications, hospitalizations and surgery, it will continue to be an attractive treatment option 
in both CD and UC. Biological agents are also associated with primary non-response, secondary 
loss of response, intolerances and side effects.  
The role of IMs, therefore, cannot be understated. They alone may control IBD in the long term, 
and also improve the efficacy of biological agents when given as co-therapy. Any evaluation of 
drug treatment also needs to take into account the long-term outcomes, particular their efficacy 
in the reduction of major long-term morbidities such as major abdominal surgery and perianal 
surgery related to chronic uncontrolled inflammation.   
1.2 IMMUNOMODULATORS 
1.2.1 THIOPURINES 
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George Hitchings and Gertrude Elion recognized that by substituting sulfur at the 6 position of the 
purine bases with oxygen, led to the inhibition of purine utilization, cell cycle arrest and apoptosis. 
Their research  led to the discovery of Mercaptopurine (MP) and Thioguanine (TG) in the 1940s 
(15,16). In 1957, they discovered Azathioprine (AZA), 1 1-methyl-4-nitro-5-imidazolyl a derivative 
of MP. These drugs are commonly known as thiopurine analogues and were initially used for the 
treatment of childhood leukaemia, for which they received the Nobel prize in 1988(16).  
The first case series of using thiopurines for the treatment of UC and CD was published in the 
1960s (17,18). In 1980 George Present et al published the seminal paper demonstrating the 
effectiveness of thiopurines for the induction of remission in CD(19). Even 60 years after its initial 
use in the treatment of IBD, there are still unanswered questions regarding the efficacy and  safety 
of these drugs(20). 
 
1.2.2 METHOTREXATE 
 
Although thiopurines are the first line IM in IBD, some patients may fail treatment or not tolerate 
treatment. As such a non-thiopurine second line agent needs to be available. Methotrexate, a 
folate antagonist reported by Sidney Farber in 1948, was first used in the treatment of childhood 
leukaemia. Since then, methotrexate has been used as an IM that is effective in treating a number 
of inflammatory disorders including IBD.  
Kozarak et al first reported on the efficacy of methotrexate in a non-randomised open label 
induction study of 12 weeks duration. Since then several uncontrolled and controlled studies have 
shown benefits in CD. However, a recent Cochrane review did not find any evidence of support 
the use of methotrexate for the maintenance of remission in UC(21). 
 
1.3 USE AND EFFICACY IN CROHN’S DISEASE  
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Surgery is one of the most objective outcome measures of treatment failure, since it is only 
performed if medication is not effective or tolerated and represents a hard endpoint in assessing 
the treatment efficacy in IBD. Surgical resection rates in published studies have varied widely, 
ranging between 24% to 61% in the first five years in CD (22). Despite several studies showing no 
change in CD intestinal resection rates, many others have shown a gradual decline over time (22-
29). A recent metanalysis of population-based studies also identified a gradual decline in surgical 
rates over the last 6 decades, which has preceded the wide spread use of biologics (30). This 
reduction in surgical rates may also represent a change in the natural history of CD. However, most 
natural history studies are unable to demonstrate a positive impact of IMs, possibly due to their 
use in more severe disease, late introduction after development of strictures or fistulas, or 
insufficient patient follow-up. 
 
1.3.1 REDUCING INTESTINAL SURGERY IN CROHN’S DISEASE.  
 
Ramdas et al studied a population-based cohort from Cardiff, UK, comprising of 341 CD patients 
diagnosed between 1986-2003. They first explored the impact of increasing use of early 
thiopurines on the surgical rates in adults. Thiopurine therapy within the first year of diagnosis 
increased from 3% in the earlier cohort to 25% in the most recent cohort (<0.0001). Corresponding 
intestinal resection rates at 5 years reduced from 59% to 25% respectively. In a multivariate cox 
regression analysis, early thiopurine use within the first year of diagnosis (HR: 0.47, 95%CI: 0.27-
0.79), year of diagnosis (HRearly cohorts: 1.71, 95% CI: 1.1-2.5), disease location and early 
corticosteroid use were independently associated with intestinal surgery. The year of diagnosis 
being identified as an independent predictor raises the possibility that other significant factors 
(such patient management paradigms during that era, surgical approach, access to diagnostic 
tests) may have contributed towards this change in surgical rates.  
Lakatos et al, also showed similar trends with early use of IMs, in a Hungarian cohort of 506 CD 
patients diagnosed between 1977-2009 (29). Early IM use within 5 years of diagnosis increased 
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from 6.2% to 46.2% over time.  They found early use of azathioprine to be associated with reduced 
need for surgery, independent of the decade of diagnosis after using strict definitions and 
propensity score matching (HR; 0.42, 95% CI: 0.26-0.67) (29). This study, therefore, suggested that 
thiopurines may successfully modify the natural history of IBD and reduce the need for surgery.  
Two recent prospective randomised controlled studies failed to demonstrate efficacy of early 
thiopurines in the management of CD (31,32). Both of these studies had a number of deficiencies. 
The sample sizes were small, follow up periods were too brief ranging from 1.5 to 3 years, the 
outcomes were subjective, and the control subjects eventually required commencement of 
thiopurines which may have negated any benefit. In addition, most studies have only focused on 
the short-term outcomes of thiopurine therapy, which are recognised to cause side effects or 
intolerance in up to 40% patients, that can lead to a negative result (33). Higher dosing at 2.5mg/kg 
in both these studies, may have also led to poor tolerance and reduced adherence, as most side 
effects of thiopurines are dose dependent(34). With use of short-term subjective outcomes as end 
points rather than surgery and weight-based dosing without therapeutic drug monitoring (TDM), 
the authors may have underestimated the effectiveness of therapy. It is known that concentration 
of 6-thioguanine nucleotide (6-TGN) is associated with  the therapeutic response (35).  
There are no population based long term studies evaluating the efficacy of Methotrexate in 
reducing surgical rates in CD. IM therapy in CD often involves thiopurines as first-line therapy and 
methotrexate is only used as second-line treatment after failure of thiopurines (36).  Therefore, 
to demonstrate the effectiveness of the early IM strategy on surgical outcomes, it requires a study 
that includes patients who are treated with thiopurines, as well as those who were started on 
methotrexate due to thiopurine intolerance or failure. Few studies have evaluated the IM strategy 
using well-described IBD cohorts with sufficient patient-years of follow up to demonstrate 
whether the need for CD surgery diminishes.  
1.3.2 PREVENTION OF SURGICAL RECURRENCE AFTER INTESTINAL RESECTION 
Given the nature of CD, surgery is not curative and post-operative recurrence is common.  Clinical 
and endoscopic recurrence one-year post surgery can be as high as 10-38% and 35-85% 
respectively (37). A recent meta-analysis of population-based studies found the overall risk of a 
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second intestinal resection to be 28.7%; with 5 and 10-year risk being 24.2% and 35% respectively 
(38). Frokllis et al, also found a significant reduction in the 10-year risk of a second surgery pre and 
post 1980: 44.6% pre versus 33.2% post 1980. Most of the studies included in this metanalysis 
predated the widespread use of biologics. (38).  
Peyrin-Biroulet et al in a recent meta-analysis demonstrated the efficacy of thiopurine analogues 
in reducing clinical and endoscopic post-operative recurrence (39). However, population-based 
studies have yet to confirm this benefit (23). Papay et al exploring the benefits of thiopurines in 
preventing surgical recurrence among 326 patients who had an intestinal resection, identified that 
maintaining thiopurines for at least 36 months significantly reduced surgical recurrence (HR: 0.41, 
95% CI: 0.23-0.76) (40). However, the study can be criticised for not addressing the immortal time 
bias favouring azathioprine, which may have contributed towards the positive findings.  
 
1.4 USE AND EFFICACY IN ULCERATIVE COLITIS  
 
Chronic relapsing and remitting inflammation causing intestinal damage and fibrosis is associated 
with increased risk of surgery in UC (12). As surgery is an objectively identifiable and clinically 
important event in the natural history of UC, it makes for an attractive clinical endpoint, 
particularly when evaluating the efficacy of therapy.  
The Stockholm county cohort of patients diagnosed between 1966-1984 had cumulative 
colectomy rates of 20%, 28% and 45% at 5, 10 and 25 years after diagnosis respectively (41). 
However, subsequent studies have consistently reported lower rates of colectomy  at 1, 5 and 10 
years after diagnosis ranging from 0.5%-6%, 3%-13% and 8.5%-19% respectively (27,42-48). A 
recent population-based cohort study from Australia reported similar colectomy rates of 15% at 
10 years and 31% at 30 years (49). The decline in colectomy rates occurred prior to biological 
agents becoming widely available. Therefore, the increasing and earlier use of thiopurines over 
time, may be responsible for the reduced need for colectomy.  
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1.4.1 REDUCING THE RISK OF COLECTOMY IN ULCERATIVE COLITIS 
 
A recent Cochrane review strongly favoured thiopurines for maintaining clinical remission, but 
lacked  high-quality evidence (50). Colectomy was not assessed as a clinical endpoint in this review.  
A number of population-based studies have tried to evaluate the impact of thiopurine 
maintenance on the risk of colectomy, with limited success. Most studies have shown a significant 
increase in the use of thiopurines over time, with an associated reduction in surgical rates. 
However, they failed to demonstrate a consistent association between the two events (51-58). 
A Canadian population-based study from Manitoba including 3,752 UC patients demonstrated a 
significant reduction in colectomy rates at 2 years among patients who were maintained on 
thiopurines for a minimum of 16 weeks (5.6% vs 12.8%)(51). A large Danish registry study 
comprising 35,783 patients diagnosed between 1979 and 2011, failed to indicate any protective 
effect of thiopurine exposure on colectomy (52). Given the nature of the study, data was not 
available on the disease severity at diagnosis, smoking status and also lacked evidence on 
medication maintenance and adherence.  
A population-based study from the United Kingdom of incident cases of UC, diagnosed between 
1989- 2009, found maintenance of thiopurines for more than 12 months to be associated with a 
71% reduction in  risk of surgery (HR: 0.29, 95%CI: 0.210.40) (53). However, early thiopurine use, 
defined as introduction of thiopurines within 1 year of diagnosis of UC, did not reduce surgical 
rates. This may be attributed to some patients with early onset of severe disease requiring 
thiopurines, being either refractory to therapy or having had insufficient time to benefit from 
thiopurines before surgery. Similar to other registry studies it lacked data on disease extent and 
severity. CañasVentura et al described an increased risk of colectomy at 5 years in patients 
receiving thiopurine therapy within first 33 months of diagnosis vs those started after this period 
(HR = 4.9, 95%CI: 3.2-7.8) (54).  
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Most of these studies failed to address the possible confounders associated with early thiopurine 
use. None of the studies used matching on propensity scores, a technique commonly used to 
control for measured confounders in observational studies(55). They also lacked a strict definition 
for thiopurine maintenance to ensure adequate exposure prior to surgery, considering the lengthy 
median time to response associated with thiopurines before deeming therapy to be futile (56-58). 
Evidence for the efficacy of methotrexate on maintenance of remission in UC is disappointing. A 
recent Cochrane review failed to demonstrate any benefit of methotrexate in the treatment of UC 
(21).  There is no long-term population-based data on the colectomy rates, due to its limited use 
in UC as compared to CD. 
 
1.4.2 REDUCING THE PROXIMAL PROGRESSION IN DISEASE IN ULCERATIVE COLITIS 
 
Disease extent in UC is dynamic, with 27% to 54% of patients who were initially diagnosed with 
proctitis or left-sided colitis progressing to more extensive involvement over time(27). Rate of 
progression from proctitis to left-sided colitis was 28%–30%, and to extensive colitis was 14%–
16%; from left-sided colitis to extensive colitis was 21%–34% (59). The 5 and 10 year risk of 
progression of disease was 17.8% (95% CI: 12.3-25.1) and 31% (95% CI: 23.5-39.7) 
respectively(59). 
Proximal disease extension appears to be a marker of severe disease, not only because it is 
associated with higher disease burden and therapeutic requirements, but also as it has been 
shown to be associated with higher rates of colectomy(27). These patients also had a higher need 
for biologics, more active disease and increased hospitalisations compared to controls who started 
with extensive colitis(60).  
Diagnosis at a young age, extra-intestinal manifestations, refractory disease and never-smoking 
status have all been associated with an increased risk of disease progression, though  these 
findings have been inconsistent (59).  
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This raises the question of whether earlier treatment of active disease can prevent disease 
progression. However, there are no studies looking at the impact of different therapeutic options 
on the risk of progression of disease in UC.  
 
1.5 USE AND EFFICACY WITH BIOLOGICS 
 
Since the approval of infliximab in 1998, anti-TNF antibodies (infliximab, adalimumab, 
certolizumab and golimumab) have revolutionized the management of IBD. Despite having an 
early clinical response rate of around 60-70%, up to 50% of those who responded initially will 
develop loss of response over time. Following loss of response, subsequent primary non-response 
to other biological agents increase, suggesting that exposure to anti-TNF agents might modify 
inflammatory pathways and increase resistance to second- and third-line biological agents (61,62). 
Up until the recent approval of vedolizumab and golimumab for UC and ustekinumab for CD, 
infliximab and adalimumab were the only anti TNF drugs licensed to treat IBD in Australia(13). It is 
therefore desirable to optimise the use of each anti TNF drug to avoid treatment failure and 
preserve treatment efficacy for as long as possible. Hence, it is crucial to identify any modifiable 
factors that are associated with response and loss of response to improve outcomes.  
 
1.5.1 IMPROVING PRIMARY RESPONSE 
  
Primary non-response to anti TNF should not be assessed before week 8-12 in both CD and UC as 
successful remission induction can be still accrued after 3 infliximab infusions at 0,2 and 6 weeks 
and 3-5 bi weekly adalimumab injections.   The reported primary non response rates in CD and UC 
are around 20-40% in clinical trials with both infliximab and adalimumab; with lower rates of 10-
20% in clinical ‘real life’ series (61,63).  
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Several factors have been identified to be associated with an increased risk of primary non-
response in CD. In patients treated with infliximab, longer disease duration, small bowel 
involvement, smoking and normal C-reactive protein (CRP) were associated with increased risk of 
primary non-response (64). A randomised controlled study looking at the benefits of early IM 
therapy started at day 0 with the first infusion of infliximab, found a greater proportion of patients 
in clinical remission at week 14 and up to week 52 (65). A recent meta-analysis of patient level 
data in the biological registration trials also confirmed this finding, showing increased odds of 
response at week 4-14 (OR, 2.02; 95% CI, 1.09–3.72) with the concomitant use of IMs (66).  
However, the evidence to support combination therapy with adalimumab is sparse. The same 
meta-analysis that showed benefit of concomitant IM therapy with infliximab, did not find similar 
association with adalimumab (OR 0.88, 95% CI, 0.58–1.35) (66). A recent prospective study 
randomizing treatment-naive patients with moderate-to-severe CD to either adalimumab 
monotherapy or combination therapy with thiopurines started at day 0, did not find a difference 
in response rate at  week 12 (67). Subgroup-analysis of patients on thiopurines, found no 
difference in response based on 6-TGN levels being >250pmol/8x108 RBCs(67).   
Conversely, a recent meta-analysis and a ‘real life’ series of patient data found adalimumab 
monotherapy to be slightly inferior to combination therapy for induction of remission (OR: 0.78, 
95% CI: 0.64–0.96, P=0.02) (68). In another recent study, Ungar et al found significantly higher 
proportion of ADAs in primary non-responders to adalimumab, developing as early as 2 weeks 
(64% vs 25%). This raises the question of whether therapeutic levels of thiopurines are required 
prior to starting adalimumab to improve primary response rates (69). The benefits of pre-
treatment IMs in reducing ADAs have been previously shown in murine models(70). This may be 
even more relevant given the slow median time to response (3.1 months) for thiopurines(19). In 
the meta-analysis by Koplyv et al biologics being started in a proportion of patients who failed IMs, 
which were continued, may have contributed towards the positive findings supporting 
combination therapy (68).  
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1.5.2 REDUCING SECONDARY LOSS OF RESPONSE 
 
An European Crohn’s and Colitis Organisation workshop recently defined loss of response as re-
emergence of clinical symptoms, and/or objective measures of inflammation(71). However, some 
authors have defined loss of response as need for anti-TNF dose intensification, and others as anti 
TNF caseation and/or surgery(72,73). Lack of uniformity in definitions and consensus make it 
difficult to estimate the real magnitude of secondary loss of response.  
Based on the need for dose intensification, two meta-analyses estimated the annual risk for loss 
of response after first 12 months to be 13% for infliximab and as high as 24% for adalimumab 
across CD trials and clinical case-series (72,74). The mean percentage of loss of response across 
all studies was 37% for both infliximab and adalimumab, with no difference found between the 
fully humanized adalimumab and chimeric IgG infliximab.  
Development of anti-drug antibodies(ADAs) is associated with secondary loss of response with 
both infliximab and adalimumab (72,74). Male gender, smoking, family history of IBD, colonic 
disease, presence of extra-intestinal manifestations, low dose induction therapy, long disease 
duration, higher initial disease activity, lack of deep remission at week 12, previous treatment with 
anti TNF and previous primary non-response to infliximab were identified as predictors of 
secondary loss of response to adalimumab (74,75).  
Concomitant IM therapy with infliximab has been shown to be associated with a significant 
reduction in the proportion of patients testing positive for ADA (72). Both SONIC and SUCCESS 
trials demonstrated higher rates of clinical remission in patients treated with combination therapy 
as compared to either treatment alone at 6 and 12 months in patients with CD and UC(76,77).   
Unlike with infliximab, concomitant IM therapy with adalimumab was not identified to reduce the 
development of ADAs nor was it useful in preventing loss of response(74). Even though there was 
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no benefit of concomitant therapy in achieving clinical remission at 26 weeks, Matsumoto et al 
found significantly higher rate of endoscopic improvement in the combination group compared to 
adalimumab monotherapy respectively (84.2% vs 63.9%)(67).  
It is unclear if continuing combination therapy long term adds benefit to regular scheduled dosing 
of infliximab(72). Sokol et al found significantly lower clinical relapses and perianal complications 
in patients maintained on combination therapy(78). The maximal CRP and the dose of infliximab 
used was  lower in  patients who continued combination therapy(78). A recent study evaluating 
three strategies of reducing the dose of thiopurines versus maintaining treatment dosing versus 
withdrawing completely, all in combination with Infliximab, found reducing the dose had similar 
benefits to maintaining the full dose(79). Another recent Cochrane review failed to arrive at a 
conclusion with regard to withdrawing IM therapy when used as combination therapy with 
biologics due to lack of evidence(80). Irrespective of the published literature, the common practice 
within the gastroenterologist community was to stop IM in patients who were in clinical remission 
after commencing anti TNF, especially with adalimumab. It is not known whether this practice is 
safer in reducing the potential for adverse effects such as infections and malignancies or increases 
the risk of loss of response to the anti TNF. 
 
1.5.3 THIOPURINE DRUG MONITORING TO IMPROVE OUTCOME 
 
The correlation between thiopurine metabolite levels and clinical response has been extensively 
investigated and confirmed in a recent meta-analysis(81). The pooled odds ratio for clinical 
remission among patients who achieved a 6-thiogunanine nucleotide level over 230 and 260 
pmol/8.108 RBC was 3.15 (95% CI 2.41-4.11) compared to those with lower levels (81).  
Data is emerging demonstrating the intensity of concomitant immunomodulation influences the 
pharmacokinetics of anti TNF therapy and clinical response. It has been shown, that methotrexate 
reduced immunogenicity to infliximab  in a dose dependent manner,  with odds of developing 
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ADAs reducing from 0.36 (95%CI 0.18-0.74) in the 5-10mg/week  dose to 0.14 (95% CI 0.07-0.28) 
in the 22.5 mg/week, relative to patients not treated with methotrexate(82).  
Bouguen et al, in a post hoc analysis of SONIC trial, evaluated if the difference in mean corpuscular 
volume of red blood cells (MCV; difference between pre- and post-treatment MCV) of 7 
femtoliters may be a surrogate marker of therapeutic 6-TGN levels. The authors assessed this MCV 
change on mucosal healing and maintaining therapeutic infliximab levels(83). Mucosal healing was 
achieved in 75% in patients with a delta MCV of > 7, compared to 47.1% in patients who had a 
delta MCV of <7 (p=0.0172) (83). Steroid free remission rates were 77.9% versus 64.4% (p=0.015) 
in the two groups (83). The odds of achieving mucosal healing at week 26 was significantly higher 
in the patients achieving delta MCV >7 (OR: 3.86, 95%CI: 1.05-14.18, p=0.042) (83). They also 
demonstrated that the percentage of patients with trough levels of infliximab above 3 mg/mL to 
be significantly higher in patients with a delta MCV >7 (68.4% versus 38.8%; P=0032) (83). This was 
the first study to demonstrate that lower 6-TGN levels might be less effective in combination 
therapy, using delta MCV as a surrogate maker of therapeutic levels of 6-TGN. Unfortunately, 
measurement of 6-TGN was not performed in the SONIC trial.  
In a cross sectional study assessing the correlation between 6-TGN levels and infliximab trough 
levels, a 6-TGN level of ³125 pmol/8.108 RBC best-predicted for higher infliximab levels (area 
under receiver operating characteristic, 0.86; p<0.001) (84). Patients in the lowest 6-TGN quartile 
had infliximab levels similar to patients not on thiopurines, 4.3 vs 4.8mcg/mL respectively (p=0.8) 
(84). Patients with 6-TGN levels <125 pmol/8.108 RBC were more likely to develop ADAs (OR: 13, 
95%CI: 2.4-72.5, p=0.01)(84).  
Similarly, in a recent open label, prospective, randomised clinical trial assessing the optimal 
azathioprine dose required to improve efficacy in combination with infliximab, a level of 105 
pmol/8.108 RBC  (Likelihood ratio 7.67; Sensitivity=67%, specificity=92%) was identified as the 
optimal cut off to predict for optimal infliximab pharmacokinetics(79).  
Currently available evidence is conflicting regarding the benefit of concomitant IM therapy with 
adalimumab in improving clinical outcomes or adalimumab pharmacokinetics (74,85). No studies 
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have evaluated the optimal dose of thiopurine, based on 6-TGN levels, needed to improve clinical 
outcomes in patients treated with thiopurines.  
 
 
1.6 USE AND EFFICACY IN ELDERLY 
 
The increase in the elderly population and rising incidence of IBD across all age groups are 
contributing towards the increasing prevalence of elderly IBD patients (86). It is estimated that 
around 25-35% of IBD patients are over the age of 60 years, with 10-15%  diagnosed after the age 
of 60 (87,88). Disease onset after the age of 60 years is widely accepted as the definition of elderly 
onset IBD (86).  
Currently, there are no age-specific treatment guidelines for elderly-onset IBD patients (86). Due 
to the differences in the disease progression, treatment efficacy and possible side effects, the 
current management practices designed for younger adult patients may not be applicable to the 
elderly (89). Presence of comorbidity and polypharmacy in elderly patients further underpins the 
challenges associated with managing this population at risk of opportunistic infections and cancers 
(90,91). It is also difficult to extract data for elderly IBD patients from clinical studies, as elderly 
and patients with comorbidity are  often excluded from clinical trials(92). 
Elderly patients with UC,  but not patients with CD, have higher risk of IBD-related hospitalization 
compared to younger patients (88,93,94). Elderly CD patients have higher risk of surgery at or 
shortly after diagnosis, but long-term surgery risk appeared to be similar to younger onset 
disease(94,95). More recent studies have all demonstrated higher surgery rates in elderly onset 
UC, compared to younger onset patients (96,97). Elderly patients with IBD have  significantly 
higher post-operative morbidity and mortality, compared to younger onset IBD patients, 
highlighting the need to optimise management in these patients (93,98,99).  
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Based on these risks and benefits, recent “European Crohn’s and Colitis Organisation Topical 
Review on IBD in the Elderly” recommends that clinicians to assess an individual’s frailty rather 
than only considering an individual’s chronological/biological age when making management 
decisions (86). 
 
1.6.1 USE AND FACTORS INFLUENCING ITS USE IN ELDERLY 
 
Studies have constantly shown lower use of IMs in elderly IBD patients compared to younger IBD 
patients(88,95,97,100-102). 
Lakatos et al reported a significantly lower azathioprine use in elderly onset CD patients (28.6%) 
compared to younger onset CD patients (42.6%), in a cohort of patients diagnosed between 1977-
2008(95). They found similar differences in UC patients(95). Similar findings were observed in a 
recent Spanish study, which reported a cumulative probability of starting on immunosuppressants 
of 15% and 36% in elderly onset and 27% and 53% in adult-onset UC patients at 1 and 5 years 
respectively (p<0.0001) (97). Similarly, the rate in CD was 28% and 57% in elderly onset and 48% 
and 80% in adult-onset patients at 1 and 5 years respectively (p<0.0001) (97).  
There appears to be a high steroid dependence, as reported by Juneja et al, in a study of 400 
elderly IBD patients, where 32% were receiving maintenance corticosteroids(103). Despite high 
rate of steroid dependency,  thiopurines and methotrexate were used in only 6% and 1% of 
patients, respectively(103). Despite having an increased risk of hospitalisation, surgery, post-
surgical complications and steroid dependency, IMs are being underutilized in the elderly onset 
IBD patients(93,94,96,99).  
No differences in efficacy or potential adverse events, have been noted with the use of 
thiopurines, based on age(104), raising the possibility of other factors influencing the use of IMs 
in elderly. One of the major determinants would be the documented increased risk of malignancy. 
Patients aged ≥65 receiving thiopurines were found to be 2.6 times more likely to develop 
lymphoma than their younger counterparts(105). The crude incidence rate of non-melanoma skin 
Chapter 1  
Page | 
Introduction and literature review 
17 
cancer was 0.84/100 and 5.70/100 patient years for patients over the age of 65, who have never 
used and currently receiving thiopurines(106). Similar findings were noted in a US population-
based study, but found the increased risk reducing to pre-exposure levels after stopping 
thiopurines(107).  
A recently published large European population-based study identified older age at diagnosis (HR: 
1.05, 95%CI 1.04-1.06) and smoking (HR: 1.4, 95%CI: 1.12-1.76) as factors associated with 
increased risk of extracolonic cancer (108). However, the use of IMs were not associated with 
increased risk in this population (108). A study from France, reported similar risk of intestinal 
cancer in elderly IBD patients and aged matched general population (109).   
Older age is known to be associated with polypharmacy and increased comorbidities in elderly IBD 
patients, similar to the general population (110). Parian et al. in a cohort study of 190 elderly IBD 
patients, described the increased reliance on steroids associated with polypharmacy. Despite the 
uncertain efficacy of mesalazine for CD (111), 70% of the elderly patients with CD were on 
mesalazine maintenance therapy, including 71% of CD patients with moderate to severe disease. 
However, they did not assess if these decisions were impacted by polypharmacy, age or 
comorbidities.  
Polypharmacy in elderly may indicate higher rates of comorbidities, frailty and potential for drug 
interactions. In these scenarios, treating physician may consider avoiding medications like IMs, 
due to potential drug interactions and side effects. Contrary to what is expected Fries et al, 
reported an increased likelihood of IM use in patients with polypharmacy (112).  
The knowledge and attitude towards IM prescription by the treating physician has never been 
assessed. Patients’ age, lack of clear evidence for drug efficacy in the elderly population, 
underestimating the increased mortality risk, hospitalization, morbidity associated poorly treated 
IBD and concerns about drug side effects, may influence their decision-making process.  
 
1.6.2 REDUCING THE RISK OF SURGERY IN ELDERLY IBD 
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Elderly onset IBD was reported to be a milder form of the disease compared to younger onset, 
with low risk of surgery across both CD (28.6% versus 33.8% respectively) and UC (1.9% versus 
4.1% respectively) (95). In a recent meta-analysis, elderly onset IBD patients were found to have 
similar risk of surgical intervention (OR: 0.70, 95%CI: 0.40-1.22) compared to younger onset 
patients (113). However, in contrast, elderly onset UC patients were significantly more likely to 
undergo surgery (OR: 1.36, 95% CI: 1.18-1.57, p<0.001) (113). More recent population cohort 
studies described similarly increased rates of colectomy, in elderly IBD patients(97).  
A recent large registry study from Sweden again demonstrated a higher surgery rate among all 
elderly patients compared to adults (13% versus 10% respectively) (101). Despite the increase risk 
of surgery, the cumulative use of IMs at 5 years was lower in the elderly patients compared to 
other younger onset (33% elderly CD patients versus 54% adults and 17% elderly UC patients 
versus 28% adults after 5 years) (101).  
Charpentier et al, assessing the impact of IM use on the risk of surgery  found no association in 
either CD or UC(100).  In a recent study using the Clinical Practice Research Datalink in the UK, 
demonstrated a 70% reduction in the risk of colectomy (HR: 0.30, 95%CI: 0.15–0.58) in elderly 
onset UC patients, who were maintained on thiopurines for more than 12 months.(114). 
Thiopurine maintenance was not associated with surgical risk (114). Overall, the lack of evidence 
to support the use of IM in the elderly may be a contributing factor to its limited use in this age 
group.  
 
1.7 PURPOSE OF THE THESIS  
 
There are number of gaps in the literature defining the role of role of immunomodulators in the 
contemporary treatment of IBD. With increasing healthcare cost related to management of IBD, 
associated with increasing incidence and cost related to biologics, affordability and cost 
effectiveness of treatment options need to be critically evaluated.  
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In this context, the overall aim of the current thesis is to investigate the long-term efficacy and use 
of immunomodulators, particularly thiopurines, in the current day treatment algorithm of IBD by: 
• Investigating the influence of early immunomodulator strategy, on the long-term surgical 
outcomes of CD; initial abdominal surgery, recurrent abdominal surgery and perianal 
surgery.  
• Investigate the impact of early thiopurine therapy on the risk of colectomy and proximal 
disease progression in UC  
• Investigate the use of thiopurines in improving clinical outcomes of biologics, particularly 
adalimumab when used in combination.  
• Identify the factors associated with the use of immunomodulators in elderly and the 
influence of early treatment on surgical outcome  
• Identify the factors influencing the prescribing patterns of physicians treating elderly IBD.  
The following hypothesis and research questions will be addressed throughout the thesis. 
 
1.7.1 HYPOTHESIS AND AIMS 
 
HYPOTHESIS 1:  
 
o Early IM use, comprising either thiopurines or methotrexate for unsuccessful 
thiopurine usage, reduces initial and recurrent surgical rates in CD  
o Aims: 
§ The primary outcome measure was the cumulative probability of major 
abdominal surgery for CD stratified by early IM use.  
§ The secondary outcome was the impact of early IM use on requirement for 
recurrent major abdominal surgery and perianal surgery.  
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HYPOTHESIS 2:  
 
o Early use of Thiopurine reduces the rate of colectomy in patients with UC 
o Aims: 
§ The primary outcome measurement was the cumulative probability of 
colectomy in UC stratified by early thiopurine use.  
§ The secondary outcome was to assess the impact of early thiopurine use on 
proximal progression of disease.  
HYPOTHESIS 3:  
 
o Concomitant use thiopurines, dosed to therapeutic levels, improves clinical 
responses and time to failure of adalimumab   
o Aims:   
§ Primary aim was to investigate the influence of concomitant 
immunomodulator therapy on clinical outcomes in Crohn’s disease patients 
treated with ADA.  
§ Secondary outcome was to assess whether therapeutic TGN concentrations 
were associated with improved outcomes compared with subtherapeutic 
TGNs in patients on thiopurine combination therapy.  
 
HYPOTHESIS 4:  
 
o Patients with elderly -onset IBD were less likely to receive IMs for IBD and that the 
decision to avoid IMs is driven by age  
o Aim: 
§ The primary was to compare IMs prescription rates between elderly-onset 
and younger IBD patients with a view to identifying patients characteristics 
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and clinical markers at presentation that predict the initiation of IMs 
therapy.  
§ The secondary outcome was the impact of early IMs use on the 
requirement of first surgery due to IBD. 
  
 
HYPOTHESIS 5:  
 
o Gastroenterologists’ decision to prescribe medical treatment or recommend 
colectomy in elderly UC patients is driven by age and not comorbidity. 
o Aim: 
§ Primary aim was to assess gastroenterologists’ decision to prescribe 
medical treatment versus colectomy in elderly UC patients, and identify the 
factors associated with their choices using logistic regression analysis. 
§ Secondary aims were to identify conditions that preclude 
gastroenterologists from prescribing immunomodulators and biological 
agents, and whether patient age is considered a limitation to prescribing 
these medication classes. 
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CHAPTER 2 : (STUDY 1) IMPACT OF EARLY IM USE, COMPRISING EITHER 
THIOPURINES OR METHOTREXATE FOR UNSUCCESSFUL THIOPURINE USAGE, 
ON INITIAL AND RECURRENT SURGICAL RATES IN CROHN’S DISEASE  
 
 
 
 
 
The content of this chapter is presented as a published study “Early Use of Thiopurines or Methotrexate Reduces 
Major Abdominal and Perianal Surgery in Crohn’s Disease” in manuscript format.  
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2.1  ABSTRACT 
BACKGROUND 
Earlier introduction of immunomodulators (IM) thiopurine or methotrexate is advocated to 
improve Crohn’s disease (CD) outcomes but whether abdominal surgery can be prevented remains 
controversial.  
METHODS 
A specialist-referred cohort of CD was recruited from 1970 to 2009. Early IM use was defined as 
commencement of azathioprine or methotrexate within 3-years of CD diagnosis and adherence of 
at least 6-months. Propensity score matching was conducted to correct for confounders 
influencing early IM introduction. Outcomes of interest were rates of initial and recurrent major 
abdominal surgery for CD and their predictive factors. 
RESULTS 
A total of 1,035 consecutive CD patients (13,061 patient-years) were recruited. The risk of first and 
recurrent major abdominal surgery at 1, 5 and 10-years were 17.5%, 28.4% and 39.5%, and 5.9%, 
19.0% and 33.3% respectively. Early IM use increased over time from 1.3% to 55.3% (P<0.0001) 
and was a significant independent predictor of lower rates of initial abdominal surgery (hazard 
ratio [HR]: 0.45, 95% confidence interval [CI]: 0.35-0.69), recurrent abdominal surgery (HR: 0.44, 
95%CI: 0.25-0.79) and peri-anal surgery (HR: 0.30, 95% CI: 0.16-0.56). Using propensity score 
matching, early IM significantly reduced surgical rates (HR: 0.54, 95%CI: 0.37-0.79). Number 
needed to treat to prevent a surgical event at 5-years from diagnosis and after initial surgery was 
6.99 (95%CI: 5.34-11.95) and 8.59 (95%CI: 6.26-23.93) respectively. 
CONCLUSION 
Early IM use with thiopurines or methotrexate was significantly associated with the reduced need 
for abdominal and perianal surgery in Crohn’s disease. 
Keywords: azathioprine; thiopurine; mercaptopurine; immunomodulator; methotrexate; Crohn's 
disease; surgery; treatment; outcome 
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2.2 INTRODUCTION 
 
Crohn's disease (CD) is a chronic, inflammatory gastrointestinal disorder with a high proportion of 
sufferers requiring abdominal surgery and recurrent surgery for relapsing disease. Intestinal 
resectional rates of up to 61% five years after the initial diagnosis have been reported.1 A decline 
in surgical rates, hence possibly a change in the natural history of CD, has been associated with 
improved medical therapy.2-6 Other studies, however, suggest that surgical rates have remained 
stable over time despite changes in medical treatment.7-10 Most natural history studies are unable 
to demonstrate a positive impact of immunomodulator (IM), possibly due to their use in more 
severe disease, late introduction after development of strictures or fistulas, or insufficient patient-
years of follow up. Two recent randomized controlled studies demonstrated a ‘top-down’ 
approach in the early introduction of thiopurines following CD diagnosis failed to reduce CD 
relapse compared to a convention ‘step-up’ approach in management.11,12 However, the sample 
sizes were relatively small, follow-up period too brief and a high proportion of control subjects 
eventually required commencement of thiopurines, which may negate any benefit. In addition, 
most studies have focused only on the short term impact of thiopurines, which are recognized to 
fail, be complicated by drug-induced idiosyncratic and dose-related adverse effects or not 
tolerated in up to 40% of patients.13 IM therapy in CD often involves thiopurines as first line 
therapy and methotrexate as second line treatment following failure of thiopurines.14,15 Therefore 
to demonstrate the effectiveness of the early IM strategy on surgical outcomes, requires a study 
recruiting not only those on thiopurines but also methotrexate in those intolerant to-, had failed- 
or for whom thiopurines were contraindicated. Scrutinizing each case to ensure study definitions 
are met and confounding factors corrected for, is required. To these ends, a prevalence population 
study approach can provide the necessary case load, review of each and every case, and obtain 
sufficient follow up to ensure robustness of results.16  
Australia has one of the highest reported incidence of CD in the world with a high surgical resection 
rate.17,18 Reimbursement for anti tumor necrosis factor alpha (anti-TNF) was unavailable until 
2008, and even after that time, complete failure of at least one IM (or intolerance to two IMs) was 
required prior to commencement of anti-TNF. As such, good characterization of the effects of IM 
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use on disease natural history is possible due to the high dependence on well-prescribed IM for 
their immunosuppressive and steroid-sparing effects. Additionally, Australian gastroenterologists 
were early adopters of thiopurine metabolite measurements and manipulation of 6-TGN levels 
through dose modification and addition of allopurinol for those with preferential shunting towards 
inactive thiopurine metabolites.19 Methotrexate is typically used in those unsuccessfully treated 
with thiopurines unless contraindicated. Defined populations within Australia may therefore be 
an ideal setting to test the strategy of early IM use of thiopurines or methotrexate on the need for 
initial and recurrent surgery in CD.   
AIMS 
The study hypothesis is that early IM use, comprising of either thiopurines or methotrexate for 
unsuccessful thiopurine usage, reduces initial and recurrent surgical rates in CD. The primary 
outcome measure assessed was the cumulative probability of major abdominal surgery for CD 
stratified by early IM use. The secondary outcome was the impact of early IM use on requirement 
for recurrent major abdominal surgery and perianal surgery.  
 
 2.3 MATERIALS AND METHODS 
PATIENT RECRUITMENT 
 
The "Sydney IBD Cohort" comprises a longitudinal cohort of patients first described in 1994.20 
Ambulatory patients were originally identified from histology records, pathology database, 
endoscopy database, medical health records and correspondence letters from Concord Hospital, 
Royal Prince Alfred Hospital and community gastroenterologists within the catchment region. The 
same methodology was replicated in 2010 to enrich the cohort and the registry was updated. 
Diagnoses were thoroughly reviewed retrospectively using the gastroenterologists’ prospective-
collected electronic and written case records, endoscopy, radiology, pathology and histology 
data.21 To ensure complete data capture, only patients with a confirmed initial diagnosis of CD 
between January 1st 1970 and December 31st 2009 were recruited. This time period provided 
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sufficient patient-years of follow up of study outcomes and sufficient variation in the time to 
commence IM. All events occurring up until July 2012 were recorded.  
 
CASE REVIEW AND COLLECTION OF DATA 
 
Patient medical records were retrospectively reviewed for prospectively collected demographic 
data, disease characteristics, medication usage and surgical history. Demographic data included 
age, year of diagnosis, sex, and smoking status at diagnosis. Those lost to follow up were contacted 
and if unavailable, were censored as at their last observation. Disease characteristics within 6 
months of the initial diagnosis were classified according to the Montreal Classification.22 To assess 
the influence of decade of diagnosis on outcomes, patients were sub-grouped into Group A 
diagnosed between 1970-1979; Group B: 1980-89; Group C: 1990-99 and Group D: 2000-09. 
Medical therapy included 5 amino-salicylates (5-ASA), IM (azathioprine, mercaptopurine, 
methotrexate), anti-TNF therapy and long-term corticosteroid use, defined as 6 months or more 
of continuous- or a total of 8 months or more of discontinuous- use within a 12-month period. 
Data on IM included time to commencement from diagnosis, side effects and duration of 
exposure. Early IM use was defined as introduction of IM within 3 years of diagnosis and 
maintained for at least 6 months.6,23 In assessing the occurrence of recurrent surgery, the identical 
definition was applied for post-operative IM use with the time period commencing from the date 
of prior surgery. Detail of surgical procedures and resections were collected including the time to 
surgery. Major abdominal surgery, the primary outcome measure, was defined as intestinal 
resection, stricturoplasty, explorative laparotomy, intra-abdominal abscess drainage and stoma 
formation. Planned two stage operations and reversal of stoma were included in the total number 
of procedures but were not considered as a recurrent major surgery for analysis. Perianal surgeries 
consisted of abscess drainage and insertion of setons for perianal fistulae. Simple examinations 
under anesthesia without abscess drainage were excluded.  
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TREATMENT WITH IMMUNOMODULATORS DURING THE STUDY PERIOD 
 
Consistent with local practice, thiopurines were used as the first-choice IM, with azathioprine 
generally used ahead of mercaptopurine. Typical dosing of azathioprine was 2- 2.5mg/kg body 
weight, and for mercaptopurine it was 1-1.5mg/kg body weight. Dose reduction may have been 
required for intolerance. In recent years, thiopurine metabolite testing to titrate dosage and 
allopurinol co-therapy were used to optimize thioguanine nucleotide levels19. Methotrexate was 
used primarily as a second line therapy following failure of thiopurines, either orally or parenterally 
initiated at a dose of 25mg per week with maintenance dosing of 15mg per week. Third line IMs 
were not analyzed as they account for a negligible case load. After initiation, IM were prescribed 
indefinitely unless ceased due to failure, side effects, complications, patient non-adherence and/ 
or other patient circumstances.  
  
STATISTICAL ANALYSIS, PROPENSITY SCORE MATCHING AND ETHICS 
 
Description of continuous variables was by median and inter-quartile ranges (IQR). Categorical 
variables were presented as percentages and analyzed by the chi-square test. Survival analysis was 
calculated using the log rank score and data demonstrated using the Kaplan–Meier curve. Cox 
proportional hazards regression models (both univariate and multivariate) are expressed as hazard 
ratios (HR) with their 95% confidence intervals (CI).  
 
Sensitivity analyses after strict propensity score matching was performed to control for possible 
confounders of treatment initiation for first major surgery. The propensity score method is a tool 
to adjust a treatment effect for measured confounders.24 The propensity scores for each patient 
were based on the covariates identified to predict the early use of IM and additional covariates 
known to be associated with requirement of surgery but not identified to be associated with early 
IM use. Using the propensity scores, early IM users were matched to CD patients without early IM, 
Chapter 2  
Page | 
Early Immunomodulator Therapy in Crohn’s Disease 
31 
using a 1 to 2 greedy matching algorithm, with a proximity caliper of 0.5. Similar matching was 
performed after excluding patients who had surgery within 6 months of diagnosis. Goodness of fit 
was evaluated by Hosmer-Lemeshow test and the P Values were non-significant. Effect on early 
IM use on the time to surgery was assessed after propensity matching and expressed as HR with 
95% CI. A P value of <0.05 was considered statistically significant. Number needed to treat (NNT) 
to prevent a surgical event at five years from diagnosis and after initial surgery was based on the 
reported HR and survival at five years (SC5) in the control group (NNR = 1/(SC5HR – SC5).25 Sample 
size target aimed to exceed similar published population-based cohorts that have recruited 3107 
to 5066 CD cases with median follow up for all time periods must be of at least 5 years. Statistical 
analysis was performed using IBM SPSS software version 20.0. The Sydney Local Health District 
Human Research Ethics Committee approved this study (HREC/10/CRGH/126).   
 2.4 RESULTS 
PATIENT CHARACTERISTICS 
 
A total of 1,035 consecutive CD patients were recruited with median patient follow-up of 11.0 
years (IQR 5.0-19.0) and a collective follow-up of 13,061 patient-years. The patient characteristics 
at diagnosis are displayed in table 2.1. Baseline characteristics at diagnosis remained similar across 
the decades of diagnosis apart from a non-significant trend towards increases in the prevalence 
of perianal and upper gastrointestinal disease locations (both P=0.07).  
 
MEDICAL INTERVENTIONS 
 
The overall prevalence of 5-ASA, long-term corticosteroids and anti-TNF therapy was 87.4%, 61.6% 
and 12.2% respectively (Table 2). Use of 5-ASA and long-term corticosteroids reduced significantly 
over time (P<0.0001). A total of 437 (44.4%) patients were started on IM and of these, 384 patients 
(87.9%) continued treatment for six months or more, with a median duration of exposure of 2 
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years (range 0-33) (Table 2.2). Immunomodulators used were thiopurines in 84.0% of cases and 
methotrexate in 14.9%, initiated following failure of thiopurines. Only 1.1% of CD subjects were 
initiated on methotrexate alone due to unfavorable thiopurine methyltransferase enzyme 
pharmacogenomics predictive of myelotoxicity and for concurrent treatment of inflammatory 
arthritic extra-intestinal manifestation of CD. The median duration of disease at the time of IM 
commencement decreased from 26.5 years in Group A to 1.0 year in Group D (P<0.0001). The 
probability of being maintained on IM at 1 and 5 years increased from 1.3% and 1.3% in Group A, 
0.4% and 2.5% in Group B, 8.3% and 26.3% in group C and 35.8 and 55.3% in Group D (P<0.0001; 
Figure 2.1).  
 
On univariate analysis, the age of diagnosis phenotype A1 (age of onset ≤ 16 years) and A2 (17 to 
40 years) predicted for early use of IM (HR: 2.98, 95% CI: 2.06-4.31, P<0.0001 and HR: 1.77, 95% 
CI: 1.36-2.3, P<0.0001 respectively). Other predictors of early IM use included: colonic disease 
location (HR: 0.77, 95% CI: 0.61-0.98), upper gastrointestinal disease location (HR: 2.76, 
95%CI:1.55-4.92, P=0.001), perianal disease (HR: 1.66, 95% CI: 1.33-2.09, P<0.0001), 5-ASA use 
(HR: 0.73, 95% CI: 0.55-0.96, P=0.026), long term corticosteroid use (HR: 1.5, 95% CI: 1.21-1.87, 
P<0.0001), anti-TNF exposure (HR: 3.56, 95% CI: 2.84-4.55, P<0.0001) and more recent time-
period of diagnosis (HR: 3.44, 95% CI: 2.93-4.04, P<0.0001). On multivariate Cox proportional 
hazard regression analysis, the significant independent predictors of early IM use were young age 
of diagnosis below 16 years (HR: 2.44, 95% CI: 1.66-3.60) and 16 to 40 years (HR: 1.59, 95% CI: 
1.21-2.09), long-term corticosteroid use (HR: 1.83, 95% CI: 1.45-2.31), anti-TNF exposure (HR: 
1.82, 95% CI: 1.41-2.36), and the most recent decades of diagnosis (HR 0.02 to 0.33, all P<0.0001; 
Table 2.3).  
MAJOR ABDOMINAL SURGERY 
 
A total of 388 (37.5%) had at least one major abdominal surgery, with 18.8% of these occurring 
within 6-months of diagnosis. Of those who had at least one recurrent operation, 117 (30.2%) 
underwent 2 or more major abdominal surgeries. A total of 9.2% of patients underwent perianal 
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surgery, with 28.4% of these requiring repeat procedures. The types of surgical procedures 
performed remained similar across all study decades (Table 2.4). The risks of major abdominal 
surgery at 1, 5 and 10 years after diagnosis were 17.5%, 28.4% and 39.5%. The risks of recurrent 
surgery at 1, 5 and 10 years after the first surgery were 5.9%, 19.0 % and 33.3% respectively.  
 
FACTORS ASSOCIATED WITH FIRST MAJOR ABDOMINAL SURGERY 
 
All baseline characteristics at diagnosis and medication use were considered for the univariate 
analyses. Early IM use (P<0.0001), long-term corticosteroid use (P=0.001), 5-ASA use (P<0.0001), 
age of diagnosis (P<0.0001), location phenotype (P<0.0001), behavioral phenotype (P<0.0001) and 
decade of diagnosis (P=0.002) were each significantly associated with time to major abdominal 
surgery (Supplement 1). Anti-TNF use, gender, smoking, perianal involvement, upper 
gastrointestinal disease location and extra-intestinal manifestations at diagnosis were not 
associated with time to first major abdominal surgery.  
 
On multivariate analysis, early IM use was associated with decreased need for first major 
abdominal surgery (HR: 0.45, 95% CI: 0.32-0.63, P<0.0001) (Table 2.5). Colonic disease location 
(HR: 0.36, 95% CI: 0.27-0.50, P<0.0001) and 5-ASA use (HR: 0.56 95% CI: 0.41-0.76, P<0.0001) were 
also associated with decreased need for surgery. Stricturing disease behaviour (HR: 2.48, 95% CI: 
1.93-3.20, P<0.0001), penetrating disease behaviour (HR: 2.97, 95% CI: 2.14-4.11, P<0.001) and 
long-term corticosteroid use (HR: 1.41, 95% CI: 1.12-1.78, P=0.004) were associated with 
increased need for first major abdominal surgery. Neither the decade of diagnosis nor the age at 
diagnosis were significant independent predictors of surgery. The NNT with IM to prevent a 
surgical event at five years was 6.99 (95%CI: 5.34-11.95). 
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PROPENSITY SCORE MATCHING AND SENSITIVITY ANALYSIS 
 
A propensity score model was developed to quantify early IM use, using the factors predictive of 
early IM use and additional factors identified to affect surgical outcome. A total of 173 (96%) early 
IM users were matched against 266 controls that did not receive early IM. The mean propensity 
score of treated and controls were 0.42 and 0.15 before matching and 0.41 and 0.35 after 
matching. After matching, the relative multivariate imbalance improved from 0.73 to 0.58. Further 
matching was performed after excluding patients who had major abdominal surgery within 6 
months of diagnosis, as IM therapy during this time may not have had sufficient time to reach peak 
efficacy to prevent surgery. A total of 165 (89%) of early IM users were matched against 251 
controls. The relative multivariate imbalance improved from 0.66 to 0.43 after matching. In the 
propensity-matched analysis, early IM use was significantly associated with the requirement for 
first major abdominal surgery in the overall cohort (HR: 0.54; 95% CI: 0.37-0.79, P=0.002) (Figure 
2.2A) and also after excluding patients who had surgery within 6 months of their diagnosis (HR: 
0.64; 95% CI: 0.42-0.96, P=0.034).  
 
FACTORS ASSOCIATED WITH RECURRENT MAJOR ABDOMINAL SURGERY 
 
All baseline characteristics at diagnosis and medication use were considered for the analysis. On 
univariate analysis, early IM use after first major abdominal surgery (P=0.014, Figure 2.2B), anti-
TNF use (P=0.024) and long-term corticosteroid use (P=0.024) were all associated with time to 
recurrent surgery. Decade of diagnosis was not associated with time to recurrent surgery 
(P=0.375). On multivariate analysis, early IM use after the first surgery predicted reduced need for 
recurrent surgery (HR: 0.44, 95% CI: 0.25-0.79, P=0.006). Anti-TNF use, however, was associated 
with an increased risk of recurrent surgery (HR: 1.7, 95% CI: 1.01-2.87, P=0.047). The NNT with IM 
post-surgery to prevent reoperation at 5 years was 8.59 (95%CI: 6.26-23.93). 
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FACTORS ASSOCIATED WITH PERIANAL SURGERY 
 
On univariate analysis early IM was associated with the reduced need for perianal surgery 
(P=0.008, Figure 2.2C). On multivariate analysis early IM use remained an independent predictor 
of reduced need for perianal surgery (HR: 0.30, 95% CI: 0.16-0.56, P<0.0001). Anti-TNF use (HR: 
1.73, 95%CI: 1.06-2.83, P=0.029), long-term steroid use (HR: 1.71, 95%CI: 1.03-2.83, P=0.038) and 
most recent decade of diagnosis (HR: 3.18, 95% CI: 1.59-6.33, P=0.001) were associated with 
increased need for perianal surgery. 
 
 2.5 DISCUSSION 
 
In this Australian specialist-based cohort study with sufficient sample size and duration of follow 
up, significant reduction in the risk of initial and recurrent major abdominal surgery for CD were 
observed with the use of early IM therapy. Importantly, rather than simply being associated with 
treatment paradigm changes in recent decades, the reduction in surgery was independently and 
significantly associated with the early introduction of IM therapy within 3 years of diagnosis and 
maintained for at least 6 months. Immunomodulator therapy was also defined by prescription of 
at least 6 months prior to the first major surgery to avoid biases of late and futile introduction of 
the drug.10 Even adjusting for possible biases through rigorous analysis with propensity score 
matching and exclusion of subjects who required surgery within 6 months of diagnosis, significant 
reductions in both initial and recurrent surgery were observed. These findings support a possible 
change in the natural history of CD resulting from early- and sustained IM early after diagnosis and 
after surgical intervention and were independent to the decade of diagnosis. Early IM therapy was 
also identified as the most significant independent predictor of the need for perianal surgery.  
 
Chapter 2  
Page | 
Early Immunomodulator Therapy in Crohn’s Disease 
36 
In Australia, the limitations on the use of anti-TNF agents have led to the increased reliance on- 
and earlier introduction of IM. Although IM comprised almost universally of thiopurines as first-
line agent, poor response, intolerance, hypersensitivity, idiosyncratic and dose-related adverse 
reactions required the introduction of methotrexate as part of the IM strategy. This may increase 
the capture of subjects who benefit from early IM therapy and the strategy might have been 
responsible for the reduction in major abdominal surgery in CD.  
 
In the pediatric CD population, early introduction of azathioprine decreased the need for 
surgery.24 However, in an adult population study from France no reduction in the surgical resection 
rate was found despite an increase in the use of azathioprine over time10,26. The latter study has 
been criticized for commencing IM too late in the disease course and hence being unable to modify 
disease natural history. A population-based study from Cardiff identified a significant reduction in 
surgical rates among patients diagnosed with CD between 1986-2003 that was independently 
associated with early introduction of azathioprine.2 However, the year of diagnosis was an 
independent predictor of surgery indicating that changes in surgical treatment paradigms over 
time may have been responsible for the reduction in surgical rates. The protective effect of IM 
was also demonstrated by Lakatos et al in a recently published study from western Hungary, in 
which early commencement of azathioprine was found to reduce the need for first surgery 
independent to the decade of diagnosis6. Strict definitions for early IM use and propensity score 
matching to eliminate bias in their study design were applied, as was the case in the present study, 
and correcting for biases may differentiate our results from the previously-published negative 
studies.  
 
The benefit of thiopurines in preventing post-operative recurrence has been demonstrated in 
clinical trial settings.27,28 However, population based studies have yet to confirm this benefit.7 A 
recent retrospective analysis demonstrated a significant reduction in post-operative recurrence 
associated with azathioprine exposure for at least 36 months, initiated between 3 to 60 months 
after the initial surgery29. The study could be criticized for not addressing the immortal time bias 
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favoring azathioprine. To correct for this bias in studying whether IM can reduce the need for 
recurrent surgery, we only included IM use within 3 years of the index major abdominal surgery 
that was maintained for at least 6 months. Using these strict definitions, we have demonstrated 
the benefit of early IM use in preventing surgical recurrence.  
 
The increased risk of recurrent surgery and perianal surgery associated with use of anti-TNF 
therapy must be interpreted with caution, given its use at the time of patient recruitment was 
prior to their regulatory approval for reimbursement. Anti-TNF treatments were given on an 
episodic basis and reserved for complicated and severe disease late in the disease course. Since 
that time, biological therapies have been given in accordance to best practice as scheduled 
maintenance and earlier in the course of disease.30 Even with scheduled maintenance biological 
agents, they may be associated with high-cost, risk of severe adverse reactions including life-
threatening infections, primary non-response in a-third of patients and progressive secondary loss 
of response. 30-32 As such, effective, cheaper, and easy-to-administer IM medications that can be 
prescribed with a high-level of confidence by physicians, are required33. 
 
There are a few limitations of this study. The study population was an ambulatory non-hospital-
based specialist referred cohort, based within the Sydney Local Health District rather from national 
databases. However, recruitment of ambulatory patients managed continuously by 
gastroenterologists with excellent longitudinal follow up and documentation allowed for excellent 
characterization of every case and ensured the definition of IM was met. Similar strategies have 
been employed in other Australian and New Zealand population-based cohorts.17,34 Reassuringly, 
the 1, 5 and 10-year risk of first surgery in the current cohort are similar to the pooled 1, 5 and 10-
year risk of surgery published from a meta-analysis of population-based studies35. The recruitment 
strategy also provided sufficient patient-years of follow up required to not only demonstrate initial 
surgical rates within 5 years of diagnosis, but also recurrent surgical rates that few studies have 
published to date. Scrutiny of individual cases is often not possible using larger population cohorts 
and misclassification may confound results. Despite having greater scrutiny, the lack of smoking 
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data in over 400 patients emphasizes the difficulties in conducting a retrospective study spanning 
40 years. This may account for smoking not been identified as a risk factors for surgery in the 
current cohort.   Secondly, patient management strategies and diagnostic tests have changed over 
time and may have accounted for changes in surgical rates. This, however, was corrected-for by 
including “decade of diagnosis” as a variable in the multivariate analysis, which failed to be an 
independent predictive variable for surgery. Early IM use was the only controllable factor that 
significantly decreased initial and recurrent major abdominal surgery in CD. Thirdly, this was not a 
randomized placebo-controlled study. However, such studies may be limited with their patient-
years of follow up in identifying surgical events and the need for recurrent surgeries. In their 
control groups, high proportions of controls eventually required commencement of 
thiopurines.11,12 Such studies may require per protocol analysis, very large sample sizes studied 
over many years to identify the true benefits of thiopurines. These studies also did not take into 
account the possible benefit of second-line methotrexate following the high dropout rates that 
occur with thiopurine treatment. This study ensured the robustness of the diagnosis, conformity 
of evidence-based management and case definitions that may be lacking in studies derived from 
insurance data, hospital coding or de-identified data that cannot be verified. Lastly this study was 
not designed to be analyzed according to intention-to-treat. The duration of IM use criteria had to 
be met on a per protocol basis in order to test the absolute benefit of early IM therapy over time. 
Reasons for ceasing IM therapy, although not specifically reported here, were similar to those 
previously published.13    
 
The strengths of this study included the large size of the cohort, the long duration of follow-up, 
and the completeness of disease characterization from the initial point of contact. Rigorous 
monitoring and validation of data capture was possible. This is the first study that included 
methotrexate use for those who had failed thiopurines to test the real-life option of the IM 
strategy. The IM strategy has been well verified in this and other studies to have steroid-sparing 
effects, but this study adds to the few that demonstrate significant reduction in both initial and 
recurrent surgery associated with their earlier initiation and sustained use. This study is also one 
Chapter 2  
Page | 
Early Immunomodulator Therapy in Crohn’s Disease 
39 
of only a few to use propensity score matching to correct for biases, which may reduce type II 
errors and also to calculate the NNT to prevent a surgical event. Given their low cost in comparison 
to biological agents and expensive and disabling surgical events, IM therapy needs to be advocated 
to remain within the armamentarium for the treatment of IBD.33 Data to demonstrate absolute 
improved outcomes, however, are also needed to support their use given their known risk of 
adverse events. These data support the earlier introduction of thiopurines and methotrexate for 
those that fail thiopurines in CD.     
In conclusion, early and sustained use of IM after diagnosis and after surgery was significantly 
associated with a reduction in the risk of abdominal and perianal surgery in CD. The results on 
abdominal surgery are independent to decade of diagnosis suggesting a true drug-induced 
beneficial effect in improving long-term outcomes and support their ongoing use in the treatment 
of CD.  
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Table 2.1: Clinical characteristics at diagnosis grouped according to the decade of diagnosis 
  
 Total 
1970-2009 
Group A 
1970-1979 
Group B 
1980-1989 
Group C 
1990-1999 
Group D 
2000-2009 
P 
Number of patients 1035 90 286 276 383  
Median follow-up in years (IQR) 11(5-19) 29 (18-35.5) 20 (9-25) 14 (11-18) 5 (2-7) <0.0001 
Patient years of follow-up 13061 2400 4955 3712 1994  
Gender N (%) 0.21 
Male 450 (43.5) 31(34.4) 119 (41.6) 125 (45.3) 175 (45.7)  
Female 585 (56.5) 59 (65.6) 167 (58.4) 151 (54.7) 208 (54.3)  
Median age at diagnosis (Range) 29 (5-92) 28 (8-72) 28 (6-92) 30 (5-84) 30 (6-87) 0.28 
Age N (%)  0.16 
Less than 16 years (A1) 76 (7.3) 5 (5.6) 21 (7.3) 16 (5.8) 34 (8.9)  
Between 17 and 40 years (A2) 653 (63.1) 68 (75.6) 179 (62.6) 171 (62.0) 235 (61.4)  
Age more than 40 years (A3) 306 (29.6) 17 (18.9) 86 (30.1) 89 (32.2) 114 (29.8)  
Disease location N (%) 0.52 
Ileal (L1) 247 (24.0) 23 (25.6) 63 (22.1) 63 (23.1) 98 (25.8)  
Colonic (L2) 388 (37.7) 23 (25.6) 109 (38.2) 112 (41.0) 144 (37.9)  
Ileo-colonic (L3) 393 (38.2) 44 (48.9) 113 (39.6) 98 (35.9) 138 (36.3)  
Not documented  7      
Gastro-duodenal (L4) 17 (1.7) 0 1 (0.4) 6 (2.2) 10 (2.6) 0.07 
Not documented 11      
Disease behaviour N (%)      0.52 
Non-stricturing/ non-penetrating 
(B1) 
697 (68.5) 52 (65.8) 186 (66.4) 196 (71.0) 263 (68.7)  
Stricturing (B2) 224 (22.0) 22 (27.8) 69 (24.6) 53 (19.2) 80 (20.9)  
Penetrating (B3) 97 (9.5) 5 (6.3) 25 (8.9) 27 (9.8) 40 (10.4)  
Not documented  17      
Peri-anal disease N (%) 0.07 
Yes 191 (18.5) 9 (10.3) 46 (16.1) 55 (19.9) 81 (21.1)  
No 840 (81.5) 78 (89.7) 239 (83.9) 221 (80.1) 302 (78.9)  
Not documented  4      
Extra-intestinal manifestations N (%) 0.10 
Yes 191 (18.6) 16 (18.6) 60 (21.2) 38 (13.8) 77 (20.2)  
No 836 (81.4) 70 (81.4) 223 (78.8) 238 (86.2) 305 (79.8)  
Not documented  8      
Smoking status N (%) 0.51 
Current smokers 118 (20.1) 2 (11.1) 16 (26.2) 38 (20.5) 62 (19.2)  
Ex-smokers  140 (23.9) 7 (38.9) 15 (24.6) 46 (24.9) 72 (22.3)  
Never-smokers  329 (56.0) 9 (50.0) 30 (49.2) 101 (54.6) 189 (58.5)  
Not documented  448      
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Table 2.2: Drug therapy during follow-up grouped according to decade of diagnosis (N (% within 
time period) 
 Total 
1970-2009 
Group A 
1970-1979 
Group B 
1980-1989 
Group C 
1990-1999 
Group D 
2000-2009 
P Value 
Long-term corticosteroid  590 (59.2) 67 (77.0) 200 (72.5) 149 (58.0) 174 (46.2) <0.0001 
5-aminosalicylate  884 (86.3) 81(95.3) 263 (93.6) 247 (89.8) 293 (76.5) <0.0001 
Anti-TNF 110 (10.6) 2 (2.2) 9 (3.1) 34 (12.4) 65 (17.0) <0.0001 
Immunomodulators 384 (39.0) 9 (12.0) 45 (18.0) 122 (44.2) 208 (54.3) <0.0001 
Immunomodulators within 
first year of diagnosis  
163 (16.6) 1(1.3) 2 (0.8) 23 (8.3) 137 (35.8) <0.0001 
Early use of 
immunomodulators  
189 (19.2) 0 3(1.2) 45 (16.3) 141 (36.8) <0.0001 
Exposed immunomodulator    0.957 
Thiopurine  367 (84.0) 8 (80.0) 43 (82.7) 118 (83.1) 198 (85.0)  
Methotrexate 5 (1.1) 0 0 2 (1.4) 3 (1.3)  
Both 65 (14.9) 2 (20.0) 9 (17.3) 22 (15.5) 32 (13.7)  
Median time to starting 
immunomodulators (years) 
2 26.5 14 4.5 1 <0.0001 
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Table 2.3: Factors affecting time to initiation of immunomodulator therapy in Crohn’s disease on 
Cox proportional hazard regression 
 
 P value Hazard Ratio 95% CI 
Age of diagnosis  <0.0001   
<16 <0.0001 2.44 1.66-3.60 
16-40 <0.001 1.59 1.21-2.09 
>40 Reference   
Location at diagnosis 0.084   
Ileal 0.72 1.05 0.81-1.37 
Colonic 0.062 0.79 0.62-1.01 
Ileo-colonic Ref   
Perianal involvement  0.017 1.33 1.05-1.68 
Long-term corticosteroid use <0.0001 1.83 1.45-2.31 
Anti TNF exposure <0.0001 1.82 1.41-2.36 
Decade of diagnosis  <0.0001   
1970-1979 <0.0001 0.02 0.01-0.06 
1980-1989 <0.0001 0.07 0.05-0.11 
1990-1999 <0.0001 0.33 0.25-0.43 
2000-2009 Reference   
Removed from the model: 5-ASA use (P=0.75) and upper gastrointestinal disease location (P=0.39) 
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Table 2.4: Types of first major abdominal surgery performed for Crohn's disease at any time during 
follow-up 
 
Procedure type N (%) 
Ileo-caecal resection/ Right hemi-colectomy with ileal resection 219 (56.4) 
Segmental resection of small bowel 67 (17.3) 
Sub-total colectomy and colostomy 7 (1.8) 
Total/ sub-total colectomy and ileostomy 47 (12.1) 
Loop ileostomy / colostomy  11 (2.8) 
Sub-total colectomy and ileo-rectal anastomosis  30 (7.7) 
Stricturoplasty  3 (0.8) 
Total colectomy and pouch formation 2 (0.5) 
Abdominal exploration / abscess drainage  2 (0.5) 
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Table 2.5: Factors affecting time to time to first major abdominal surgery in Crohn’s disease on 
Multivariate Cox proportional hazard regression 
 
 P value Hazard Ratio 95% CI 
Early IM use <0.0001 0.45 0.32-0.63 
Long term steroid use 0.004 1.41 1.12-1.78 
5 ASA use  <0.0001 0.56 0.41-0.76 
Location at diagnosis  <0.0001   
Ileal 0.244 1.16 0.91-1.48 
Colonic <0.0001 0.36 0.27-0.50 
Ileo-colonic Ref   
Behaviour at diagnosis  <0.0001   
Inflammatory Ref   
Stricturing <0.0001 2.48 1.93-3.20 
Penetrating <0.0001 2.97 2.14-4.11 
Removed from the model: age at diagnosis (P=0.239), decade of diagnosis (P=0.309) 
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Supplement 2.1.  Factors affecting time to time to first major abdominal surgery in Crohn’s disease 
univariate analysis 
 
 P value Hazard Ratio 95% CI 
Gender 0.336 1.10 0.90-1.35 
Smoking status 0.434   
Never Ref   
Current 0.213 1.24 0.88-1.75 
Ever but not current 0.450 1.14 0.82-1.58 
Age at diagnosis <0.0001   
<16 0.001 1.96 1.33-2.88 
17-40 <0.0001 1.67 1.30-2.15 
>40 Ref   
Location at diagnosis  <0.0001   
Ileal 0.210 1.15 0.92-1.44 
Colonic <0.0001 0.26 0.19-0.34 
Ileo-colonic Ref   
Upper GI involvement  0.064 0.27 0.07-1.08 
Behaviour at diagnosis  <0.0001   
Inflammatory Ref   
Stricturing <0.0001 3.49 2.79-4.37 
Penetrating <0.0001 3.76 2.79-5.08 
Perianal involvement 0.81 0.97 0.75-1.25 
EIM at diagnosis  0.34 0.88 0.67-1.15 
Early IM use <0.0001 0.50 0.36-0.71 
Long term steroid use 0.001 1.46 1.17-1.83 
5ASA use <0.0001 0.55 0.42-0.72 
Anti TNF use 0.213 1.21 0.90-1.64 
Decades of diagnosis  0.002   
1970-1979 <0.0001 1.85 1.33-2.59 
1980-1989 0.026 1.36 1.04-1.79 
1990-1999 0.344 1.15 0.86-1.53 
2000-2009 ref   
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Figure 2.1: Immunomodulator use according to the decade of diagnosis in patients with Crohn’s 
disease (P<0.0001) 
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Figure 2.2: (A) Association between early immunomodulator use and major abdominal surgery 
after propensity matching (P=0.001) (B) Association between early immunomodulator use and 
second major abdominal surgery (P=0.014) (C) Association between early immunomodulator use 
and perianal surgery (P=0.008) 
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CHAPTER 3 : (STUDY2) IMPACT OF EARLY THIOPURINE MAINTENANCE, ON 
THE RATE OF COLECTOMY AND PROXIMAL PROGRESSION OF DISEASE EXTENT 
IN ULCERATIVE COLITIS 
 
 
 
 
 
 
The content of this chapter is presented as a manuscript submitted for publication to Journal of Crohn’s and Colitis 
“Early Sustained Maintenance of Thiopurine Reduces Colectomy Rate and Progression of Disease Extent in Patients 
with Ulcerative Colitis 
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What is already known about this subject? 
• Recent population-based studies have shown decreased colectomy rates in patients with 
ulcerative colitis  
• The decline in colectomy rates occurred prior to biological agents becoming widely 
available   
• Thiopurines are effective as steroid sparing drugs in ulcerative colitis. Whether early 
initiation of thiopurines after diagnosis decreases proximal disease progression and 
colectomy rates are not well known  
What are the new findings? 
• Early thiopurines maintenance was associated with a 90% reduction in the probability of 
colectomy using a propensity score model.  
• Number of subjects needed to be treated to prevent one colectomy at 5 and 10 years was 
18 and 12 
• Proximal progression of disease extent was associated with 2.2-fold increase risk of 
colectomy   
• Early thiopurine maintenance was associated with a 71% reduced risk of proximal 
progression of disease extent.  
How might it impact on clinical practice in the foreseeable future? 
• Thiopurines should be considered early on in the treatment of ulcerative colitis, as a steroid 
sparing agent, as well to prevent proximal disease progression and decrease colectomy 
rates.  
• Patients with proctitis and left sided colitis should be closely followed up as disease 
progression is associated with a significant increase in the risk of colectomy.  
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3.1 ABSTRACT 
 
BACKGROUND 
Thiopurines effectively maintain remission in ulcerative colitis (UC) patients. Whether early 
initiation of thiopurines after UC diagnosis decreases proximal disease progression and colectomy 
rates is not known.  
 
METHODS 
We conducted a cohort study of UC subjects recruited from 1970 to 2009. Early thiopurines 
maintenance was defined as commencement of azathioprine or mercaptopurine within 5-years of 
diagnosis and maintenance for at least 6-months. Propensity score matching was conducted to 
correct for confounders influencing early thiopurine introduction. Outcomes of interest were 
colectomy rate and endoscopic proximal disease extension.  
 
RESULTS 
982 consecutive UC subjects (12,879 patient-years) were recruited with 116 requiring colectomy. 
Thiopurines initiation and maintenance increased over time with median time to thiopurine 
commencement decreasing from 23 years in the first decade to 2 years in the last decade 
(P<0.0001). Multivariate analysis showed that early thiopurine maintenance significantly 
decreased the need for colectomy (hazard ratio [HR]: 0.13; 95% confidence interval [CI]: 0.03-0.55; 
P=0.006). The number of subjects needed to be treated to reduce one colectomy at 5 and 10 years 
was 18 (95% CI: 16-36) and 12 (95%CI: 11-25). After propensity score matching, early thiopurine 
maintenance was significantly associated with decreased colectomy (HR: 0.10, 95%CI: 0.03- 0.43, 
P=0.002) and proximal progression of disease extent (HR: 0.26, 95%CI: 0.10-0.78, P=0.015). 
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CONCLUSIONS 
Early thiopurine maintenance for > 6 months is significantly associated with reduced colectomy 
and with proximal progression of disease extent in UC. 
  
Chapter 3  
Page | 
Early Thiopurine Therapy in Ulcerative colitis  
59 
3.2 INTRODUCTION 
 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a prevalence of 17.4 per 
100,000 [1, 2] with 70-90% of patients following a continuous or relapsing-remitting course [3, 4]. 
Conventional treatment of mild-to-moderate UC includes mesalazine [5] but more severe UC may 
require systemic corticosteroids, azathioprine, mercaptopurine, anti-tumour necrosis factor 
agents (infliximab, adalimumab, golimumab) or the anti-integrin vedolizumab [5].  
 
Historically, colectomy rates were reported at 46 % of all patients with extensive chronic UC, within 
the first 10 years of diagnosis [4]. However, more recent population-based colectomy rates show 
lower colectomy rates of 15% at 10 years and 31% at 30 years [6]. The decline in colectomy rates 
occurred prior to biological agents becoming widely available. Therefore, the increasing and earlier 
use of thiopurines over time may be responsible for the reduced need for colectomy. In Crohn’s 
disease (CD), early and sustained use of immunomodulators (IM) has been shown to significantly 
reduce the rates of major abdominal, perianal or recurrent surgery [7, 8]. The odds ratio (OR) for 
CD surgery was 1.006 (95% confidence interval [CI] 1.004-1.008) for each month of delay in 
starting thiopurines [7]. In UC, whether early sustained use of thiopurines reduces the need for 
colectomy or proximal progression of disease extent on colonoscopy is not established. Earlier 
commencement of thiopurines to control colitis may reduce progressive intestinal damage. The 
role for thiopurines in the management of IBD has been questioned with the advent of biological 
agents [9]. However, thiopurines are cheap and widely available in comparison to biological 
agents. Primary non-response and secondary loss of response result in lower persistence of 
biological agents and therefore more durable treatments are required. In developing parts of the 
world where IBD prevalence is increasing, tuberculosis rates are high and limitations exist in the 
reimbursement of high-cost medications, thiopurines may be an important treatment for UC [10].  
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The aim of maintenance therapy is to decrease flares, decrease the need for corticosteroids, and 
increase mucosal healing. Intestinal damage is a recognised result of IBD and may be irreversible 
[11]. Therefore, we aimed to determine whether commencement of thiopurine maintenance 
therapy within 5 years of diagnosis of UC prior to the development of irreversible submucosal 
fibrosis and intestinal damage [11], can reduce progression of colitis and colectomy.     
We hypothesised that early maintenance of thiopurines may reduce colectomy rates in UC 
patients. The primary outcome measure was cumulative probability of colectomy in UC stratified 
by early thiopurines maintenance. The secondary outcome was the impact of early thiopurines 
maintenance on proximal progression of disease extent.  
 
3.3 MATERIALS AND METHODS 
PATIENT RECRUITMENT 
 
The ‘Sydney IBD Cohort’ is a longitudinally collected cohort of ambulatory subjects recruited from 
central Sydney as part of the Sydney Local Health District. Recruitment was from medical records 
(paper and electronic), endoscopy database, pathology database and correspondence letters from 
Concord Repatriation General Hospital, Royal Prince Alfred Hospital and community 
gastroenterologists within the Sydney Metropolitan region, using the prospectively collected 
electronic and written case records, endoscopy, radiology, pathology and histology data [12] of 
the gastroenterologists. The cohort was first described in 1994 [13] and data was updated using 
the same methodology in 2010 and 2012 to expand the cohort [6, 8, 14, 15]. Subjects were defined 
using Copenhagen criteria [16]. This time period was selected to allow for sufficient patients-years 
of follow up and complete dataset for the assessment. Prior to 2009, biological therapies were not 
reimbursed in Australia, so subjects were rarely prescribed. However, a few UC subjects received 
on-demand non-sustained therapy for refractory disease.  
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DATA COLLECTION 
 
Prospectively collected demographic data, disease characteristics, medication usage and surgical 
history were obtained from patient medical records. Age, year of diagnosis, sex and smoking status 
were included in demographic data. Patients lost to follow up were contacted and were censored 
as at their last observation if unavailable. Patients with IBD-unclassified and a change in their 
diagnosis to non-IBD pathology were excluded. Montreal classification [17] was used to classify 
disease characteristics at baseline and/or within 6 months of first diagnosis.  Changes in disease 
extent during follow up were recorded using endoscopy and imaging data. Disease extension from 
proctitis to left sided colitis or pancolitis and left sided colitis to pancolitis, was considered as 
proximal disease extension. Influence of decade of diagnosis on outcomes were assessed by 
patient sub-groups with Group A diagnosed between 1970-1979, Group B between 1980-89, 
group C between 1990-99 and Group D between 2000-09. 
Mesalazine, IMs (azathioprine, mercaptopurine, methotrexate), anti-TNF therapy (adalimumab 
and infliximab) and long-term corticosteroid use, defined as 6-months or more of continuous, or 
total of 8 months or more of discontinuous use within a 6-month period, was collected.  IMs data 
included time to initiation from diagnosis, side effects and period of exposure.  To assess the 
impact on surgery and disease progression, early thiopurines maintenance was considered. Early 
thiopurines maintenance was defined as introduction of thiopurines within 5 years of diagnosis 
and maintained for at least 6-months prior to surgery. Patients who started thiopurine after 5 
years, were included in the non-exposed arm. Subjects with methotrexate maintenance were 
excluded from the analysis, due to recent studies demonstrating methotrexate not to be superior 
to placebo in maintenance therapy in UC [18]. The primary outcome measure was colectomy due 
to UC, which was defined as bowel resection due to UC activity and not from dysplasia. Data on 
time to surgery and specifics of surgical procedures and resections were collected. Patients who 
had emergency colectomy at presentation and colectomy for the diagnosis of cancer were 
excluded from factors associated surgery analysis as they did not test the strategy of thiopurines 
controlling disease activity.   
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TREATMENT WITH THIOPURINES DURING THE STUDY PERIOD 
 
In Australia, the first choice of thiopurines historically was AZA and this was used more commonly 
than MP. Thiopurines were started in patients who were steroid dependent or had active disease 
while on maintenance therapy with mesalamine or in high risk patients as determined by the 
treating gastroenterologist, based on the clinical presentation. Dosage of thiopurines was weight-
based (AZA 2-2.5mg/kg and MP 1-1.5mg/kg) and guided by thiopurine metabolite testing (with 
target thioguanine nucleotide level of 235-450 units) or a lower dose if thiopurine was not 
tolerated. To achieve the target thioguanine nucleotide level some subjects received split dosing 
or thiopurine dose reduction combined with allopurinol co-therapy. Thiopurine therapy was 
continued indefinitely after initiation except in a few, unless stopped due to failure, side effects, 
complications, patient non-adherence, and/or other circumstances. Thiopurine maintenance was 
confirmed using history and prescription data.  
  
STATISTICAL ANALYSIS, PROPENSITY SCORE MATCHING AND ETHICS 
 
Continuous variables were described by median and interquartile ranges (IQR), while categorical 
variables were shown as percentages and analysed by chi-square test.  Survival analysis was 
performed using log-rank score and displayed by the Kaplan-Meier method. Univariate and 
multivariate cox proportional hazards regression models were performed, expressed as hazard 
ratios (HR) with respective 95% confidence intervals (CI). Covariates identified a priori with P < 0.1 
on univariate analysis were entered into a multivariate backward stepwise model. 
Using propensity scoring allows for adjustment of treatment effect for measured confounders 
[19]. Strict propensity score matching was thus performed to control for possible confounders of 
early thiopurines initiation through selection bias of treatment trends based on era. Covariates 
recognised to predict early use of IM were used as the basis for propensity scores for each patient. 
Effect of early thiopurines maintenance on time to surgery and proximal progression of disease 
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were assessed after propensity matching and expressed as hazard ratio (HR) with 95% confidence 
interval (CI). A P-value of <0.05 was considered statistically significant. Number needed to treat 
(NNT) to prevent a surgical event at 5 years from diagnosis and after initial surgery was based on 
the reported HR and survival at 5 years (NNR= 1/[SC5HR – SC5]) [20]. IBM SPSS software version 
25.0 was used to perform statistical analysis. The Sydney Local Health District Human Research 
Ethics Committee approved this study (HREC/10/CRGH/126).  
 
3.4 RESULTS 
 
A total of 982 patients with UC were recruited with median follow up of 11.0 years (IQR: 5-20) and 
a collective follow up of 12,879 patient-years. Table 3.1 displays the patient characteristics at 
diagnosis showing similar baseline characteristics across the 4 decades of diagnosis. The majority 
of patients were never-smokers (71.3%) and 58.6% were diagnosed between the ages of 17-40 
years. The diagnosis of pancolitis was more prevalent in the decade 1970-1979 compared to other 
decades (P<0.0001).  
 
MEDICATIONS 
 
The overall prevalence of mesalazine, thiopurines, long term corticosteroids, and anti-TNF therapy 
use was 96.6%, 18%, 37.9% and 2.5% respectively (Table 3.2). Long term steroid use significantly 
decreased over time (P<0.021) while thiopurine-use increased significantly (P<0.0001) (Figure 
3.1). The total number of subjects started on thiopurines were 177 and of these, 127 subjects 
(71.7%) were maintained on thiopurines for 6-months or more. The time to commencing 
thiopurines became earlier over the 4 decades (Figure 3.1). The median duration of UC at the time 
of thiopurines commencement decreased from 21 years in Group A to 2 years in Group D 
(P<0.0001). The proportion of subjects on thiopurines maintenance for 6-months or longer 
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increased through the decades (P<0.0001). Early thiopurine maintenance increased significantly 
over the decades from 0.7% in Group A to 2.4% in Group B, 7.7 Group C and 18.3% in Group D 
(p<0.0001) (Table 3.2). The median duration of thiopurine exposure in the early thiopurine 
maintenance group was 4 years (IQR: 2-8). 
 
FACTORS ASSOCIATED WITH EARLY USE OF THIOPURINES 
 
On univariate analysis, earlier thiopurine use was associated with disease extent, proctitis (ref 
Pancolitis) (HR: 0.35, 95%CI: 0.22-0.56, P<0.0001), younger  age at diagnosis (HR: 0.98 [older compared to 
younger age groups], 95%CI, 0.97-0.99, P<0.0001), anti-TNF exposure (HR: 9.60, 95%CI, 6.15-14.98; 
P<0.0001), long-term corticosteroid exposure (HR: 5.46, 95%CI, 3.84-7.77, P<0.0001) and  being 
diagnosed in Group D compared to Group A, B or C (P<0.0001) (Table 3.3).   
On multivariate Cox proportional hazard regression analysis, younger age of diagnosis (HR:0.98, 
95% CI, 0.98-0.99; P=0.002), long-term corticosteroid use (HR:5.19, 95%CI, 3.60-7.45, P<0.0001), 
anti-TNF exposure (HR:2.28, 95%CI, 1.43-3.64, P<0.0001) and earlier decades of diagnosis (HR: 
0.03 (ref Group D), 95%CI: 0.01-0.06, P<0.0001) were associated with early use of thiopurines. 
 
COLECTOMY RELATED TO ULCERATIVE COLITIS 
 
A total of 116 subjects had colectomy (Supplement Table 1). Six subjects had emergency 
colectomy at diagnosis and 15 were for dysplasia or colorectal cancer. The probability of colectomy 
at 5, 10 and 20 years from diagnosis was 6.3%, 9.3% and 15.1% (Figure 3.2a). Across the 4 decades 
from A to D, the 10-year risk of colectomy was 9.7%, 12.8%, 7.5% and 7.8% (p=0.012) (Figure 3.2b). 
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FACTORS ASSOCIATED WITH COLECTOMY 
 
All baseline characteristics and medication use were considered in the univariate analysis (Table 
3.4). Long-term corticosteroids use (HR: 6.14, 95%CI: 3.72-10.16, P<0.0001), anti-TNF exposure 
(HR: 3.58, 95%CI: 1.65-7.74, P=0.001) and disease extent (P<0.0001) were significantly associated 
with time to colectomy. Early thiopurines maintenance was not significantly associated with time 
to colectomy (HR 0.31, 95%CI: 0.07-1.25, P=0.09).  
 
On multivariate analysis, early thiopurines maintenance decreased the need for surgery (HR: 0.13, 
95%CI: 0.03-0.55, P=0.006) (Figure 3.3). Decade of diagnosis was not associated with time to 
colectomy (P=0.11). Number of subjects needed to be treated to reduce one colectomy at 5 and 
10 years was 18.18 (95% CI: 16.39 - 35.71) and 12.58 (95%CI: 11.22-24.81).  
After propensity score matching, early thiopurine maintenance was associated with significantly 
reduced probability of colectomy (HR: 0.10, 95%CI: 0.03- 0.43, P=0.002). 
 
PROXIMAL PROGRESSION OF DISEASE 
 
A total of 30.8 % of subjects with proctitis and 13.0% of subjects with left sided colitis experienced 
proximal progression of disease extent during follow-up. The probability of disease extent 
progression at 5 and 10 years was 18.6% and 33.1% for subjects with initial diagnosis of proctitis 
and 6% and 11.0% for subjects with left sided colitis (P<0.0001, Figure 3.4a). Disease extent 
progression was associated with increased risk of colectomy (HR: 2.20, 95%CI: 1.07-4.54, P=0.032) 
and early maintenance of thiopurines (HR: 2.53, 95%CI: 1.47-4.34, P=0.001) using time dependent 
Cox regression analysis. After propensity score matching, early thiopurine maintenance was 
associated with reduced risk of proximal progression of disease extent (HR: 0.29, 95%CI: 0.10-0.78, 
P=0.015) (Figure 3.4b). 
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3.5 DISCUSSION 
 
Hospitalization and surgery are considered to be markers of more severe disease and cost-drivers 
in UC. Effective treatment strategies, therefore, should not only result in disease and symptom 
remission, but also demonstrable endpoints such as decreased need for colectomy. Thiopurines 
maintain remission in UC [21], promote mucosal healing [22] and decrease CD complications as 
well as relapses following surgery [8, 23]. Additionally, early commencement of thiopurines might 
help prevent intestinal damage and reduce both colectomy rates and proximal disease 
progression. Previously, thiopurine use was temporally linked to decreased colectomy rates [24, 
25], but strategies to remove bias such as propensity score matching were not performed and 
confounders might be responsible for this observed relationship.  
In this cohort study, thiopurines started early and maintained for >6 months were associated with 
a significant reduction in colectomy rate and progression of disease extent. Commencing 
thiopurines early before cumulative damage to the bowel might be an appropriate strategy to 
reduce submucosal fibrosis, which predicts the need for colectomy [11]. Fibrosis in ulcerative 
colitis is directly linked to severity and chronicity of mucosal inflammation. Thiopurines typically 
require up to 16 weeks to be efficacious [26]. Commencing and maintaining treatment earlier 
might reduce cumulative submucosal fibrosis that results from recurrent flares [11]. Early 
aggressive and ‘top-down’ strategies have been advocated for treatment of Crohn’s disease [27]. 
To avoid biases of futile late introduction of thiopurines therapy, we defined early thiopurine 
therapy as starting within 5 years of diagnosis and maintenance for at least 6 months.  
During the study period, immunomodulators were not first line maintenance therapy for UC and 
as such very few would start these in the first year or so. Patients often cycle through oral and per 
rectal mesalazine and courses of steroids before moving onto a thiopurine, unless dictated by 
severe uncontrolled disease. Five years was an arbitrary value that reflected more modern practice 
of thiopurine initiation. The median time to commencing thiopurine in the most recent 2 decades 
of analysis was 2 and 6 years respectively. Five years would capture sufficient subjects for analysis, 
consistent with practice and biologically plausible in modifying disease progression. Selecting a 
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shorter time frame risks too fewer participants in the early thiopurine commencement arm in 
order to allow for meaningful analysis. 
Twelve percent of our subjects underwent colectomy during follow up, consistent with prior 
studies [3, 24, 28]. The need for colectomy decreased over time and paralleled an increase in the 
use of thiopurines from 7.2% in group A to 27% in group D. Early commencement of thiopurines 
was significantly associated with decreased colectomy rate (HR 0.13) on multivariate analysis and 
a 90% reduction of probability of colectomy using the propensity score model. Thus, to prevent 
one colectomy at 5 and 10 years after UC diagnosis, approximately 18 and 12 patients, 
respectively, need early treatment with thiopurines. Although thiopurines may cause some short 
and long term side effects [29], colectomy is also associated with 2-4% in-hospital mortality and 
30% risk of surgical and infection complication rates [25, 30]. Colectomy can also result in diarrhea, 
stomal hernia and pouchitis and increase health-care cost and affect quality of life. In a previous 
population based study, early thiopurine maintenance  resulted in a 71% reduction in the rate of 
colectomy compared with use for a shorter period of time [31]. Contrary to our findings, this 
beneficial effect was not observed in early thiopurines users defined as treatment initiation within 
the first year of diagnosis. The difference with our study findings could be explained in part by 
differing definitions of early commencement of thiopurines and that our study also required 
medication maintenance of 6-months or more. Commencing thiopurines in the first year of 
diagnosis is usually reserved for subjects with severe adverse phenotypes most likely to require 
subsequent surgery. Our study also excluded patients who had emergency colectomy at diagnosis, 
where there was no chance to use thiopurines as a maintenance agent. In our study, by correcting 
for all confounder variables, the propensity score matching clearly showed a beneficial effect of 
thiopurines in decreasing colectomy rate.  
 
In 20.1% of patients with proctitis or left sided colitis, disease extent progressed proximally and 
was associated with 2.2 fold increased risk of colectomy, consistent with other studies [3]. Early 
thiopurine maintenance was associated with reduced risk of disease progression (71%) using 
Chapter 3  
Page | 
Early Thiopurine Therapy in Ulcerative colitis  
68 
propensity score matching. A previous meta-analysis also showed azathioprine to be effective in 
the maintenance of remission, endoscopic improvement and mucosal healing [21].  
 
Strengths of this study include the large sample size, long duration of follow up, and thoroughness 
of disease characterization at the time of diagnosis. Furthermore, meticulous monitoring and 
validation of data capture ensured that the timing of thiopurine initiation and medication was 
precisely captured. Our study method was also more robust than studies using insurance data, 
hospital coding or population data where patient and disease characteristics, medication dose and 
adherence and indication for colectomy cannot be verified with certainty. Unlike previous 
publications [24, 25], this study also sought to eliminate type II biases by propensity matching. 
Additionally, it conforms to evidence-based management and case definitions, which may not be 
found in insurance data, hospital coding, or de-identified data. We also used two robust and 
objective endpoints of disease being proximal progression of disease based on endoscopy data 
and colectomy.  
 
There are limitations of this study. First, the study population was from a single geographical 
region and might limit generalizability. However, this was an established and well-characterized 
cohort across several ambulatory clinics and private rooms that had been validated against other 
IBD endpoints with long duration of follow up [6, 8, 14, 15].  Second, changing treatment 
paradigms and diagnostic methods over time may be responsible for the differences in colectomy 
rate. However, accounting for the decade of diagnosis in the multivariate analysis and propensity 
score matching excluded diagnostic era as an independent predictor for colectomy. Third, this was 
a cohort study and did not test the effects of thiopurines on surgery using a prospective 
randomized controlled trial (RCT) design. A RCT that tests thiopurine in reducing colectomy rates, 
however, would require a large sample size and prolonged patient-years of follow up in order to 
collect sufficient colectomy rates and would not be practical. The use of biological agents would 
confound the data. The inclusion of patients who started and maintained thiopurines after 5 years 
into the non-exposed arm, would have provided survival benefit to this group of patients. Finally, 
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our studies may underestimate the potential efficacy of thiopurines as therapeutic drug 
monitoring of 6-thioguanine nucleotide (6-TGN) levels were not consistently performed during the 
study period. Thus, our data may be an underestimation of the efficacy of thiopurines, and the 
true beneficial effect of thiopurines on UC patients is at least as good as those presented.  
In conclusion, early thiopurine maintenance for more than 6 months within 5 years of diagnosis of 
UC was associated with a significant reduction in the risk of colectomy and proximal progression 
of disease. These findings were consistent regardless of the decade of diagnosis after propensity 
matching, suggesting that a drug-induced beneficial effect is seen.  
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Table 3.1 Demographics and patient characteristics at time of diagnosis 
 
 
 
 
 
  
 
Total  
(1970-2009) 
Group A  
(1970-1979) 
Group B 
 (1980-1989) 
Group C 
 (1990-1999) 
Group D  
(2000-2009) 
P 
No of patients 982 138 292 237 315 
 
Median follow up 
(interquartile range),yr 
11 (5-20) 24 (18-34) 18 (7-24) 14 (10-17) 4 (2-7) <0.0001 
Patient-years of follow up 12879 3548 4796 3069 1466 
 
Gender, N (%) 
     
0.78 
  Men 515 (52.4) 74 (53.6) 158 (54.1) 118 (49.8) 165 (52.4) 
 
Age, N(%) 
     
0.07 
  Less than 16 year (A1) 56 (5.7) 12 (8.7) 21 (7.2) 14 (5.9) 9 (2.9) 
 
  Between 17 and 40 year (A2) 575 (58.6) 72 (52.2) 165 (56.5) 149 (62.9) 189 (60.0) 
 
  Age more than 40 years (A3) 351 (35.7) 54 (39.1) 106 (36.3) 74 (31.2) 117 (37.1) 
 
Disease extent, N (%) 
     
<0.0001 
  Proctitis (L1) 286 (29.2) 25 (18.1) 74 (25.4) 74 (31.2) 113 (35.8) 
 
  Left sided colitis (L2) 424 (43.2) 53 (38.4) 136 (46.7) 105 (44.3) 130 (41.3) 
 
  Pancolitis (L3) 271 (27.6) 60 (43.5) 81 (27.8) 58 (24.5) 72 (22.9) 
 
  Not documented 1      
Smoking status, N (%) 
     
0.50 
  Current smokers 54 (10.6) 5 (18.5) 6 (9.5) 17 (11.5) 26 (9.6) 
 
  Ex-smokers 92 (18.1) 5 (18.5) 8 (12.7) 23 (15.5) 56 (20.7) 
 
  Never-smokers 363 (71.3) 17 (63.0) 49 (77.8) 108 (73.0) 189 (69.7) 
 
  Not documented 473 
     
Extraintestinal, N(%) 
     
0.21 
  Yes 154 (15.7) 23 (16.7) 35 (12.0) 43 (18.1) 53 (16.8) 
 
  No 828 (84.3) 115 (83.3) 257 (88.0) 194 (81.9) 262 (83.2) 
 
  Not documented 0 
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Table 3.2 Drug therapy during follow-up grouped according to decade of diagnosis (N [%] within 
time period 
 
 
 
 
  
 
Total 
 (1970-2009) 
Group A 
(1970-1979) 
Group B  
(1980-1989) 
Group C  
(1990-1999) 
Group D 
 (2000-2009) 
P 
Long-term 
corticosteroid 
372 (37.9) 59 (42.8) 124 (42.6) 90 (38.0) 99 (31.4) 0.021 
Mesalazine 949 (96.6) 136 (98.6) 286 (97.9) 228 (96.2) 299 (94.9) 0.107 
Anti-TNF 25 (2.5) 0 (0) 2 (0.7) 4 (1.7) 19 (6.0) <0.0001 
Thiopurines 
Exposure  
177 (18.0) 10 (7.2) 27 (9.2) 53 (22.4) 87 (27.6) <0.0001 
thiopurines 
maintenance  
127 (12.9) 7 (5.1%) 19 (6.5) 37 (15.6) 64 (20.4) <0.0001 
Early 
thiopurines 
83 (8.5) 1 (0.7) 7 (2.4) 18 (7.7) 57 (18.3) <0.0001 
Median time to 
starting 
thiopurines 
(years, IQR) 
3 (1-9) 23 (14-30) 10 (3-14) 6 (2-11) 2 (1-4) <0.0001 
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Table 3.3 Factors Affecting time to Initiation of Thiopurine Therapy in UC on Cox Proportional 
Hazard Regression 
 
Covariant Univariate Multivariate 
 HR (95% CI) P HR (95% CI) P 
Gender 0.86 (0.64-1.15) 0.31   
Age at diagnosis  0.98 (0.97-0.99) <0.0001 0.98 (0.98-0.995) 0.002 
Disease extent   <0.0001  <0.0001 
Proctitis (E1) 0.35 (0.22-0.56) <0.0001 0.37 (0.23-0.60) <0.0001 
Left-sided (E2) 0.84 (0.61-1.15) 0.28 0.72 (0.52-0.99) 0.044 
Pancolitis(E3) Reference  Reference  
Extra-intestinal 1.33 (0.93-1.91) 0.12   
Mesalazine use 5.89 (0.84-42.02) 0.08   
Long-term steroids use 5.46 (3.84-7.77) <0.0001 5.19 (3.60-7.45) <0.0001 
Anti-TNF use 9.60 (6.15-14.98) <0.0001 2.28 (1.43-3.64) 0.001 
Decade of diagnosis   <0.0001  <0.0001 
   1970-1979 0.44 (0.20-0.96) <0.0001 0.03 (0.01-0.06) <0.0001 
   1980-1989 0.10 (0.06-0.17) <0.0001 0.08 (0.05-0.13) <0.0001 
   1990-1999 0.36 (0.25-0.53) <0.0001 0.33 (0.23-0.49) <0.0001 
   2000-2009 Reference    
Excluded from the model mesalazine use (p=0.28)  
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Table 3.4 Factors Affecting Time to first intestinal resection on Multivariate Cox Proportional 
Hazard regression 
 
Covariant Univariate Multivariate 
 HR (95% CI) P HR (95% CI) P 
Gender 0.79 (0.52-1.18) 0.25   
Age at diagnosis  1.0 (0.99-1.01) 0.99   
Disease extent 
  Proctitis (E1) 
  Left-sided (E2) 
  Pancolitis (E3)  
 
0.12 (0.06-0.25) 
0.26 (0.16-0.41) 
Reference                                
<0.0001 
<0.0001 
<0.0001 
 
0.18 (0.09-0.40) 
0.27 (0.17-0.42) 
Reference 
<0.0001 
<0.0001 
<0.0001 
EIM 0.99 (0.59-1.69) 0.99   
Smoking ever 1.55 (0.76-3.17) 0.23   
Early thiopurine 
maintenance  
0.29 (0.07-1.20) 0.09 0.13 (0.03-0.55) 0.006 
Mesalazine use 1.26 (0.31-5.10) 0.75   
Long-term steroids use 6.14 (3.72-10.16) <0.0001 4.91 (2.92-8.26) <0.0001 
Anti-TNF use 3.58 (1.65-7.74) 0.001 2.52 (1.13-5.60) 0.02 
Decade of diagnosis   0.03  0.11 
   1970-1979 1.40 (0.65-2.98) 0.39 0.65 (0.29-1.43) 0.28 
   1980-1989 2.11 (1.01-4.07) 0.03 1.23 (0.62-2.42) 0.55 
   1990-1999 1.07 (0.51-2.25) 0.86 0.79 (0.37-1.70) 0.54 
   2000-2009 Reference    
EIM=extra-intestinal manifestation 
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Supplement table 3.1: Types of first major abdominal surgery performed for UC at any time during 
follow up 
 
Supplement Table 1. Types of first major abdominal surgery performed for UC at any time during 
follow up  
Procedure type N (%) 
Subtotal colectomy & ileorectal anastomosis 12 (10.3) 
Total colectomy and ileostomy 63 (54.3) 
Total colectomy and pouch formation 32 (27.6) 
Subtotal colectomy and mucous fistula formation  1 (0.9) 
Right hemicolectomy   5 (4.3) 
Anterior resection 2 (1.7) 
Segmental resection  1 (0.9) 
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Figure 3.1 Kaplan-Meier curve showing cumulative probability of Thiopurine use according to 
decade of diagnosis in patients with UC (p<0.0001). 
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Figure 3.2 Kaplan-Meier curve showing (a) cumulative probability of colectomy, (b) in the different 
decades of diagnosis 
(a). 
 
(b) 
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Figure 3.3 Kaplan-Meier curve showing cumulative probability of colectomy in early thiopurines 
maintenance after adjusting for confounders. 
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Figure 4. Kaplan-Meier curve showing cumulative probability of disease progression (a) according 
to the extent of disease on diagnosis and (b) with early thiopurines maintenance after adjusting 
for confounders.  
(a) 
 
(b) 
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CHAPTER 4 (STUDY 3) IMPACT OF CONCOMITANT USE OF THIOPURINES, 
ON THE CLINICAL RESPONSES AND TIME TO FAILURE OF ADALIMUMAB 
 
 
 
 
 
 
 
This chapter is presented as a published journal article, “Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in 
Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or 
Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease” in 
manuscript format  
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Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab is more 
effective than sub-therapeutic thiopurine based combination therapy or adalimumab 
monotherapy during induction and maintenance in patients with long standing Crohn’s disease.  
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4.1 ABSTRACT 
 
BACKGROUND AND AIMS  
The benefit of concomitant immunomodulation (CIM) with adalimumab (ADA) in Crohn’s disease 
is poorly understood. We aimed to compare ADA monotherapy with combination therapy with 
thiopurines, stratified by thioguanine nucleotides (TGNs). 
 
METHODS 
Retrospective observational study of ADA induction and maintenance. Thiopurines were classified 
according to TGNs (>235 pmol/8x108RBC therapeutic). 
 
RESULTS  
At induction, response was more frequent in combination than ADA monotherapy (83 vs 61%, p = 
0.02) and with therapeutic compared to sub-therapeutic TGNs (87 vs 70% p = 0.011). Amongst 
280 maintenance semesters in 91 patients; remission was higher with combination than 
monotherapy (81 vs 60%, p < 0.0001) and therapeutic vs sub-therapeutic TGNs (85 vs 58%, p = 
0.004). Therapeutic TGN (OR 4.32, 95% CI: 1.41–13.29, p = 0.01) and albumin (OR 1.09, 95% CI: 
1.01–1.18, p = 0.03) were predictors of response to induction. Therapeutic TGN (OR 3.71, 95% CI: 
1.87–7.34, p < 0.0001) and ileal disease (OR 0.21, 95% CI: 0.08–0.57, p = 0.002) were predictors 
of remission semesters. CIM at induction was associated with longer time to failure (69 vs 36 
months, p = 0.009). Therapeutic TGN at induction (p = 0.03) and male gender (p = 0.026) were 
associated with time to failure. 
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CONCLUSION 
Combination therapy was superior to ADA monotherapy for induction and during maintenance. 
This benefit was increased further when thiopurines resulted in therapeutic TGNs. Early use of 
adequately dosed thiopurines (≥3 months prior to starting ADA) was associated with improved 
clinical outcomes. 
Keywords: Crohn’s disease, thiopurine, combination therapy, adalimumab 
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4.2 INTRODUCTION  
 
Adalimumab, (ADA, Humira, Abbott Laboratories, Abbott Park, IL) a fully humanized monoclonal 
IgG antibody directed against tumor necrosis factor alpha, is effective at inducing and maintaining 
remission in patients with moderate-to-severe Crohn’s disease.1-5 However, a proportion of 
patients fail to respond to ADA. Of those that do respond, approximately 30% lose response by 12 
months, with a further 10% losing response annually thereafter.5-7 Accordingly, there is a need to 
understand whether there are factors that are associated with response and loss of response to 
improve outcomes. 
 
Immunogenicity is a well-recognized mechanism implicated in ADA failure8. Antibodies to ADA 
have been shown to influence the pharmacokinetics of ADA, leading to increased drug clearance 
and lower ADA levels.9 The use of concomitant immunomodulation, (CIM) with anti-TNF agents 
decreases anti-drug antibody formation.10-12 In the case of infliximab, (IFX) combination therapy is 
superior to monotherapy, both for patients with Crohn’s disease and those with ulcerative colitis 
UC.11-13 However, there is less evidence for a similar effect with ADA. A recently published 
prospective open-label study of 176 treatment naïve patients with moderate to severe CD 
randomized to ADA monotherapy compared to combination therapy with azathioprine found no 
difference in rates of clinical remission at week 2614. Further, there were no differences in the 
proportion of patients meeting the primary endpoint when patients were stratified according to 
week 12 thioguanine nucleotide threshold of 250pmol/8 x 108 red blood cell (RBC), (p = 0.13). 
However, they found significantly higher endoscopic remission at week 26 in the combination 
group, indicating likely benefit of combination therapy. Further evidence regarding the need for 
CIM when using ADA is based on sub-analysis of randomized controlled trials and retrospective 
studies.8,15 The results of these studies are conflicting, suggesting that further data would be of 
use. Studies assessing whether the intensity of CIM, (in the case of thiopurines measured using 6-
thioguainine nucleotide metabolites (TGN)) is of importance are lacking, an area recently 
addressed in two IFX-treated cohorts.16,17  
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The aim of this study was, therefore, to investigate the influence of CIM on clinical outcomes in a 
well characterized and prospectively assessed cohort of Crohn’s disease patients treated with 
ADA. In addition, we aimed to assess whether therapeutic TGN concentrations were associated 
with improved outcomes compared with sub-therapeutic TGNs in patients on thiopurine 
combination therapy. 
 
4.3 METHODS 
 
STUDY DESIGN 
 
We performed a retrospective single-centre cohort study of consecutive patients with moderate-
to-severe Crohn’s disease, who commenced ADA at Guy's and St. Thomas' Inflammatory Bowel 
Disease Centre between January 2006 and June 2013. 
 
STUDY POPULATION 
 
The diagnosis of Crohn’s disease was based on standard endoscopic, histological and radiological 
criteria.18 Only patients who commenced ADA at our centre were included. Data were collected 
prospectively from January 2009 through our Virtual Biologic Clinic which has been  described 
previously.19 Within this setting, patients are reviewed prior to commencing ADA and 
subsequently every 3-6 months, unless indicated earlier. All other data were retrieved from the 
electronic patient record. 
 
Thiopurines (azathioprine (AZA), mercaptopurine (MP) and thioguanine) or Methotrexate (MTX) 
were commenced at the treating physician’s discretion. AZA and MP were initially dosed according 
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to body weight (2-2.5mg/kg AZA, 1-1.5mg/kg MP) after measurement of thiopurine-S-
methyltransferase (TPMT) activity20-22 with dose reduction by 50% in TPMT heterozygotes.23 We 
routinely measure thiopurine metabolites in all patients (TGN and methylated metabolites)24 four 
weeks after starting therapy to guide dose adjustment; a TGN of 230-450 pmol/8x108RBC is 
considered therapeutic.25 Patients with sub-therapeutic TGNs, evidence of hepatotoxicity or 
intolerance in conjunction with a metabolite profile consistent with hypermethylation, (defined as 
methylated metabolites to TGN ratio > 11:1) were changed to allopurinol 100mg co-prescription 
with thiopurine dose reduction to 25-33% of the original dose.26 During maintenance TGNs are 
routinely performed in patients every 6-12 months. MTX was dosed at 15-25mg weekly orally with 
folic acid supplementation27 and thioguanine at 20-40mg daily. 
 
Biologics were started as a step-up therapy in patients who either failed or intolerant of 
immunomodulators. ADA was initiated as the first line biologic or after failure of IFX. All patients 
initiated ADA at standard induction dosing, (160mg/80mg weeks 0 and 2) followed by 
maintenance (40mg every other week). In those with an incomplete response after induction or 
secondary loss of response, ADA was intensified to 40mg each week. Dose reduction back to 40mg 
every other week was considered after attainment of remission, based on a combination of 
clinical, biochemical, endoscopic and radiological parameters.  
 
ASSESSMENT OF RESPONSE – INDUCTION 
 
Response to induction was assessed at 12 weeks by physician global assessment after 
consideration of clinical activity, (Harvey-Bradshaw Index28 (HBI)) biomarkers (C-reactive protein, 
(CRP), faecal calprotectin) and imaging or endoscopy, where available. HBI of <4 , CRP < 5 mg/L 
and calprotectin <50 mg/g were considered as markers of response. Patient response was 
assessed and documented by at least 2 or more experienced IBD physicians after considering all 
available parameters.  
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Patients maintained on a stable dose of immunomodulator ≥ 3 months prior to ADA induction and 
who continued for a ≥ 6 months after induction were defined as CIM at induction. All other 
patients were classified as not being on CIM at induction. Patients taking thiopurines were further 
classified according to TGN levels; > 235 was considered therapeutic.  
 
ASSESSMENT OF RESPONSE – MAINTENANCE 
 
Beginning after the first 12 months of treatment, patients were assessed for long-term clinical 
response, per 6-monthly semesters. Semesters with ≥ 3 months of CIM therapy were considered 
CIM semesters. Patients on thiopurines were again stratified according to TGNs measured from 
each semester, where available.  
Semesters were classified per one of three definitions:  
Flare semester: active clinical disease resulting in treatment intensification (ADA dose escalation, 
new corticosteroids or addition of CIM), hospital admission due to active Crohn’s disease, new 
perianal disease or Crohn’s disease-related surgery not leading to ADA withdrawal.  
Remission semester: semester without a flare either on every other week or weekly dosing.  
Failure semester: Failure, defined as withdrawal of ADA due to primary non-response, secondary 
loss of response despite dose-intensification, or due to development of adverse effects or 
complications.  
 
FACTORS ASSOCIATED WITH CLINICAL RESPONSE 
 
 Covariates that were assessed for response to induction, ADA failure, dose intensification and 
semester outcomes included: gender, disease duration, age at diagnosis, disease location and 
behaviour as per Montreal classification29, smoking status, weight, previous anti-TNF exposure, 
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previous surgery, CIM 3 ≥ months prior to starting therapy, CIM status during semester, and CRP 
and Harvey-Bradshaw Index at commencing ADA. Interactions between weight and need for ADA 
dose intensification were also explored. 
 
STATISTICAL ANALYSIS 
 
Categorical variables are presented as number and percentage, and quantitative data as mean 
with standard deviation or median with interquartile range, as appropriate. Between group 
comparisons were performed using Pearson’s Chi-squared, independent sample t-test, or Mann–
Whitney U test. Multivariate analysis was performed using Cox regression for time to failure and 
binary logistic regression for factors associated with induction outcome, dose escalation and 
semesters of remission. Covariates identified a priori with p < 0.1 on univariate analysis were 
entered into a multivariate backward stepwise model. Variables with p < 0.05 were retained in the 
final model and reported as adjusted hazard ratios (HRs) in the Cox regression and odds ratios 
(ORs) in logistic regression with 95% confidence intervals (CIs). Time to ADA failure was calculated 
using Kaplan-Meir survival analysis and comparisons between groups were made using the log-
rank test.  Two-sided P-values < 0.05 were considered significant. Statistical analyses were carried 
out using SPSS v23.0 (SPSS Inc., Chicago, IL). 
 
ETHICAL CONSIDERATION 
According to the guidelines of the U.K. Health Research Authority as the data collected were done 
so as part of routine clinical care and were evaluated retrospectively, ethical approval was not 
required.30 
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 4.4 RESULTS 
 
PATIENT CHARACTERISTICS 
 
156 patients commenced ADA between January 2006 and June 2013; 123 met inclusion criteria 
for the induction analysis (Figure 4.1). Patient characteristics are shown in Table 4.1. CIM was 
prescribed for ≥ 3 months prior to starting ADA in 77/123 (63%); thiopurines were used in 67/77, 
MTX in 6, thioguanine in 3 and mycophenolate mofetil in 1. 57 and 59% of patients had previously 
been exposed to anti-TNF in the CIM, and no CIM cohorts, respectively. No significant differences 
in baseline CRP, (p = 0.49), albumin (p = 0.19) or Harvey-Bradshaw Index (p = 0.052) were observed 
between CIM and no-CIM groups. Follow-up was similar in both groups (20 vs 22 months, p = 0.4) 
 
280 semesters amongst 91 patients were available for the maintenance analysis; 201 (72%) were 
classified as CIM semesters (143 with immunomodulators ≥ 3 months prior to starting ADA vs. 58 
who were not) compared with 79 (28%) ADA monotherapy semesters (20 in patients treated with 
immunomodulators ≥ 3 months prior to starting ADA vs. 59 who were not) (p < 0.001). Thiopurines 
were used in 84% of semesters, of these TGNs were available in 92%. 135 (88%) were therapeutic 
and 19 (12%) sub-therapeutic.  
 
PRIMARY RESPONSE  
 
Complete response was seen in 92/123 (75%) at week 12; The mean CRP improved from 18.8 mg/L 
to 4.4 mg/L and the HBI from 7.5 to 1.6 (Supplement 1a). Among complete responders’ clinical 
remission with HBI £ 4 was seen among 92% and biochemical remission with CRP normalization 
(<5mg/L) in 84%. A total of 76.5% achieved both clinical and biochemical remission (Supplement 
1b). The rate of primary non-response was significantly lower among patients treated with CIM 
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(12 vs 30%, p = 0.02) (Figure 4.2).  In addition, complete response was also higher amongst those 
treated with CIM compared to those not treated with CIM (83 vs 61%, p = 0.02).  
 
Most, (97%) patients treated with thiopurines had TGNs measured prior to starting ADA; 16% were 
sub-therapeutic. Response to induction was seen in 48 (87%), 7 (70%) and 28 (61%) of those with 
therapeutic TGNs, sub-therapeutic TGNs and no CIM, respectively (p = 0.011) (Figure 4.3). 
 
In univariate analysis CIM use at induction and serum albumin were significantly associated with 
response at week 12 (Table 4.2). On multivariate analysis, therapeutic TGN levels (OR 4.32, 95% 
CI: 1.41-13.29, p = 0.01) and albumin level (OR 1.09, 95% CI: 1.01-1.18, p = 0.03) were independent 
predictors of response to induction. (Table 4.2). 
 
SEMESTER ANALYSIS 
 
Of 280 semesters, every other week dosing was observed in 200 (72%) and weekly in 80 (29%). A 
similar proportion of CIM and non-CIM semesters were observed in each dosing regimen (every 
other week 74 vs weekly 68%, p = 0.31). More CIM semesters were classified as remission 
compared to non-CIM semesters (81 vs 60%, p < 0.0001, Figure 4.3). Considering CIM semesters, 
patients with therapeutic TGNs were more likely to be in remission compared to those with sub-
therapeutic TGNs (86 vs 58%, p = 0.004) (Figure 4.4.) 
 
In univariate analysis, ileal location (p = 0.001), extra-intestinal manifestations of disease (p = 0.03, 
and semesters with therapeutic TGNs (p < 0.0001) were associated with remission (Table 4.3). 
These covariates remained significant after multivariate analysis (ileal disease location: OR 0.21, 
95%CI: 0.08-0.57, p = 0.002, therapeutic TGN: OR 3.71 95% CI: 1.87-7.34, p < 0.0001). 
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FACTORS ASSOCIATED WITH ADA FAILURE  
 
35/123 (29%) ceased ADA during the study; 5/35 withdrew due to sustained clinical remission.  A 
further 2/35 prescribed ADA to down-stage inflammation pre-operatively were not continued 
post-operatively.  Hence, 28 patients were subsequently analyzed with regards to ADA failure. 
Mean time to failure was 58 months (95% CI: 50.5–66.3). CIM ≥ 3 months prior to ADA was 
associated with longer time to failure compared to those not treated with CIM (68.5 vs 35.7 
months, p = 0.009 log rank) (Figure 4.5)   
 
On univariate analysis, male gender (p = 0.033) and therapeutic TGN (p = 0.03) were associated 
with time to failure (Table 4.4). Therapeutic TGN ≥ 3 months prior to ADA (HR 0.37, 95%CI: 0.15–
0.89, p = 0.026) and male gender (HR 0.39, 95% CI: 0.17–0.91, p = 0.028) were independently 
associated with time to failure on Cox regression analysis. Dose escalation did not predict 
subsequent ADA failure (p = 0.20). CIM ≥ 3 months prior to ADA was independently associated 
with time to failure (HR 0.37, 95% CI 0.17–0.81, p = 0.012).  
 
DOSE ESCALATION AND FACTORS ASSOCIATED WITH DOSE ESCALATION 
 
ADA was escalated to weekly dosing in 34/123 (28%) patients. Mean time to dose escalation was 
12.5 months (SD 8.7). All base line characteristics were considered for univariate analysis 
(Supplement 2). On multivariate analysis CIM ≥ 3 months prior to starting adalimumab was not 
associated with time to dose escalation (HR 0.55, 95%CI: 0.28-1.09, p = 0.088). Baseline CRP (HR 
1.01, 95% CI 1.001–1.024, p = 0.035) and 5-ASA treatment at ADA initiation (HR 3.97, 95%CI 1.68–
9.40, p = 0.002) were significant independent predictors associated with time to dose escalation 
on multivariate analysis.  
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ADVERSE EVENTS 
 
Serious adverse events occurred in 5 patients during the study. 2 malignancies occurred; 
metastatic breast cancer after 19 months of combination treatment with thioguanine and ADA 
and transitional cell carcinoma of the bladder after 27 months of ADA monotherapy. A 25-year-
old male treated with thioguanine and ADA developed primary EBV infection and recovered after 
discontinuing both drugs. Two patients developed intra-abdominal sepsis, 4 and 10 months into 
treatment; one was on ADA monotherapy, the other on combination therapy with azathioprine.  
 
4.5 DISCUSSION 
 
We have demonstrated that in patients with Crohn’s disease starting ADA, combination therapy 
with an immunomodulator was associated with higher rates of clinical response after induction 
compared to ADA monotherapy, and observed lower rates of subsequent ADA failure. During 
maintenance, combination therapy was associated with a decrease in the proportion of flare 
semesters. We assessed the relationship of thiopurines stratified according to TGN levels, not 
previously reported in the literature, and found that sub-therapeutic TGNs at induction and during 
maintenance therapy were associated with worse clinical outcomes and an increased risk of ADA 
failure compared to patients with therapeutic TGNs. 
The situation regarding combination therapy in patients taking infliximab has been studied 
extensively. In a retrospective analysis of 584 semesters amongst 121 patients with IBD, Sokol et 
al found a significantly decreased incidence of flares (32 vs 19%), perianal complications (12 vs 
4%), and mean CRP (11 vs 9%) in those treated with combination therapy compared with infliximab 
monotherapy.31 Many of the patients in this cohort started infliximab upon failure of 
immunomodulator therapy and continued CIM after initiating infliximab, suggesting that there is 
a benefit of combination therapy in all patients starting IFX, not just those naïve to 
immunomodulators. This has also been supported by a recent meta-analyses of patient level data 
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in the biologic registration trials.32 In addition, combination therapy has been shown to improve 
rates of deep remission, (defined as clinical remission together with normalization of CRP and 
mucosal healing) compared to infliximab monotherapy in patients who were previously naïve to 
both drugs (65 vs 25%, p = 0.037).17 
Although the benefits of combination therapy with infliximab appear robust, evidence to support 
the same benefit with ADA is relatively sparse. The same meta-analysis of randomized controlled 
trials demonstrating a benefit of combination therapy in induction of clinical remission at 6 months 
with IFX, found no such association for combination therapy with ADA (OR 0.88, 95%CI: 0.58–
1.35).32 A recent prospective study randomizing treatment naïve patients with moderate-to-
severe Crohn’s disease to either ADA monotherapy, or combination therapy with a thiopurine 
found no difference in clinical remission at week 26 between the two treatment arms (72 vs 68%) 
although an improvement in endoscopic activity at week 26 and higher ADA trough levels were 
observed in those treated with combination therapy.14  
Conversely, a recent meta-analysis amongst patients with CD found that ADA monotherapy was 
slightly inferior to combination therapy for induction of remission (OR 0.78, 95%CI: 0.64–0.96, p= 
0.02) although no such benefit was seen for maintenance of clinical remission (OR 1.08, 95% CI: 
0.79–1.48, p = 0.48) nor was combination therapy superior to monotherapy in terms of need for 
dose escalation (OR 1.13, 95%CI: 0.69–1.85, p = 0.62).33  
Our study builds on previously published open data. A retrospective study from two large centres 
described 207 patients with Crohn’s disease and found that CIM maintained for 3 months or more 
within 6 months of initiating ADA was associated with a lower risk of ADA failure and fewer flare 
semesters during maintenance.15 CIM was not, however, associated with improved rates of 
response to induction therapy, nor was ongoing CIM associated with fewer semesters of flare nor 
with a lower risk of ADA failure.  Semesters in which ADA was dosed weekly, rather than every 
other week, were classified as flares, even if the patient remained well during the semester, which 
may have influenced these results. It is recognized that secondary loss of response occurs in a 
significant proportion of patients during ADA maintenance and that dose escalation can recapture 
response in many.6 It is possible to argue that patients who regain response on dose escalation 
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and remain well on weekly dosing are, therefore, not treatment failures but, rather, represent a 
subgroup of patients who require higher dosing to achieve therapeutic drug levels to maintain 
remission.34 In the current study, therefore, a semester requiring dose escalation was classified as 
a flare; subsequent semesters were classified according to clinical status and were not 
automatically recorded as flare semesters based on the need for weekly dosing. Interestingly, dose 
escalation was not associated with time to failure, supporting our study design.  
For the first time, we report the association between adequate dosing of thiopurines (TGN > 235 
pmol/8x108RBC) and clinical response. We found significantly higher response rates in patients 
with therapeutic compared with sub-therapeutic TGNs at both induction (88 vs 70%) and during 
maintenance (85 vs 58%). In this regard, data are beginning to emerge demonstrating that the 
intensity of concomitant immunomodulation influences the pharmacokinetics of anti-TNF therapy 
and subsequent clinical outcomes. A Dutch group found that MTX reduced immunogenicity to IFX 
in a dose-dependent manner, with the odds of developing anti-drug antibodies being 0.36 (95% 
CI: 0.18–0.74) in the 5-10mg/week, 0.22 (95% CI: 0.10–0.46) in the 12.5-20mg/week and 0.14 
(95% CI 0.07–0.28) in patients on >22.5mg/week) relative to patients not treated with MTX.35 In 
addition, in a post-hoc analysis of the SONIC study, patients on combination therapy with 
azathioprine with an increase of 7 femtoliters in the mean corpuscular volume (delta MCV), used 
as a surrogate marker for therapeutic TGN levels, were more likely to achieve mucosal healing (75 
vs 47% for delta MCV >7, p = 0.017) and maintain therapeutic trough infliximab levels > 3 μg/mL 
at week 30 (68 vs 39% for delta MCV >7, p = 0.003).36 Similarly, in a cross-sectional analysis of 72 
patients with inflammatory bowel disease, IFX drug levels were higher amongst those on 
combination therapy with a thiopurine compared with IFX monotherapy (13 vs 4.8 μg/mL,) and a 
TGN cut-off of 125 pmol/8x108RBC best predicted a significantly higher IFX trough level.16 Taken 
together with the findings that higher anti-TNF drug levels are associated with improved rates of 
remission37,38 these findings suggest that the dose of thiopurine may be of significant importance.  
A recent Australia New Zealand Consortium cohort study comparing IFX/ADA with or without IM 
suggested that corticosteroids used at induction or in the preceding 12 months was associated 
with 9-13 times greater risk of flare semester during maintenance39. There was significantly higher 
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use of steroids at induction in the none-CIM arm in the current cohort. However, most of these 
patients were either intolerant of or failed IM therapy and steroids were used as a bridge to 
biologic therapy. Additionally there was no difference in steroid use between patents with 
therapeutic and sub-therapeutic TGN levels at induction ( 21.8% vs 37.5%, p=0.07).  
 
The utility of measuring TGN in patients taking thiopurines as combination therapy is perhaps even 
greater when one considers rates of non-adherence and the impact of hypermethylation. 
Adherence to thiopurines is a well-recognized problem in inflammatory bowel disease.40 Similarly, 
under dosing with thiopurines has been reported in 29% when weight based dosing is employed.24 
Thiopurine hypermethylation, whereby shunting occurs away from the therapeutic TGNs towards 
a methylated metabolite profile, is seen in 15-20% and is associated with an inability to achieve 
therapeutic TGN.41 Without thiopurine metabolite testing a large proportion of patients will fail to 
achieve a therapeutic TGN; the structured approach to optimisation of thiopurines in our cohort 
may explain why a greater benefit of CIM was observed compared with other cohorts. 
The development of antibodies against ADA has been implicated as a mechanism leading to 
secondary loss of response and treatment failure.42,43  Combination therapy can improve the 
pharmacokinetics of infliximab by increasing drug levels44 and by decreasing anti-infliximab 
antibody production (RR: 0.50, 95% CI: 0.42 – 0.59, p < 0.00001).44 A recent study demonstrated 
the beneficial effect of concomitant thiopurine in reducing immunogenicity, regardless of previous 
clinical response to thiopurines45. In a retrospective analysis of 536 samples collected from 148 
patients analyzed using a drug tolerant homogenous mobility shift assay, antibodies to ADA were 
detected in 20% after a median of 34 weeks8. CIM was associated with decreased antibody 
formation (HR: 0.23, 95% CI: 0.06–0.86) and antibodies were associated with future elevated CRP 
(p = 0.0013) and discontinuation of ADA due to loss of response (OR 3.04, 95%CI: 1.039–9.093). 
Such immunogenicity occurs early during ADA therapy. A prospective observational cohort study 
of 272 patients treated with ADA for rheumatoid arthritis found antibodies to ADA in 28% over a 
3 year follow-up; in 67% antibodies occurred within the first 28 weeks of therapy.46 Similarly, 
antibodies to IFX have also been found to occur early. In a prospective observational study of 125 
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patients with IBD, anti-drug antibodies occurred in 46% at a median time of 1.5 months (IQR 0.5–
5.5); 90% developed within 12 months and anti-drug antibody free survival was longer in patients 
taking combination therapy compared with IFX monotherapy (p = 0.003).47 These findings suggest 
that early concomitant immunomodulation, perhaps even prior to starting anti-TNF therapy is 
important, as has previously been shown in murine models.48  Thiopurines have a slow onset of 
action, with a mean time to response of 3.1 months.21 Therefore, it is possible that some of the 
beneficial effects of combination therapy may be greater in those patients who are established on 
therapy prior to starting ADA.  
Given the findings from our study (and some others) that early combination therapy is beneficial, 
and that immunogenicity occurs largely in the first 12 months of ADA therapy, a key question is 
whether combination therapy should be continued during maintenance. Such a decision must 
weigh up the benefits and risks of continued combination therapy against withdrawal to ADA 
monotherapy. In this regard, we demonstrated higher rates of remission semesters in those 
treated with CIM vs ADA monotherapy (81 vs 60%) and in those with therapeutic compared with 
non-therapeutic TGNs (85 vs 58%). Further, CIM use during a semester was an independent 
predictor of remission (OR 2.92, 95% CI: 1.62–5.25, p < 0.0001). Our results are in agreement with 
those from the Oxford/Liege cohort, where combination therapy beyond 6 months was associated 
with fewer semesters with flares (14 vs 36%, p = 0.02, OR = 0.31).15 Recent studies have called into 
question the benefit of continued concomitant immunomodulation during maintenance therapy, 
suggesting that a lower dose of thiopurine may be equally efficacious as full weight-based dosing.49 
We were unable to explore this association in the current study as only a small proportion of 
patients (3/65) were found to have TGNs <125. The benefits of combination therapy must, of 
course, be balanced with the risks particularly in light of recent safety signals regarding the use of 
thiopurines.50,51 
 
We acknowledge several limitations with the study. First patients were not randomized to 
combination therapy or ADA monotherapy, hence despite the groups being similarly matched in 
terms of phenotype, previous anti-TNF exposure and disease severity they are not directly 
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comparable. As we did not measure ADA drug levels or antibodies to ADA we cannot prove that 
the benefit seen with CIM was due to improvements in ADA pharmacokinetics and reductions in 
immunogenicity. Third, assessment of response to induction and during maintenance was made 
using a combination of Harvey-Bradshaw Index, CRP and fecal calprotectin. Fourth, a relatively 
high number of patients were treated with corticosteroids during induction (53%) which may 
contribute to the relatively high response rate seen overall (75%).  However, there was no 
difference in corticosteroid use in patients who had therapeutic and sub-therapeutic levels of TGN.  
Finally, a relatively small proportion of patients had sub-therapeutic TGNs during induction (15%) 
and maintenance (12%), hence the conclusion that response rates are superior with therapeutic 
compared with sub-therapeutic TGNs should be interpreted with caution until it has been 
confirmed in other cohorts. We acknowledge that this distribution of TGNs limited our ability to 
apply further relevant statistical methodology such as a quartile or ROC analysis. 
CONCLUSION 
 
Combination therapy was found to be superior to ADA monotherapy in this cohort of patients with 
moderate-to-severe Crohn’s disease with improved response at induction, more semesters in 
remission and a longer time to ADA failure. Further, adequately dosed thiopurines when used as 
concomitant immunomodulation was associated with improved clinical outcomes. We propose 
that, after carefully balancing the risk and benefit and noting the association of increased risks of 
lymphoma, non-melanoma skin cancer and possibly other malignancies,50 immunomodulators 
should be initiated early when considering ADA therapy, dosed to a TGN > 235, and continued 
during maintenance therapy. Further randomized controlled studies are needed that incorporate 
thiopurine metabolite testing during both induction and maintenance. 
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Table 4.1 Baseline characteristics at adalimumab (ADA) initiation (n = 123) 
 
Characteristic  CIM (n = 77) No CIM (n = 46) p value 
Male, number (%) 40 (51.9) 25 (54.3) 0.79 
Age at diagnosis, median (IQR) 21 (17-28) 22 (18-29) 0.32 
Disease duration years, median (IQR) 11 (4.5-16) 9 (3.5-17.2) 0.46 
Location L1:L2:L3 (%) 15.6; 19.5; 64.9 10.9; 28.3; 60.9 0.46 
Upper GI involvement (%) 16.9 19.6 0.71 
Behavior B1:B2:B3 (%) 36.4; 44.2; 19.4 37.0; 43.5; 19.5 0.99 
Perianal disease (%) 31.2 41.3 0.25 
EIM (%) 19.7 21.7 0.79 
Weight kg,  median (IQR) 66.0 (54.4-78.9) 69.5 (59.5-83.5) 0.35 
Current smoker (%) 10.6 22.0 0.28 
Family history (no:1st deg:other) (%) 90.3; 6.5; 3.2 84.6; 12.8; 2.6 0.54 
Prior surgery, number (%) 41(53.2) 18 (39.1) 0.13 
Perianal surgery, number (%) 13 (16.9) 7 (15.2) 0.81 
Steroids at ADA induction (%) 19.5 41.3 0.01 
5-ASA (%) 6.5 17.4 0.06 
Prior anti-TNF exposure (%) 
IFX/ADA/both (%) 
55.8 
50.0; 2.6; 3.9 
58.7 
45.7; 2.2; 10.9 
0.76 
0.52 
CRP mg/L mean (SD) 20.7 (28.5) 25.1 (30.3) 0.49 
Albumin (g/L) mean (SD) 42.3 (6.6) 42.0 (4.1) 0.20 
HBI, mean (SD) 7.1 (4.4) 9.0 (4.5) 0.05 
CIM: concomitant immunomodulation, ADA: adalimumab, EIM: extra-intestinal manifestation, CRP: c-reactive protein, HBI: 
Harvey-Bradshaw Index, SD: standard deviation, IQR: interquartile range 
 
 
  
Chapter 4  
Page | 
Combination therapy with thiopurine and adalimumab for CD 
104 
Table 4.2 Univariate and multivariate predictors of response at week 12 
 
 
 
  
Covariant  Univariate Multivariate 
 OR (95% CI) p  OR (95% CI) p 
Gender 0.51 (0.20-1.28) 0.15   
Age at diagnosis  1.02 (0.97-1.08) 0.46   
Disease duration at start of ADA  1.00 (0.95-1.05) 0.99   
Montreal location (reference L3) 
L1 
L2 
 
0.65 (0.18-2.31) 
0.73 (0.25-2.16) 
 
0.51 
0.57 
  
Montreal location L4 1.04 (0.32-3.43) 0.94   
Montreal behaviour (reference B3) 
B1 
B2 
 
1.22 (0.35-4.23) 
1.16 (0.35-3.85) 
 
0.76 
0.81 
  
EIM 1.91 (0.52-7.00) 0.33   
Weight (kg)  1.02 (0.98-1.05) 0.31   
Current smoker  0.83 (0.45-1.54)  0.55   
Family history of IBD 1.39 (0.36-5.33) 0.63   
Prior bowel resection 1.01 (0.41-2.49) 0.98   
Exposure to anti-TNF 1.02 (0.41-2.54) 0.97   
Steroids at induction 0.66 (0.25-1.73) 0.39   
5-ASA at induction 0.74 (0.19-2.94) 0.67   
CIM (reference no CIM) 
Sub-therapeutic TGN 
Therapeutic TGN 
 
3.94 (0.45-34.12) 
3.57 (1.24-10.26) 
 
0.21 
0.18 
 
3.36 (0.38-29.79) 
4.32 (1.41-13.29) 
 
0.28 
0.01 
CRP at induction 0.99 (0.98-1.00) 0.09 Removed  0.35 
Albumin at induction 1.08 (1.01-1.17) 0.03 1.09 (1.01-1.18) 0.03 
HBI at induction 0.95 (0.86-1.05) 0.95   
ADA = adalimumab, EIM = extra-intestinal manifestation, IBD = inflammatory bowel disease, CIM = concomitant 
immunomodulation, TGN = thioguanine nucleotide, CRP = c-reactive protein, HBI = Harvey-Bradshaw Index 
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Table 4.3 Univariate and multivariate predictors of remission semesters 
 
 
 
 
  
Covariant Univariate Multivariate 
 OR (95% CI) p OR (95% CI) p 
Gender 1.69 (0.97-2.95) 0.06 1.77 (0.91-3.44) 0.09 
Age at diagnosis  0.99 (0.97-1.02) 0.72   
Disease duration at start of ADA 1.03 (0.99-1.07) 0.09 Removed  0.26 
Montreal location (reference L3) 
L1 
L2 
 
0.25 (0.11-0.56) 
0.57 (0.29-1.09) 
 
0.001 
0.09 
 
0.21 (0.08-0.57) 
0.50 (0.24-1.04) 
 
0.002 
0.064 
Montreal location L4 0.83 (0.43-1.59) 0.57   
Montreal behaviour (reference B3) 
B1 
B2 
 
0.54 (0.23-1.31) 
0.46 (0.20-1.07) 
 
0.17 
0.07 
 
Removed  
 
0.49 
0.25 
EIM 2.08 (1.07-4.07) 0.03 Removed  0.11 
Weight (kg) 1.00 (0.98-1.02) 0.87   
Current smoker  0.93 (0.63-1.36)  0.69   
Family history of IBD 0.97 (0.53-1.93) 0.97   
Prior bowel resection 0.91 (0.53-1.56) 0.73   
Prior perianal surgery 0.47 (0.24-0.91) 0.25 Removed 0.99 
Exposure to anti-TNF 0.79 (0.44-1.42) 0.44   
Steroids at induction 0.76 (0.43-1.33) 0.33   
5-ASA at induction 0.50 (0.24-1.03) 0.06 Removed 0.15 
CIM induction (reference no CIM) 
Sub therapeutic TGN 
Therapeutic TGN 
 
0.71 (0.24-2.05) 
1.58 (0.83-3.02) 
 
0.52 
0.17 
  
Semester CIM (reference no CIM) 
Sub therapeutic TGN 
Therapeutic TGN 
 
0.94 (0.34-2.58) 
3.91 (2.04-7.53) 
 
0.90 
<0.0001 
 
1.11 (0.37-3.26) 
3.71 (1.87-7.34) 
 
0.86 
<0.0001 
CRP at induction 0.56 (0.97-1.01) 0.56   
Albumin at induction 1.01 (0.86-1.06) 0.81   
ADA = adalimumab, EIM = extra-intestinal manifestation, IBD = inflammatory bowel disease, CIM = concomitant 
immunomodulation, TGN = thioguanine nucleotide, CRP = c-reactive protein, HBI = Harvey-Bradshaw Index 
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Table 4.4 Univariate and multivariate predictors of ADA failure 
 
 
 
 
  
Covariant  Univariate Multivariate 
 OR (95% CI) p OR (95% CI) p 
Gender (reference female) 0.42 (0.19-0.93) 0.03 0.39 (0.17-0.91) 0.028 
Age at diagnosis  0.99 (0.96-1.04) 0.94   
Disease duration at start of ADA 1.01 (0.97-1.06) 0.60   
Montreal location (reference L3) 
L1 
L2 
 
1.74 (0.63-4.80) 
1.34 (0.55-3.26) 
 
0.28 
0.51 
 
 
 
 
Montreal location L4 0.82 (0.45-2.75) 0.82   
Montreal behavior (reference B3) 
B1 
B2 
 
0.49 (0.17-1.39) 
0.84 (0.34-2.09) 
 
0.18 
0.71 
  
 
Perianal disease 1.15 (0.54-2.47) 0.72   
EIM 0.40 (0.12-1.32)  0.13   
Weight (kg) 0.98 (0.95-1.01) 0.18   
Current smoker  1.07 (0.64-1.78)  0.80   
Family history of IBD 0.32 (0.52-2.02) 0.23   
Prior bowel resection 0.73 (0.34-1.55) 0.41   
Prior perianal surgery 1.10 (0.42-2.89) 0.85   
Exposure to anti-TNF 1.19 (0.54-2.60) 0.67   
Steroids at induction 1.61 (0.76-3.42) 0.21   
5-ASA at induction 1.81 (0.73-4.48) 0.20   
CIM induction (reference no CIM) 
Sub-therapeutic TGN 
Therapeutic TGN 
 
0.31 (0.04-2.38) 
0.38 (0.16-0.91) 
 
0.52 
0.03 
 
0.42 (0.04-2.38) 
0.37 (0.15-0.89) 
 
0.263 
0.026 
CRP at induction 1.01 (0.99-1.02) 0.37   
Albumin at induction 0.98 (0.92-1.03) 0.40   
HBI at induction 1.00 (0.91-1.10) 0.99   
ADA dose escalation 0.46 (0.19-1.11) 0.08 Removed 0.203 
ADA = adalimumab, EIM = extra-intestinal manifestation, IBD = inflammatory bowel disease, CIM = concomitant 
immunomodulation, TGN = thioguanine nucleotide, CRP = c-reactive protein, HBI = Harvey-Bradshaw Index 
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Supplement Table 4.1 – (A) CRP and HBI based on response status at week 12. (B) CRP and HBI 
normalization based on response at week 12 
 
 
  
(A) 
Response   
 
(n) 
Pretreatment CRP 
(mg/L) 
Mean (median) 
Week 12 CRP 
(mg/L) 
Mean (median) 
Pretreatment HBI 
Mean (median) 
Week 12 HBI 
 
Mean (median) 
No response 31.97 (18.00) 32.66 (12.00) 8.68 (8) 9.32 (8) 
Partial response 20.00 (8.00) 9.81 (5.00) 7.13 (8) 4.63 (4) 
Complete response 18.77 (10.00) 4.35 (2.50) 7.49 (8) 1.61 (1) 
(B) 
 No response Partial response Complete response p 
HBI £ 4    n (%) 2 (10) 4 (50) 75 (92) P<0.0001 
CRP (<5mg/L)    n (%) 7 (30) 5 (63) 75 (84) P<0.0001 
CRP (<5mg/L) & HBI £ 4  
n(%) 
1 (4.8) 2 (25) 62 (76.5) P<0.0001 
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Supplement table 4.2: Univariate and multivariate predictors of ADA dose escalation 
 
 
  
Covariant  Univariate Multivariate 
 OR (95% CI) p OR (95% CI) p 
Gender (reference female) 1.18 (0.60-2.33) 0.63   
Age at diagnosis  1.01 (0.98-1.05) 0.57   
Disease duration at start of ADA 0.98 (0.94-1.02) 0.38   
Montreal location (reference L3) 
L1 
L2  
 
1.41 (0.52-3.81) 
1.64 (0.74-3.62) 
 
0.50 
0.22 
 
 
 
 
Montreal location L4 0.84 (0.35-2.04) 0.70   
Montreal behavior (reference B3) 
B1 
B2 
 
1.20 (0.46-3.14) 
0.97 (0.37-2.53) 
 
0.71 
0.94 
  
 
Perianal disease 1.04 (0.50-2.15) 0.92   
EIM 0.95 (0.43-2.12)  0.91   
Weight (kg) 0.99 (0.97-1.02) 0.89   
Weight at dose escalation (Kg) 1.01 (0.98-1.03) 0.64   
Current smoker  0.95 (0.58-1.57)  0.85   
Family history of IBD 1.31 (0.59-2.87) 0.51   
Prior bowel resection 0.84 (0.43-1.66) 0.62   
Prior perianal surgery 1.07 (0.44-2.63) 0.88   
Exposure to anti-TNF 1.37 (0.68-2.78) 0.38   
Steroids at induction 1.72 (0.86-3.45) 0.12   
5-ASA at induction 2.54 (1.15-5.65) 0.02 3.98 (1.68-9.40) 0.002 
CIM induction (reference no CIM) 
Sub-therapeutic TGN 
Therapeutic TGN 
 
0.23 (0.03-1.71) 
0.51 (0.23-1.09) 
 
0.15 
0.08 
Removed 0.30 
CRP at induction 1.01 (1.00-1.02) 0.03 1.01(1.001-1.02) 0.035 
Albumin at induction 0.98 (0.93-1.03) 0.33   
HBI at induction 1.05 (0.98-1.12) 0.20   
ADA dose escalation 0.46 (0.19-1.11) 0.08   
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Figure 4.1 Flow diagram of patient recruitment. ADA = adalimumab 
 
 
 
 
 
  
Chapter 4  
Page | 
Combination therapy with thiopurine and adalimumab for CD 
110 
Figure 4.2 Clinical response after induction comparing concomitant immunomodulation to 
adalimumab monotherapy. Complete response to induction was observed more frequently in 
patients treated with ADA and CIM compared to ADA monotherapy (83.1 vs 60.9%, p = 0.02) CIM 
= concomitant immunomodulation, ADA = adalimumab 
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Figure 4.3 Clinical response after induction stratified by TGN and ADA monotherapy. Complete 
response was observed more frequently in patients with therapeutic TGN vs sub-therapeutic TGN 
vs ADA monotherapy (87.3 vs 70.0 vs 60.9%, p = 0.011). TGN = thioguanine nucleotide, ADA = 
adalimumab monotherapy 
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Figure 4.4 Association between semester outcomes overall, and according to CIM and TGN status. 
CIM = concomitant immunomodulation, TGN = thioguanine nucleotide level 
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Figure 4.5 Time to adalimumab failure. Kaplan-Meier analysis illustrating time to ADA failure 
(months) in patients treated (n = 77) and not treated (n = 46) with CIM for ³3 months prior to 
commencing ADA (and continued for first 6 months). CIM = concomitant immunomodulation, ADA 
= adalimumab 
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CHAPTER 5  (STUDY 4) USE AND OF IMMUNOMODULATORS IN ELDERLY 
IBD PATIENTS AND ITS IMPACT ON SURGICAL OUTCOMES 
 
 
 
 
 
 
 
 
This chapter is presented as a published journal article, “Comorbidities Rather Than Age Are Associated with the Use 
of Immunomodulators in Elderly-onset Inflammatory Bowel Disease” in manuscript format.  
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5.1 ABSTRACT 
 
BACKGROUND AND AIMS 
The use of immunomodulators (IMs) is often avoided in elderly patients with inflammatory bowel 
disease (IBD) due to concerns about complications. Our aim is to compare the use of IMs in elderly 
and younger patients with Crohn’s disease (CD) or ulcerative colitis (UC) and identify markers that 
predict their use.  
 
METHODS 
In this retrospective cohort study, patients diagnosed with IBD from 1970 to 2009 were recruited 
from the “Sydney IBD Cohort”. Patients diagnosed at age ≥60 and between 16-40 were classified 
as ‘elderly-onset’ and ‘young-onset’ respectively.  
 
RESULTS 
Total of 255 elderly-onset patients (115 CD, 140 UC) and 1244 young-onset patients (657 CD, 587 
UC) were recruited. Most elderly-onset patients had colonic CD (61.4%), whereas young-onset 
patients had predominantly ileocolonic CD (42.8%, P<0.0001). Left-sided UC was the most 
common disease localisation for both elderly-onset (52.1%) and young-onset patients (42.2%, 
P=0.013). The cumulative probability of IM exposure at 5 years post diagnosis was significantly less 
in elderly-onset patients compared to young-onset patients for CD (20.0% vs 33.4%, P=0.0002) 
and UC (7.8% vs 13.4%, P=0.0007). Age at diagnosis was not associated with the time to IMs 
introduction. Charlson Comorbidity Index was shown to delay IM introduction in CD (HR 0.863, 
95%CI 0.787-0.946, P=0.002) and UC (HR 0.807, 95%CI 0.711-0.917, P=0.001). Early IM use was 
associated with reduced need for abdominal and perianal surgery in CD (HR 0.177, 95% CI 0.089-
0.351, P<0.0001).  
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CONCLUSIONS 
Comorbidity and not age at diagnosis is associated with IM introduction. Early IM is associated 
with reduced surgery in both young and elderly onset CD but not UC 
Keywords: inflammatory bowel disease; geriatric; elderly; ageing; immunomodulators; surgery 
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 5.2 INTRODUCTION 
 
Inflammatory bowel disease (IBD) comprising Crohn’s disease (CD) and ulcerative colitis (UC), are 
inflammatory disorders that typically affect the younger age group. Patients aged 60 or older 
comprise only 10-15% of incident IBD cases1,2. Currently, there are no age-specific treatment 
guidelines for elderly-onset IBD. Because the natural history of IBD varies according to the age of 
onset, the current management practices designed for adult patients may not be applicable to the 
elderly3,4. Presence of comorbidity and polypharmacy in elderly patients further underpins the 
challenges associated with managing this population5 at risk of opportunistic infections and 
cancers 
 
The conventional treatment practice adopts a “step-up” approach starting with 5-aminosalicylic 
acid (5-ASA). Thus, most studies are unable to demonstrate the positive effects of 
immunomodulators (IMs) due to their use in a more severe disease, after development of 
strictures or fistulas or insufficient patient-years of follow-up. Recent evidences demonstrate 
efficacy in the “top-down” approach which involves introducing IMs and biologics early in the 
disease course6,7. This may be more effective in controlling inflammation and preventing 
irreversible damage to the intestinal mucosa from the first flare-up than the “step-up” approach8,9. 
Additionally, introduction of IMs early in the disease course has been suggested to delay first major 
surgery for CD6,10.   
 
IMs are used to maintain remission in steroid-dependent or refractory patients11. Their use in the 
elderly is tentative due to higher risks of adverse effects and opportunistic infections12,13. IMs can 
cause adverse events in approximately 15% of patients and this can be classified into allergic 
(pancreatitis, fever, rash and arthralgia) and non-allergic (leukopenia, thrombocytopenia, infection 
and hepatitis) reactions. Of a greater concern is the increased risk of malignancy as patients aged 
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≥65 receiving thiopurines were found to be 2.6 times more likely to develop lymphoma than their 
younger counterparts14. Physicians may therefore avoid IMs use in older patients with IBD. 
 
Data on surgical outcome within the elderly-onset IBD patients are scarce. Elderly CD patients 
undergo surgery less often compared to their younger counterparts, whereas the rates are 
comparable for elderly UC and adult UC patients15. It is unclear whether elderly onset CD takes a 
generally milder course or whether physicians have higher threshold for surgical interventions. 
Elderly patients with IBD experience higher rate of postoperative morbidity and mortality, as well 
as increased length of hospital stay and operation time16,17. Given the preventative effects of IMs 
on surgery, elderly patients with IBD may benefit from early treatment if those likely to require 
the therapy could be identified at diagnosis.  
 
We hypothesized that elderly onset patients with IBD were less likely to receive IMs for IBD and 
that the decision to avoid IMs is driven by age. The primary study aim therefore was to compare 
IMs prescription rates between elderly onset and younger IBD patients with a view to identifying 
patients characteristics and clinical markers at presentation that predict the initiation of IMs 
therapy. The secondary outcome was the impact of early IMs use on the requirement of first 
surgery due to IBD.  
 
 5.3 MATERIALS AND METHODS 
 
POPULATION 
 
Data of ambulatory patients with IBD from 1942 to 2014 were retrospectively collected from 2 
tertiary hospitals and 6 private consultant rooms in Sydney metropolitan region. The “Sydney IBD 
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cohort” was first described in 1994 and the methodology was repeated in 2010 and 2012 to 
augment the cohort18. Diagnoses were confirmed retrospectively by a review of the clinical and 
endoscopic reports as well as radiological, histological and pathological investigations. To focus on 
a more recent cohort of patients and with adequate duration of follow up, only those with a 
definitive diagnosis of CD or UC between January 1, 1970 and December 31, 2009 were included. 
Patients with indeterminate colitis or those who had a change of diagnosis to a non-IBD pathology 
were excluded.  
Patients were categorised into 2 groups according to their age at diagnosis. The first group of 
patients who were diagnosed at age 60 or older were classified as ‘elderly-onset’ IBD patients. The 
second group consisted of patients diagnosed from 16 to 40 years of age and were referred as 
‘young-onset’ IBD patients.  
 
DATA COLLECTION 
 
All demographic data in addition to medical therapy and surgical interventions were collected. 
Clinical records, operation reports and discharge summaries were reviewed for patient 
demographics, disease characteristics, use of medications, surgical history, and presence of 
polypharmacy and comorbidity. Those lost to follow-up were contacted, and if unavailable, were 
excluded as of their last observation. Disease characteristics were categorised at diagnosis 
according to the Montreal classification and any changes with the treatment were updated until 
the most recent follow-up.  
Medical therapy consisted of 5-ASA, corticosteroid, IMs (Azathioprine (AZA), Mercaptopurine (6-
MP) and methotrexate (MTX)) and anti-tumour necrosis factor (TNF) alpha agents (adalimumab 
and infliximab). Long-term steroid use was referred as ≥6 months of continuous use of steroids 
within a 12-month period. Those who used either AZA, 6-MP or MTX continuously for 6 months 
were considered as being “maintained” by IMs. Early IM use was defined as introduction of an IM 
within 3 years of diagnosis and being on the medication continuously for ≥6 months6. 
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Patients’ comorbid status was quantitatively expressed using the Charlson comorbidity index 
(CCI)19 at the time of diagnosis. Rate of hospitalisation was calculated by dividing the total number 
of IBD-related hospital admissions by the duration of follow-up. Details of major abdominal, 
perianal or resectional surgeries were recorded. Simple surgical interventions under anaesthesia 
without abscess drainage were excluded. 
 
TREATMENT PRACTICES  
 
Throughout the study period, thiopurines were used as the first IM of choice, with AZA used more 
preferentially than 6-MP. Typical dosing of AZA was 2 to 2.5mg/kg body weight, and for 6-MP it 
was 1 to 1.5mg/kg body weight. Consistent with the national guidelines, MTX replaced AZA/6-MP 
when a patient became intolerant to the drug. Patients with thiopurine methyltransferase 
deficiency or arthritic extraintestinal manifestation were initiated on MTX immediately. MTX was 
prescribed at an initial dose of 25mg per week with maintenance dosing of 15mg per week 
thereafter, taken either orally or parenterally. IM therapy was ceased in cases of failure, adverse 
events, patient non-compliance, pregnancy, and/or other patient circumstances. Otherwise, once 
initiated, IMs were prescribed continuously.  
 
STATISTICAL ANALYSIS 
 
Statistical analysis was performed using IBM SPSS software version 23.0. Qualitative data was 
reported as percentages and was analysed using chi-square test. Continuous variables were 
described using either median and interquartile range (IQR) and analysed with the Mann-Whitney 
U test if non-parametrically distributed. Normally-distributed continuous variables were described 
using mean and standard deviation and analysed using the T test. A P-value of <0.05 was 
considered statistically significant.  
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Survival analyses of the IM introduction and surgery were calculated using the log-rank score and 
were displayed on the Kaplan-Meier curve. Hazard ratios (HR) were calculated using Cox 
proportional hazards regression models (both univariate and multivariate) with 95% confidence 
intervals (CI) when determining predictors of IM exposure and surgery. All baseline characteristics 
at diagnosis, medication use, comorbidity and polypharmacy were tested using the univariate 
analysis. Any variables with P-value less than 0.1 were included into the multivariate analysis. 
 
ETHICAL CONSIDERATION 
 
Ethics approval was obtained from the Sydney Local Health District Human Research Ethics 
Committee (HREC/10/CRGH/126).  
 
5.4 RESULTS 
 
PATIENT DEMOGRAPHICS 
 
A total of 255 elderly-onset (115 CD, 140 UC) patients and 1,244 young-onset (657 CD, 587 UC) 
patients were recruited (Table 5.1). The median duration of follow-up was 8.0 (IQR 3.0-13.0) for 
the elderly-onset group and 11.0 (IQR 5.0-20.0) for the young-onset group for CD (P<0.0001). For 
UC, the median duration of follow-up was 8.0 (IQR 3.0-14.8) for the elderly-onset group and 11.0 
(IQR 4.0-20.0) for the young-onset group (P<0.0001).  
The ileocolonic CD phenotype was the commonest location in young-onset patients (42.8%), 
whereas colonic CD was found in 61.4% of elderly-onset patients (P<0.0001). In UC, left-sided 
location was the commonest location for both young-onset (42.2%) and elderly-onset groups 
(52.1%, P=0.013).  
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MEDICAL INTERVENTIONS 
 
A significantly lower proportion of elderly-onset CD patients compared to young-onset CD patients 
were exposed to (24.5% vs 49.7%, P<0.0001) and maintained on (19.0% vs 42.5%, P<0.0001) IMs 
(Table 5.2). In UC, IM exposure (8.1% vs 20.5%, P=0.001) and IM maintenance (5.2% vs 16.5%, 
P=0.001) were considerably lower in elderly-onset versus young-onset groups respectively (Table 
5.2). In UC, early IM use was significantly lower in the elderly-onset (3.0%) versus the young-onset 
group (7.8%, P=0.048). Thiopurine was the commonest IM prescribed to both elderly-onset and 
young-onset groups in CD and UC. 
In CD, the cumulative probability of IM exposure at 5 years after diagnosis was 20.0% in elderly-
onset patients versus 33.4% in young-onset patients (P=0.002, Figure 5.1a). In UC, the cumulative 
probability of IM exposure at 5 years after diagnosis was 7.8% in elderly-onset patients and 13.4% 
in young-onset patients (P=0.007, Figure 1b).  
 
COMORBIDITY, POLYPHARMACY AND RATE OF HOSPITALISATION  
 
Elderly-onset subjects had significantly higher comorbidities than young-onset subjects in both CD 
(median CCI: 5.0 [IQR: 2.0-6.0] versus median CCI: 0.0 [IQR: 0.0-1.0] respectively, P<0.0001) and 
in UC (median CCI: 5.0 [IQR: 4.0-7.0] versus median CCI: 1.0 [IQR: 0.0-2.0] respectively, P<0.0001). 
Pearson’s correlation analysis was performed between age and CCI. Correlation was 0.58 
(p<0.0001) in the CD cohort and 0.79 (p<0.0001) in the UC cohort. 
 
The median total number of medications taken was 8.0 (IQR 4.75-9.25) by elderly-onset CD 
compared to 2.0 (IQR 1.0-3.0) for young-onset CD. For UC, the median was 6.0 (IQR 3.0-9.0) for 
elderly-onset and 2.0 (IQR 1.0-3.0) and young-onset groups (P<0.0001). Elderly-onset patients 
were admitted to hospital more frequently than young-onset patients for both CD and UC. In CD, 
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there were 0.23±0.40 hospital admissions per year in young-onset patients and 0.41±0.82 
hospital admissions per year in elderly-onset patients (P=0.023). Young-onset UC patients were 
admitted 0.09 ± 0.26 times per year, while elderly-onset UC patients were admitted 0.23 ± 0.54 
times per year (P<0.0001).  
 
FACTORS AFFECTING TIME TO INITIATION OF IM THERAPY  
 
For both UC and CD, age of diagnosis was not associated with the time at which IMs were 
introduced (Tables 5.3). In CD, CCI was significantly associated with delayed introduction of IM 
(HR: 0.86, 95%CI: 0.79-0.95, P=0.002). Out of the baseline characteristics considered, only extra-
intestinal manifestation was associated with early introduction of IM (HR: 1.47, 95%CI: 1.01-2.14, 
P=0.042). Long-term steroid use (HR: 1.91, 95%CI: 1.42-2.58, P<0.0001), anti-TNF use (HR: 1.68, 
95%CI: 1.20-2.34, P=0.003) and number of hospital admissions per year (HR: 1.49, 95%CI 1.22-
1.81, P<0.0001) were associated with the need for earlier IM therapy. 
 
In UC, multivariate analysis revealed that having higher CCI predicted for delayed use of IM (HR: 
0.81, 95%CI: 0.71-0.92, P=0.001). Proctitis (HR: 0.45, 95%CI: 0.23-0.89, P=0.021) was associated 
with delayed initiation of IMs compared to pancolitis. Long-term steroid use (HR: 4.45, 95%CI 2.69-
7.36, P<0.0001), anti-TNF exposure (HR: 2.12, 95%CI: 1.03-4.40, P=0.042) and number of hospital 
admissions per year (HR: 2.21, 95%CI: 1.24-3.94, P=0.007) were associated with the need for 
earlier IM therapy.  
 
FACTORS AFFECTING TIME TO FIRST IBD-RELATED SURGERY 
 
The 10-year cumulative probability of undergoing major abdominal or perianal surgery for CD was 
27.0% for elderly-onset patients versus 42.7% for young-onset patients (P=0.003, Figure 5.2a). 
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Median time to first surgery was 5.0 years (IQR: 2.0-11.2) for young-onset patients and 5.5 years 
(IQR: 2.0-10.0) for elderly-onset patients (P=0.477). Multivariate analysis revealed that early IM 
use was associated with delayed need for surgery (HR: 0.18, 95%CI: 0.09-0.35, P<0.0001, Table 
5.4). Patients with colonic CD (HR: 0.25, 95%CI: 0.13-0.48, P<0.0001) were less likely to require 
surgery than ileocolonic CD. Patients with the inflammatory phenotype (HR: 0.44, 95%CI: 0.26-
0.74, P=0.002) were less likely to have early surgery than those with the penetrating phenotype. 
Frequent hospitalisation was also an indicator for earlier surgery (HR 1.48, 95%CI: 1.23-1.77, 
P<0.0001). 
 
For UC, the 10-year cumulative probability of undergoing colectomy was 10.9% for elderly-onset 
patients and 5.9% for young-onset patients (P=0.22, Figure 5.2b). Median time to first intestinal 
resection was 7.0 years (IQR: 3.0-13.0) for elderly-onset patients versus 11.0 years (IQR: 4.0-20.0) 
for young-onset patients (P<0.0001). On multivariate analysis, proctitis (HR: 0.18, 95%CI: 0.07-
0.48, P=0.001) and left-sided UC (HR: 0.29, 95%CI: 0.16-0.54, P<0.0001) were less likely to require 
a surgery than pancolitis (Table 5.4). Long-term steroid use (HR: 3.45, 95%CI: 1.85-6.43, P<0.0001), 
anti-TNF use (HR: 8.17, 95%CI: 2.74-24.42, P<0.0001) and the number of hospital admissions per 
year (HR: 3.05, 95%CI: 1.95-4.76, P<0.0001) were predictors for early surgery. Early IM use was 
not a significant predictor of colectomy on the univariate model.  
 
5.5 DISCUSSION 
 
In this cohort study, we examined the factors driving the use of IMs for IBD in eldery-onset versus 
young-onset patients with IBD. In contrast to our hypothesis, age-related factors including 
comorbid status rather than age itself were associated with IMs use. Comorbidity was shown to 
delay the time at which IMs were introduced in both CD and UC whereas age at diagnosis was not 
associated with IMs introduction. Physicians, therefore, did not base IMs treatment on age alone. 
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Comorbidities influenced the use of IMs and the overall use of IMs, therefore, was significantly 
lower in elderly-onset IBD patients than in young-onset IBD patients.  
 
The decrease rate in IMs prescription in the elderly is consistent with many studies.15,20-22 It is often 
hypothesised that this difference in utilisation may have been due to lower disease severity in the 
elderly, particularly for CD.23 In contrast to other studies, we found that elderly onset patients may 
also experience severe disease: the rates of hospitalisations for examples were higher for elderly 
onset IBD patients than those with young onset. The requirement for surgery was greater for 
elderly onset patients with UC, and although less elderly onset patients with CD required surgery, 
the time to surgery was similar to young onset patient. Based on our data it is therefore 
questionable whether elderly onset IBD is per se prone to take a milder course. 
 
Elderly patients experience complications associated with IMs more frequently than younger 
patients, contributing to their lesser use.14,24,25 Although steroid dependence has been shown to 
be more common in the elderly,26 this was not seen in our cohort in which long term steroid usage 
was similar between the two age-groups. Steroid sparing IMs, therefore, might be advantageous 
in the elderly IBD patients despite the potential for side effects 14,27, 28 which are more common in 
the elderly. These side effects should be put in the balance when prescribing these drugs to the 
elderly who on the other hand are frail and less able to tolerate severe or prolonged periods of 
disease activity. 29 Our study showed no difference between the two groups in the proportion of 
patients who stopped the IM after being initiated. Although the exact reasons are not available, 
we assume that side effects constitute an important cause for discontinuing the drug.   
 
Comorbidity is an exemplary age-related factor that is more prevalent in the elderly than in 
younger populations. Most studies on elderly-onset IBD fail to acknowledge the importance of 
comorbidity when assessing patients’ treatment outcome. Whilst this study confirms the lesser 
use of IMs within the elderly, age of diagnosis itself was not a factor that restricted the use of IMs. 
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Instead, it is comorbidity that delayed the initiation of IM therapy. Comorbidity can alter the 
prognosis of IBD and increase the likelihood of drug-to-drug interaction5. Thus, it appears that 
physicians base their decision in elderly onset patients appropriately on comorbidity rather than 
age.  
Fewer elderly-onset CD patients underwent surgery compared to young-onset CD patients. In UC, 
the opposite was observed until 20 years after diagnosis, which then the probability converged for 
the two groups. Two factors may contribute to this observation. First, given that more elderly-
onset patients presented with left-sided or pancolitic UC, elderly-onset UC may progress as a more 
aggressive disease than young-onset UC. Pancolitis being associated with increased risk of 
colectomy, may also support this finding. Secondly, surgical risk is highest among patients with 
ileal or ileocolonic disease6. Thus, without being curative, surgery in the elderly CD is less 
imperative and potentially harmful, due to higher risk of postoperative complications and longer 
hospital stay16,17. Surgery for UC, however, is curative, thus physicians and patients may prefer a 
more definite surgical intervention than long term IM therapy. Likewise, a Pennsylvanian study by 
Juneja et al15 found that patients with CD diagnosed at <65 years of age were more likely to 
undergo surgery than those diagnosed at ≥65 years of age. However, the UC colectomy rate in 
this cohort was similar among the two groups.  
 
The recommended clinical practice is evolving towards the “top-down” approach with early 
initiation of immunosuppressive therapy. Such therapy ensures patients’ quality of life throughout 
the disease course and be more efficacious in inducing remission than the conventional approach7. 
We observed that early IM use (≤3 years since diagnosis) is associated with a delay in major 
abdominal or perianal surgery for CD. This was seen even among elderly onset patients, despite 
having a lower surgical rate and lower use. This observation has also been made by other 
studies6,7,30. This indicates that healthy elderly-onset patients with minimal comorbidities should 
be considered for early IM therapy to prevent future surgical risk. Similar finding was not displayed 
for UC, possibly due to smaller number of patients receiving IM. 
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The strengths of this study include its abundant patient-years of follow-up, and complete record 
of disease characterisation at diagnosis. The present study followed the standardised 
management regimes and case definitions that may be lacking in studies derived from insurance 
data, hospital coding, or de-identified data. The Montreal Classification system, which is an 
objective marker of disease severity, was employed to prevent bias associated with recall or 
misclassification. Such strategies were adopted in other Australian and New Zealand population-
based studies. Most importantly, this was one of the few studies that identified age and age-
related factors as separate variables when determining predictors of time to IM introduction.  
 
There are a few limitations to this study. It is a retrospective study based on ambulatory specialist-
-referred cohort within the Sydney Local Health District. This mode of data acquisition and 
geographic isolation may have exposed the study to selection bias. However, recruitment of 
patients managed by gastroenterologists with exceptional longitudinal follow-up and 
documentation allowed precise characterisation of every cause and ensured the definition of IM 
was met. Secondly, our data was affected by changes in treatment practices and governmental 
regulations over the past decades. This may account for the smaller number of patients receiving 
biologics within the population.  
 
In conclusion, young-onset IBD and elderly-onset IBD showed a distinct difference in disease 
phenotypes and medication use. Our study showed that in clinical practice age does not have a 
correlation with the time at which IMs are introduced but age-related factors, especially 
comorbidities, are used instead to assess the appropriateness of IMs therapy. Further research 
into the effects of comorbidity on efficacy and safety of IMs is required. Furthermore, newer 
agents such as gut directed therapy with Vedolizumab and potentially less side effects may prove 
a safer option for elderly onset patients in future. Meanwhile, IMs should be prescribed with care 
in patients with high comorbid status, regardless of their age or severity of disease. Elderly patients 
who are fit and healthy should be considered for earlier use of IMs in their disease course for 
maximal quality of life and to reduce risk of surgery.  
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Table 5.1 Demographics and Clinical Characteristics of Crohn’s Disease and Ulcerative Colitis 
Patients at Diagnosis 
 
 Crohn’s Disease Ulcerative Colitis 
 Young-onset 
(16-40) 
Elderly-onset 
(≥60) P Young-onset (16-40) Elderly-onset (≥60) P 
No. of patients 657 115  587 140  
Median age (IQR) 26 (22-31.5) 68 (64-76) <0.0001 28 (24-33) 67 (64-74) <0.0001 
Median follow-up (IQR) 11 (5-20) 8 (3-13) <0.0001 11 (4-20) 8 (3-14.8) <0.0001 
Patient-years of follow-up 8589 1002  7824 1327  
Gender, N (%) 
  Male 
  Female 
 
280 (42.6) 
377 (57.4) 
 
43 (37.4) 
72 (62.6) 
0.295  
285 (48.6) 
302 (51.4) 
 
81 (57.9) 
59 (42.1) 
0.048 
Disease location, N (%) 
  Ileal (L1) 
  Colonic (L2) 
  Ileocolonic (L3) 
  Not documented 
 
161 (24.8) 
211 (32.5) 
278 (42.8) 
7 
 
15 (13.2) 
70 (61.4) 
29 (25.4) 
1 
<0.0001    
Upper GI (L4), N (%) 
  Yes 
  No 
  Not documented 
 
10 (1.5) 
637 (98.5) 
10 
 
0 (0.0) 
114 (100) 
1 
0.181    
Disease phenotype, N (%) 
  Inflammatory (B1) 
  Stricturing (B2) 
  Penetrating (B3) 
  Not documented 
 
427 (66.5) 
144 (22.4) 
70 (10.9) 
15 
 
78 (67.8) 
26 (22.6) 
11 (9.6) 
0 
0.947 
 
 
   
Perianal disease, N (%) 
  Yes 
  No 
  Not documented 
 
126 (19.3) 
526 (80.7) 
5 
 
17 (14.9) 
97 (85.1) 
1 
0.265    
Disease location, N (%) 
Proctitis (E1) 
Left-sided (E2) 
Pancolitis (E3) 
Not documented 
     
201 (34.2) 
248 (42.2) 
138 (23.5) 
0 
 
30 (21.4) 
73 (52.1) 
37 (26.4) 
0 
0.013 
Extra-intestinal, N (%) 
  Yes 
  No 
  Not documented 
 
117 (18.9) 
502 (81.1) 
38 
 
22 (20.0) 
88 (80.0) 
5 
0.787  
90 (15.6) 
487 (84.4) 
10 
 
18 (13.3) 
117 (86.7) 
5 
0.509 
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Table 5.2 Medication Use in Crohn’s Disease and Ulcerative Colitis Patients During Follow-up 
 
 Crohn’s Disease Ulcerative Colitis 
 Young-onset 
(16-40) 
n=657 
Elderly-onset 
(≥60) 
n=115 
P Young-onset 
(18-40) 
n=587 
Elderly-onset 
(≥60) 
n=140 
P 
5-ASA (%) 538 (86.9) 94 (87.0) 0.972 559 (96.9) 139 (99.3) 0.112 
Long-term steroids (%) 384 (60.8) 63 (57.3) 0.490 218 (37.1) 45 (32.1) 0.361 
Anti-TNF (%) 66 (10.6) 3 (2.7) 0.009 17 (2.9) 1 (0.7) 0.142 
IMs exposure (%) 309 (49.7) 27 (24.5) <0.0001 118 (20.5) 11 (8.1) 0.001 
IMs maintenance (%) 251 (42.5) 20 (19.0) <0.0001 95 (16.5) 7 (5.2) 0.001 
Early IM use (%) 147 (24.9) 18 (17.1) 0.086 45 (7.8) 4 (3.0) 0.048 
Exposed IM Type (%) 
  Thiopurine 
  MTX 
  Both 
 
268 (86.7) 
1 (0.3) 
40 (12.9) 
 
21 (77.8) 
2 (7.4) 
4 (14.8) 
0.001 
 
 
 
117 (92.9) 
2 (1.6) 
7 (5.6) 
 
11 (91.7) 
0 (0.0) 
1 (8.3) 
0.845 
 
Median time to starting 
 IMs, yr (IQR) 
6.0 (2.0-16.0) 6.0 (1.5-13.0)  0.220 9.0(3.0-20.0) 8.0 (3.0-15.0) 0.077 
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Table 5.3 Univariate and Multivariate Predictors of Time to Initiation of IM Therapy and Time to 
Surgery in Crohn’s Disease Patients 
 
 Time to Initiation of IM Therapy Time to Surgery 
Covariant Univariate Multivariate Univariate Multivariate 
 HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Gender 0.94 (0.75-1.18) 0.59   1.18 (0.93-1.50) 0.18   
Age groups 0.53 (0.35-0.80) 0.003  0.45 0.54 (0.35-0.82) 0.004  0.86 
Disease location 
  Ileal (L1) 
  Colonic (L2) 
  Ileocolonic (L3)  
 
0.86 (0.64-1.15) 
0.90 (0.70-1.17) 
Reference 
0.55 
0.31 
0.45 
   
1.36 (1.05-1.77) 
0.29 (0.20-0.40) 
Reference 
<0.0001 
0.02 
<0.0001 
 
1.21 (0.82-1.78) 
0.25 (0.13-0.48) 
 
<0.0001 
0.33 
<0.0001 
Disease phenotype 
  Inflammatory (B1) 
  Stricturing (B2) 
  Penetrating (B3) 
 
0.84 (0.59-1.20) 
0.88 (0.58-1.31) 
Reference 
0.63 
0.34 
0.52 
   
0.29 (0.20-0.40) 
0.90 (0.63-1.29) 
Reference 
<0.0001 
<0.0001 
0.57 
 
0.44 (0.26-0.74) 
0.89 (0.52-1.51) 
 
0.001 
0.002 
0.66 
Perianal involvement 1.64 (1.27-2.12) <0.0001  0.30 0.88 (0.64-1.21) 0.43   
Extra-intestinal 1.35 (1.02-1.78) 0.04 1.47 (1.01-2.14) 0.04 0.76 (0.55-1.06) 0.10   
5-ASA use 0.85 (0.61-1.18) 0.33   0.57 (0.41-0.79) 0.001  0.13 
Long-term steroids 
use 
1.45 (1.13-1.85) 0.003 1.91 (1.42-2.58) <0.0001 1.58 (1.21-2.08) 0.001 1.70 (1.17-2.48) 0.006 
Anti-TNF use 3.79 (2.88-4.99) <0.0001 1.68 (1.20-2.34) 0.003 1.03 (0.69-1.53) 0.89   
Early IM use     0.23 (0.13-0.39) <0.0001 0.18 (0.09-0.35) <0.0001 
CCI 0.87 (0.80-0.95) 0.002 0.86 (0.79-0.95) 0.002 0.23 (0.13-0.40) <0.0001 0.18 (0.09-0.35) <0.0001 
Number of 
medications 
1.01 (0.96-1.05) 0.83   1.08 (0.99-1.17) 0.07   
CD-related surgery 0.99 (0.79-1.24) 0.92   1.04 (0.98-1.10) 0.17   
Number of hospital 
admissions per year 
1.53 (1.33-1.75) <0.0001 1.49 (1.22-1.81) <0.0001 1.58 (1.36-1.83) <0.0001 1.48 (1.23-1.77) <0.0001 
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Table 5.4 Univariate and Multivariate Predictors of Time to Initiation of IM Therapy and Time to 
Surgery in Ulcerative Colitis Patients 
 
 Time to Initiation of IM Therapy Time to Surgery 
Covariant Univariate Multivariate Univariate Multivariate 
 HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Gender 0.74 (0.53-1.05) 0.096  0.67 0.72 (0.42-1.22) 0.22   
Age groups 0.44 (0.24-0.82) 0.010  0.12 1.49 (0.78-2.84) 0.22   
Disease location 
  Proctitis (E1) 
  Left-sided (E2) 
  Pancolitis (E3)  
 
0.30 (0.17-0.54) 
1.04 (0.71-1.53) 
Reference 
<0.0001 
<0.0001 
0.83 
 
0.45 (0.23-0.89) 
 
0.066 
0.021 
 
 
0.11 (0.04-0.28) 
0.27 (0.15-0.49) 
Reference 
<0.0001 
<0.0001 
<0.0001 
 
0.18 (0.07-0.48) 
0.29 (0.16-0.54) 
<0.0001 
0.001 
<0.0001 
Extra-intestinal 1.32 (0.86-2.02) 0.20   1.26 (0.66-2.39) 0.48   
5-ASA use 20.94 (0.18-
2495) 
0.21   20.91 (0.01-
32271) 
0.42   
Long-term 
steroids use 
4.90 (3.30-7.27) <0.0001 4.45 (2.69-7.37) <0.0001 4.40 (2.43-7.94) <0.0001 3.45 (1.85-6.43) <0.0001 
Anti-TNF use 9.48 (5.65-15.92) <0.0001 2.12 (1.03-4.40) 0.04 4.29 (1.70-10.80) 0.002 8.17 (2.74-24.42) <0.0001 
Early IM use     0.36 (0.05-2.59) 0.31   
CCI 0.78 (0.68-0.90) 0.001 0.81 (0.71-0.92) 0.001 0.36 (0.05-2.60) 0.31   
Number of 
medications 
1.02 (0.97-1.08) 0.42   0.82 (0.56-1.20) 0.31   
UC-related surgery 1.25 (0.75-2.08) 0.40   0.98 (0.83-1.16) 0.83   
Number of 
hospital 
admissions per 
year 
2.15 (1.66-2.79) <0.0001 2.21 (1.24-3.95) 0.007 5.45 (3.58-8.29) <0.0001 3.05 (1.95-4.76) <0.0001 
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Figure 5.1 Cumulative probability of IM exposure over time since diagnosis in elderly-onset and 
young-onset patients with CD (1a, P=0.002) and UC (1b, P=0.007).  
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Figure 5.2Cumulative probability of first IBD-related surgery since diagnosis in elderly-onset and 
young-onset patients with CD (2a, P=0.003) and UC (2b, P=0.219). 
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6.1 ABSTRACT 
 
BACKGROUND AND AIMS  
Increased risk of comorbidity, polypharmacy, malignancy and infection complicates drug 
treatment of elderly patients with inflammatory bowel diseases (IBD). Age, therefore, might 
influence a physician’s preference in the prescription of immunosuppressive therapies or surgery.  
 
METHODS 
A case-based survey was conducted worldwide assessing gastroenterologists’ selection of drug 
treatments based on patients’ comorbidity and age in the management of moderate-to-severe 
ulcerative colitis (UC). Primary aim was to assess gastroenterologists’ decision to prescribe medical 
treatment versus colectomy in elderly UC patients, and identify the factors associated with their 
choices using logistic regression analysis. 
 
RESULTS 
A total of 424 respondents from 41 countries were included. Vedolizumab (53.2%) and thiopurines 
(19.4%) were the top treatment preferences for moderate-to-severe UC (p<0.0001). Comorbidity 
reduced the probability of prescribing immunomodulators for elderly- (odds ratio (OR): 0.25, 95% 
confidence interval (CI): 0.16-0.38, p<0.001) and for younger-patients (OR: 0.56, 95%CI: 0.39-0.82, 
p<0.001) compared to elderly patients without comorbidities. Conversely, elderly- and younger-
patients with comorbidities were more likely to receive vedolizumab (OR: 2.71, 95%CI: 1.98-3.71, 
p<0.0001, and OR: 1.37, 95%CI: 1.01-1.86, p=0.04, respectively) and colectomy (OR: 5.40, 95%CI: 
2.74-10.64, p<0.0001, and OR: 4.46, 95%CI:2.25-8.87, p<0.0001, respectively]. 93.9% of 
respondents considered that patient age was not a limit for vedolizumab, while 37.9% considered 
age as a limiting factor in prescribing thiopurines (p<0.001)).  
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CONCLUSIONS 
Patient comorbidity is a major determinant in the selection of medical and surgical therapy, rather 
than age alone in moderate-to-severe UC.  There is worldwide acceptance of vedolizumab as  the 
drug of choice in elderly IBD.  
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6.2 INTRODUCTION 
 
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is 
increasing in incidence and prevalence globally across all age groups [1][2]. Elderly IBD patients 
include those diagnosed at a younger age who transition to an elderly age, and those diagnosed 
after the age of 60 years (elderly-onset IBD) [3]. Approximately 25-35% of IBD patients are over 
the age of 60 years, with 10-15% of these with elderly-onset IBD [4-6]. With the aging population, 
IBD prevalence also increases with age and peaked at 1,061 per 100, 000 in patients >85 years old 
[7].  
 
Conventional IBD therapy consists of mesalazine, corticosteroids, and the immunomodulators 
thiopurine and methotrexate. In the past two decades, biological agents have led a paradigm shift 
in the management of IBD. Anti-tumour necrosis factor (TNF)-α agents (infliximab [8]-[11], 
adalimumab [12]-[16], certolizumab pegol [17][18], and golimumab[19][20]), as well as anti-
integrin agents (vedolizumab) [21][22] were approved for induction and maintenance therapy in 
both moderate-to-severe CD and UC. More recently, ustekinumab [23] and tofacitinib [24] have 
been added. Most pivotal studies excluded the recruitment of elderly patients, therefore, efficacy 
and safety data of these drugs in the elderly is deficient. Despite increased risk of hospitalisation, 
surgery, post-surgical complications and steroid dependency [25]-[28] associated with elderly IBD, 
immunomodulators and biological agents are underutilized with dependence on steroid and 
mesalazine maintenance for its management [29][30]. Moreover, elderly IBD patients often have 
comorbidities, polypharmacy with potential for drug interactions, medication adherence issues, 
which may further complicate the management of this group of patients [30][31]. 
 
Currently there are no age-specific treatment guidelines for IBD in the elderly [3]. Therefore, the 
attending physicians’ preferences, knowledge and attitude towards the use of immunomodulators 
and biological agents in the elderly may influence prescription practice. We therefore conducted 
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a survey to determine the preference of gastroenterologists on the decision to prescribe medical 
treatment versus colectomy in elderly IBD patients, and the factors associated with their choices. 
Secondary aims were to identify conditions that preclude gastroenterologists from prescribing 
immunomodulators and biological agents, and whether patient age is considered a limitation to 
prescribing these medication classes. 
 
6.3 MATERIALS AND METHODS 
SURVEY DESIGN 
 
This investigator-initiated study was conducted in collaboration with two operational boards of 
the European Crohn’s and Colitis Organisation (ECCO): Young-ECCO (Y-ECCO) and the clinical 
committee of ECCO (ClinCom). The decision to support this proposal was made by these 
committees through an independent review board following an international call to submit 
projects. The first version of the survey was designed by VK, SK and RL, and reviewed by Y-ECCO, 
ClinCom and the members of the ECCO governing board. After two rounds of modifications, the 
final version of the survey was approved by consensus. The survey consisted of 17 questions and 
was divided into four categories. First, gastroenterologists’ demographics, including medical 
position, continent and country of practice, years in gastroenterology practice, number of IBD 
patients reviewed per week, and practice type, were collected. Second, we devised three clinical 
scenarios to determine gastroenterologists’ preference on the use of immunomodulators and 
biological therapies in elderly IBD patients. Third, we assessed the conditions that precluded 
gastroenterologists from prescribing the immunomodulators and biologic agents. Fourth, the age 
limits of ordering such medications were recorded. The estimated time to complete the survey 
was 5 minutes. (Supplement 1). 
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THE CASE SCENARIOS  
 
Three case scenarios were designed to assess the impact of elderly-age alone, elderly-age with 
comorbidities and younger-age with comorbidities. 
The first case scenario was a 76-year-old female with steroid-refractory UC, despite adherence to 
oral mesalazine 4g daily. She required 3 courses of oral corticosteroids over a 9-month period 
(Supplement 1). Her colonoscopy revealed extensive colitis with Mayo endoscopic sub score of 3. 
The patient had no other comorbidity. Scenario 2 was similar to the first one, but the patient had 
comorbidities of type 1 diabetes mellitus with diabetic nephropathy and ductal adenocarcinoma 
of the left breast in remission. Scenario 3 was identical to the scenario 2 but the patient was now 
28 years old.  
 
All three case scenarios included 5 treatment options including prescribing immunomodulators, 
high dose maintenance corticosteroids, mono- or combination therapy with anti-TNF, mono- or 
combination therapy with vedolizumab, and colectomy. The participants were asked to rank their 
5 choices of treatment, with 1 the most preferred and 5 the least. 
 
STUDY POPULATION 
 
The survey was first distributed anonymously in hard copy format amongst participants at a 
gastroenterology conference in Australia and the ECCO conference in February 2017. Thereafter, 
the questionnaire was deployed in an online platform (SurveyMonkey), using a viral networking 
technique to further increase the reach of the survey beyond those initially targeted. 
Gastroenterologists from the Asian Organization for Crohn's & Colitis [AOCC], Belgian Intestinal 
Research and Development [BIRD], British Society of Gastroenterology [BSG], Grupo Español de 
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Trabajo de Crohn y Colitis Ulcerosa [GETECCU], Italian Group for the study of IBD [IG-IBD] were 
also invited through emails to participate into the survey.  
 
The inclusion criteria were adult gastroenterologists that consulted ≥2 IBD patients per week and 
completed >50% of the questionnaire. Gastroenterologists who cared for two or more IBD 
patients per week were pragmatically defined as IBD specialists. The anonymous survey was 
approved by the Centralised Institutional Review Board of SingHealth Research(CIRB Reference 
number: 2019/2056) and completion and return of the survey was considered informed consent.  
 
STATISTICAL ANALYSIS 
 
Standard descriptive statistics summarized demographic data and overall responses for each 
question. Categorical variables were expressed as frequencies and percentages, and continuous 
variables were expressed as medians and interquartile range [IQR]. Comparison of responses 
between groups was by chi-square test, Kruskal-Wallis H test, and ANOVA t test, as appropriate. 
Univariate and multivariate binary logistic regression was used to determine variables associated 
with each treatment choice. Variables with a p-value of <0.05 in univariate analysis were included 
in to multivariate analysis. Results are expressed as odds ratios (OR) and their 95% confidence 
intervals (95% CI). Statistical analyses were conducted using SPSS [IBM SPSS Statistics for Windows, 
version 23 (IBM Corp., Armonk, N.Y., USA)]. 
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6.4 RESULTS 
STUDY COHORT 
 
The questionnaire was distributed in 41 countries covering five continents. The precise 
questionnaire return rate was an estimate based on the return rate of the survey handouts at 
major conferences and the online survey website. Based on our best estimate, a response return 
rate of 80% was received.  
A total of 550 gastroenterologists responded to the survey, of whom 424 physicians met the 
inclusion criteria (Figure 6.1). Characteristics of the gastroenterologists included are depicted in 
Table 6.1 (and Supplement 2). Of those surveyed, 43.9% (n = 186) were from Europe, 23.3% (n = 
99) from Asia, and 22.6% (n = 96) from Oceania with a median of 12 years (IQR: 5.0–20.75 years) 
of experience in gastroenterology. Most IBD specialists worked in public hospitals (68.6%) and 
67.5% of all respondents treated >10 IBD patients per week.  
 
RESPONSE TO CASE SCENARIOS 
 
Vedolizumab was the most preferred treatment choice in all 3 case scenarios, with 43.9%, 64.9 
and 50.9% selecting it as the first choice for cases 1, 2 and 3 respectively (Table 6.2). 
Immunomodulators was the second choice overall, being recommended as the first choice by 
28.5%. 10.9% and 18.7% for cases 1, 2 and 3 respectively. Comorbidity was the decisive factor in 
selecting colectomy over age. Overall, 13.3% of respondents selected colectomy as the preferred 
option for the elderly with comorbidity, 11.5% for the young patient with comorbidity, while only 
2.8% of gastroenterologists selected colectomy for the elderly without comorbidity (p<0.0001). 
Overall, Only 2.7% of respondents selected increasing the dose and maintaining prednisolone as 
the preferred maintenance treatment. 
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FACTORS ASSOCIATED WITH TREATMENT CHOICES 
 
On multivariate analysis, the presence of comorbidity was associated with a lower probability of 
prescribing immunomodulators. The probability of prescription of thiopurines in elderly patients 
with comorbidities (OR: 0.25, 95%CI: 0.16-0.38, p<0.001) and young patients with comorbidities 
(OR: 0.56, 95%CI: 0.39-0.82, p=0.001) was lower compared to elderly patients without 
comorbidities (Table 6.3). European and North American physicians had a significantly lower 
probability of prescribing immunomodulators than Asian physicians (OR:0.52, 95%CI 0.34-0.80, 
p=0.003 and OR: 0.03, 95%CI; 0.004-0.22, p=0.001) respectively. As expected, having a perceived 
age limit to prescribing immunomodulators was associated with lower probability of prescribing 
immunomodulators (OR: 0.43, 95%CI: 0.28-0.66, p<0.0001). On the other hand, having an age 
limit to prescribing biological therapies was associated with a higher probability of prescribing 
immunomodulators (OR: 1.74, 95%CI: 1.04- 2.90, p=0.034, and OR: 3.34, 95%CI: 1.70-6.54, 
p<0.0001 for anti-TNF and vedolizumab respectively). 
 
In the elderly, the presence of comorbidities significantly decreased the likelihood of prescribing 
an anti-TNF (OR: 0.28, 95%CI: 0.17-0.46, p<0.0001). More experienced physicians (OR: 0.98, 
95%CI: 0.96-0.99, p=0.017) and those seeing a higher number of IBD patients per week (OR 0.50, 
95%CI 0.31-0.79, p=0.003) were less likely to prescribe anti-TNF.  
The presence of comorbidities increased the likelihood of preferring vedolizumab as first option, 
for both elderly- (OR: 2.71, 95%CI: 1.98-3.71, p<0.0001) and younger patients (OR: 1.37, 95%CI: 
1.01-1.86, p=0.04) compared to the elderly patient without comorbidity. Gastroenterologists who 
saw a higher number of IBD patients per week (OR: 1.90, 95%CI: 1.35 – 2.69, p<0.0001) and North 
American physicians compared against Asia (OR: 5.59, 95%CI: 2.96-10.53, p<0.0001) were more 
likely to prescribe vedolizumab. Having a perceived age limit for prescribing thiopurines was 
associated with higher likelihood of using vedolizumab (OR: 1.51, 95%CI: 1.15-1.99, p=0.003).  
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On multivariate analysis, the presence of comorbidities was the only independent predictor for 
selecting colectomy and this was irrespective of age. Elderly patients with comorbidities (OR: 5.40, 
95%CI: 2.74-10.64, p<0.0001) and younger patients with comorbidities (OR: 4.46, 95%CI: 2.25-
8.87, p<0.0001) had significantly higher probability of having colectomy than elderly patients 
without comorbidities. Perceived age barrier in the prescription of vedolizumab was also 
associated with a higher probability of selecting colectomy (OR: 2.95, 95%CI: 1.37-6.32, p=0.006). 
Corticosteroid use was not associated with age or comorbidities (Supplement 3). 
 
CONDITIONS PRECLUDING IMMUNOMODULATORS AND BIOLOGICAL AGENTS IN ELDERLY PATIENTS WITH IBD 
 
History of lymphoma (94%) and opportunistic infection (78.3%) were most frequently reported as 
conditions precluding the use of thiopurine and anti-TNF in elderly IBD patients respectively (Table 
6.4). Opportunistic infection (57.4%) was the commonest condition considered as 
contraindications to vedolizumab in elderly IBD patients. 
 
AGE LIMIT FOR PRESCRIBING IMMUNOMODULATORS AND BIOLOGICAL THERAPY 
 
Vedolizumab and corticosteroids were prescribed without an age limit by 93.9% and 93.7% 
respondents respectively. However, 37.9% of gastroenterologists considered age as a limiting 
factor in prescribing thiopurines (Figure 6.2). 
 
6.5 DISCUSSION 
 
This is the first global survey that examined therapeutic options made on UC patients and factors 
relating to these decisions. The presence of comorbidity was the single most important factor 
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associated with this decision-making process rather than age. Surgery was also recommended to 
patients based on the presence of comorbidity and not age. These findings are in accordance with 
recommendations made by the ‘European Crohn’s and Colitis Organisation Topical Review on IBD 
in the Elderly’ that recommended management decisions to be made based on patients’ frailty 
rather than their chronological or biological ages [3]. Around 40% of gastroenterologists avoided 
prescribing thiopurines for patients >50 years old, while majority of IBD specialists, did not 
consider an age limit for prescribing vedolizumab. The topic of patients’ age, as a limit for 
prescribing immunomodulators and biological therapies has not been studied in an IBD population 
before. In clinical trials for infliximab [8]-[11] and golimumab [19][20], no upper age limit was set. 
For certolizumab [17][18], adalimumab [12]-[16], and vedolizumab [21][22], the upper age limits 
were 65, 75 and 80 years, respectively. In a recent meta-analysis, the absolute risk of lymphoma 
in IBD patients treated with thiopurines was highest in patients >50 years old (1:354 cases per 
patient-year, with a relative risk of 4.78) [40]. This could potentially explain the age limit of 
thiopurine prescription observed in this study.  
 
The ageing population and rising incidence of IBD contribute towards the increasing prevalence of 
elderly IBD patients [3]. Presence of comorbidity and polypharmacy in elderly patients further 
underpins the challenges associated with managing this population at risk of opportunistic 
infections and cancers [32][33]. The influence of comorbidity on treatment choices is poorly 
researched. Kariyawasam et al[31] recently reported the impact of comorbidity in the use of 
immunomodulators in a comparative study of elderly and younger onset IBD patients. Charlson’s 
Comorbidity Index was significantly associated with lower probability of prescribing 
immunomodulators, in CD (Hazard ratios (HR): 0.86, 95%CI: 0.79-0.95) and UC (HR: 0.81, 95%CI: 
0.71-0.92)[30]. Age of diagnosis was not an independent predictor of Immunomodulator use [31]. 
According to the consensus guidelines of the European Crohn's and Colitis Organisation for the 
treatment of UC [35], patients with steroid-dependency of at least moderate severity should be 
treated with a thiopurine, anti-TNF (preferably combined with a thiopurine), vedolizumab, or 
methotrexate. Our survey identified that vedolizumab ranked first among the five choices in all 3 
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scenarios. Comorbidity, but not age, was independently associated with the selection of 
vedolizumab as the treatment option. A recently published study on real world experience of 
vedolizumab, demonstrated safety in the elderly [36]. There are limited data to demonstrate the 
safety of vedolizumab in subjects with comorbidity. Through its targeted, gut selective mechanism 
of action, however, vedolizumab is an attractive option in the elderly and in patients with 
comorbidities. Our survey confirms that prednisolone is to be avoided as maintenance medication 
in the elderly. However, some real-world data demonstrate high rates of prednisolone usage as 
maintenance therapy [37][38]. 
 
The presence of comorbidity was the single most important factor in influencing the decision in 
recommending colectomy. Colectomy, whilst sometimes viewed as being a curative option in UC, 
mostly results in the cessation of all immunomodulator and biological drugs. However, this 
decision must be balanced against the increased rate of postoperative morbidity and mortality in 
operative subjects aged over 60 years with comorbidities [26-28][39]. Recent population-based 
studies demonstrated higher surgical rates in elderly-onset UC compared to young-onset UC 
patients. The increased surgical rate was associated with very low immunomodulator use. 
Therefore, the decision to perform colectomy might have been driven by the treating physician’s 
decision to select colectomy to avoid medical therapy, rather greater severity of the patients’ UC. 
Conversely the lower rate of use of immunomodulator in the elderly also represented the 
physicians’ choice.  
 
Lymphoma was regarded as the major contraindication to thiopurines in elderly patients. 
Following the diagnosis of a solid organ cancer, as many as 2-3 times more gastroenterologists 
would stop thiopurines (65.1%) or anti-TNF agents (57.4%) than vedolizumab. Overall, the 
prescribing pattern from the 3 scenarios suggest that vedolizumab has emerged as the first line 
therapy for elderly patients with moderate-to-severely active UC, with or without comorbidity, 
and in patients with significant comorbidities of any age. There was a surprisingly high proportion 
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of respondents to this survey that did not avoid using anti-TNF in the presence of demylination, 
recent melanoma or congestive heart failure.  
 
The strength of the study is the large sample size of gastroenterologists from across the world to 
reflect the global practice pattern of the IBD specialists on the use of immunomodulators and 
biological agents in the elderly IBD population. It shows the emerging trend of selecting 
vedolizumab in all countries where that drug has been launched. The longer the country has had 
approval for vedolizumab, the greater the preference is for its use in UC patients with 
comorbidities. There are some limitations in our study. Firstly, due to the recruitment across 
multiple countries, the absolute number of gastroenterologists were relatively small in certain 
countries. This could affect the generalisability of the study results globally. However, when 
analysing on a per-continent basis, there was consistency in the results across country-groups with 
the main differences being countries that had vedolizumab longer tended to select this as an 
option over thiopurines. Secondly, selection bias might also be present through only those with 
interest in managing IBD responding. However, we tried to invite survey respondents not only 
from IBD conferences but by emailing survey links to increase the variety of respondents. We also 
analysed subjects according to the numbers of IBD cases seen per week to determine whether IBD 
expertise drove their survey responses. Thirdly, we did not explore other IBD populations or 
phenotypes in this survey such as pediatric subjects, luminal Crohn’s disease or perianal Crohn’s 
disease, which might reduce the choice of vedolizumab as a preferred option. However, this was 
to keep the survey simple and easy to complete. We also limited the IBD phenotype to UC to 
ensure consistency across the 3 scenarios and isolating age and comorbidities as independent 
variables. Fourthly, we did not explore newer treatment options such as ustekinumab [23] and 
tofacitinib [24]. However, at the time of the survey ustekinumab was not yet available in most 
parts of the world and there were no data available for its use in UC.  
 
In conclusion, comorbidity was the major determinant in the selection of either medical or surgical 
therapy in moderate-to-severe UC, whereas patient age alone was not. Vedolizumab has emerged 
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as the preferred first line agent worldwide, in the treatment of elderly IBD patients with moderate-
to-severe ulcerative colitis refractory to corticosteroids, with or without comorbidity, and in 
younger patients with comorbidity. In elderly IBD patients, the presence of opportunistic infection 
and lymphoma were the main barriers in prescribing biological therapies and thiopurines, 
respectively. Around 40% of gastroenterologists avoided prescribing thiopurines for patients >50 
years old, while majority of IBD specialists, did not consider an age limit for prescribing 
vedolizumab.  
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Table 6.1 Gastroenterologists’ Demographic and Clinical Characteristics 
 
Gastroenterologists’	Characteristics	 N	=	424	(%)	Continent	 	Asia	 Total	=	99	(23.3%)	Australia	and	Oceania		 Total	=	96	(22.6%)	Europe	 Total	=	186	(43.9%)	North	America	 Total	=	35	(8.3%)	South	America	 Total	=	8	(1.9%)	Years	in	practice		Median	(years	(IQR))	<5	years	6-10	years	11	–	15	years	>15	years	 	Missing	
		12													(IQR	5	–	20.75)	98	 (23.1)	77	 (18.2)	60	 (14.2)	152	 (35.8)	37													(8.7)	 											Number	of	IBD	patients	seen	per	week		2-5	patients	6-10	patients	>10	patients	
		78	 (18.6)	59	 (13.9)	286	 (67.5)	Practice	setting		Public		Private	Mixed	(public	+	private)	 	Missing	
		291	 (68.6)	56	 (13.2)	76													(17.9)	1																(0.2)	
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Table 6.2 First Choices of Treatment Based on Case Scenarios 
 
 
 
  
 Case Scenarios  
First Choice of 
Treatment 
Elderly  
(Case 1) 
Elderly with 
comorbidity (Case 2) 
Young with 
comorbidity (Case 3) 
Overall  p value 
Prescribe 
Immunomodulators 
28.5% (113/396) 10.9%   
(43/394) 
18.7%  
(73/390) 
19.4% P<0.0001 
Increase dose of 
prednisolone and 
continue on that dose 
for maintenance  
3.0% 
(7/397) 
3.0% 
(12/395) 
2.1%  
(8/389) 
2.7% P=0.622 
Prescribe Anti-TNF  23.8% 
(95/400) 
8.8% 
(35/396) 
18.3% 
(72/394) 
17.0% P<0.0001 
Prescribe Vedolizumab  43.9% 
(175/399) 
64.9% 
(259/399) 
50.9% 
(200/393) 
53.2% P<0.0001 
Colectomy  2.8% 
(11/397) 
13.3% 
(53/399) 
11.5% 
(45/393) 
9.2% P<0.0001 
Chapter 6  
Page | 
Immunomodulator and Biological agent Use in Elderly UC  
167 
Table 6.3 Multivariate Logistic Regression Analysis of Variables Associated With the selection of 
treatment options as first line treatment 
  
Covariates Immunomodulators Anti-TNF Vedolizumab Surgery 
OR  (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Scenario 
Scenario 1 
Scenario 2 
Scenario 3 
 
1 
0.25 (0.16-0.38) 
0.56 (0.39-0.82) 
 
 
<0.0001 
0.003 
 
1 
0.28 (0.17-0.46) 
0.70 (0.48-1.04) 
 
 
<0.0001 
0.76 
 
1 
2.71 (1.98-3.71) 
1.37 (1.01-1.86) 
 
 
<0.0001 
0.043 
 
1 
5.40 (2.74-10.64) 
4.46 (2.25-8.87) 
 
 
<0.0001 
<0.0001 
Continent 
Asia 
Oceania 
Europe  
North America 
South America 
 
1 
1.15 (0.73-1.81) 
0.52 (0.34-0.80) 
0.03(0.004-0.022) 
0.25 (0.03-2.02) 
 
 
0.55 
0.003 
0.001 
0.197 
 
1 
0.72 (0.41-1.26) 
1.55 (0.98-2.45) 
0.67 (0.29-1.55) 
3.97 (1.34-11.82) 
 
 
0.249 
0.61 
0.35 
0.013 
 
1 
1.44 (0.099-2.09) 
1.23 (0.89-1.69) 
5.59 (2.96-10.53) 
0.56 (0.20-1.56) 
 
 
0.53 
0.21 
<0.0001 
0.269 
 
1 
0.53 (0.25-1.10) 
1.41 (0.85-2.33) 
0.56 (0.21-1.54) 
0.41 (0.05-3.48) 
 
 
0.088 
0.182 
0.265 
0.413 
Years as 
gastroenterologist  
(in years) 
*  0.98 (0.96-0.99) 0.017 *  *  
Number of IBD 
patients reviewed 
per week 
2-5 
6-10 
>10 
*   
 
 
1 
0.76 (0.42-1.37) 
0.50 (0.31-0.79) 
 
 
 
 
0.36 
0.003 
 
 
 
1 
1.03 (0.66-1.61) 
1.90 (1.35-2.69) 
 
 
 
 
0.88 
<0.0001 
 
* 
 
 
Place of Practice  
Public 
Private 
Mixed 
 
1 
1.69 (1.05-2.73) 
1.25 (0.81-1.04) 
 
 
0.031 
0.312 
*  *   
1 
0.46 (0.20 -1.07) 
0.51 (0.26 -1.01) 
 
 
0.072 
0.054 
Age limit for 
thiopurines  
0.43 (0.28-0.66) <0.0001 *  1.51 (1.15-1.99) 0.003 *  
Age limit for 
vedolizumab 
3.34 (1.70-6.54) <0.0001 *  0.24 (0.12-0.48) <0.0001 2.95 (1.37 - 6.32) 0.006 
Age limit for anti-
TNF 
1.74 (1.04-2.90) 0.034 *  0.72 (0.49-1.04) 0.082 1.66 (0.98 – 2.81) 0.057 
Age limit for 
Steroids 
0.32 (0.13-0.80) 0.014 2.02 (1.05-3.91) 0.036 * * *  
Age limit for 
combination 
therapy 
0.68 (0.45-1.01) 0.056 *  *  *  
* Factors not statistically significant on univariate analysis 
OR – odds ratio, CI – confidence interval, p – p value 
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Table 6.4 Conditions precluding the use of immunomodulators and biological agents in elderly 
patients with IBD 
 
 
 
  
Conditions  Preclude commencing medications  
(% from respondents within the drug) 
 Missing input 
(% of total) 
Immuno-
modulator 
Anti TNF Vedolizumab p value 
History of lymphoma  16 94.0 69.0 30.4 <0.0001 
History of solid organ cancer  5.7 65.1 57.4 20.0 <0.0001 
Melanoma skin cancer  16.3 44.7 61.0 20.6 <0.0001 
Non-melanoma skin cancer  14.3 53.2 29.2 13.6 <0.0001 
Congestive heart failure  16.1 5.3 76.6 12.1 <0.0001 
Demyelination  14.2 7.8 61.8 19.5 <0.0001 
Osteoporosis  16.3 1.5 1.0 0.7 0.627 
Hepatotoxicity 5.8 69.1 22.2 19.1 <0.0001 
Opportunistic infection 16.2 72.6 78.3 57.4 <0.0001 
Drug to drug interaction  14.5 52.3 31.4 38.2 <0.0001 
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Figure 6.1 Flow diagram showing the recruitment of gastroenterologist globally 
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Figure 6.2 Cumulative percentage of gastroenterologists who have age limits for prescribing 
immunomodulators and biological agents. 
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Supplement 6.1: Questionnaire  
Gastroenterologists’ Preference on the Use of Immunomodulators and Biological Therapies in Elderly 
Patients with Ulcerative Colitis 
Physician Demographics 
(a) Current medical position:   
 □ Gastroenterologist     □ Fellow     □ Registrar     □ Resident     □ Other: ______________ 
(b) Country of practice: _________________________________ 
(c) Year Gastroenterology specialist qualification obtained (if applicable): _____________ 
(d) Average number of IBD patients seen per week: 
 □ 0-1 patient    □ 2-5 patients
  
   □ 6-10 patient
  
   □ >10 patients 
(e) Where is your primary place of practice? 
 □ Public hospital     □ Private practice     □ Mixed practice 
SCENARIO 1 
A 76 year old female with extensive ulcerative colitis has been in remission and adherent on 
mesalazine 4g a day. She has, however, required 3 courses of prednisolone in the past 9 months 
for symptomatic flares (abdominal pain, bloody diarrhoea). Colonoscopy showed Mayo 3 pancolitis 
(erosions, superficial ulceration). She has been on steroids for 3 months and has weaned down to 
10mg of prednisolone and continues to experience diarrhoea with urgency. The patient has no 
other comorbidity. How would you treat this patient? (Please place in order 1 to 5 with 1 = most 
preferred option, 5 = least preferred option) 
Prescribe azathioprine or mercaptopurine; but no biological agent  
Increase dose of prednisolone and continue on that dose for maintenance   
Prescribe infliximab, adalimumab or golimumab (with or without an immunomodulator)  
Prescribe vedolizumab (with or without an immunomodulator) 
Recommend colectomy  
SCENARIO 2 
If the same patient also has Type 1 Diabetes Mellitus with diabetic nephropathy (serum creatinine 
135µmol/L) and a history of ductal adenocarcinoma of left breast treated with mastectomy and 
chemo-radiotherapy 2 years ago without recurrence at present. How would you treat this patient? 
(Please place in order 1 to 5 with 1 = most preferred option, 5 = least preferred option)  
Prescribe azathioprine or mercaptopurine; but no biological agent  
Increase dose of prednisolone and continue on that dose for maintenance   
Prescribe infliximab, adalimumab or golimumab (with or without an immunomodulator)  
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Prescribe vedolizumab (with or without an immunomodulator) 
Recommend colectomy  
SCENARIO 3 
The patient is now a 28 year old female with similar presentation as Scenario 2. How would you 
treat this patient? (Please place in order 1 to 5 with 1 = most preferred option, 5 = least preferred 
option)  
Prescribe azathioprine or mercaptopurine; but no biological agent  
Increase dose of prednisolone and continue on that dose for maintenance   
Prescribe infliximab, adalimumab or golimumab (with or without an immunomodulator) Prescribe vedolizumab 
(with or without an immunomodulator) 
Recommend colectomy  
Managing Elderly Patients with IBD 
(a) Which conditions would stop you from commencing a 70 year old patient on azathiopurine, 
mercaptopurine or methotrexate? (Tick all that apply) 
□ Lymphoma 
□ Solid organ cancer 
□ Melanoma skin cancer 
□ Non-melanoma skin cancer 
□ Congestive heart failure 
□ Demyelination  
□ Osteoporosis 
□ Hepatotoxicity/nephrotoxicity 
□ Opportunistic infections  
□ Drug-to-drug interactions 
 
(b) Which conditions would stop you from commencing a 70 year old patient on anti-TNF agent? 
(Tick all that apply) 
□ Lymphoma 
□ Solid organ cancer 
□ Melanoma skin cancer 
□ Non-melanoma skin cancer 
□ Congestive heart failure 
□ Demyelination  
□ Osteoporosis 
□ Hepatotoxicity/nephrotoxicity 
□ Opportunistic infections  
□ Drug-to-drug interactions 
 
(c) Which conditions would stop you from commencing a 70 year old patient on vedolizumab? (Tick 
all that apply) 
□ Lymphoma 
□ Solid organ cancer 
□ Demyelination  
□ Osteoporosis 
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□ Melanoma skin cancer 
□ Non-melanoma skin cancer 
□ Congestive heart failure 
□ Hepatotoxicity/nephrotoxicity 
□ Opportunistic infections  
□ Drug-to-drug interactions 
 
(d) Starting at what patient age would you NOT prescribe the following drugs?   
I never start corticosteroid in a patient of age >__________ / I have no age barrier. 
I never start azathioprine/mercaptopurine in a patient of age >__________ / I have no age barrier. 
I never start methotrexate in a patient of age >__________ / I have no age barrier. 
I never start anti-TNF agent in a patient of age >__________ / I have no age barrier. 
I never start corticosteroid with anti-TNF with azathioprine/mercaptopurine in a patient of age 
>__________ / I have no age barrier. 
I never start vedolizumab in a patient of age >__________ / I have no age barrier. 
<END OF QUESTIONNAIRE> 
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Supplementary table 6.2. Gastroenterologists’ Demographic and Clinical Characteristics 
Gastroenterologists’ Characteristics N = 424 (%) 
Continent Country of residence   
Asia China   
Hong Kong  
India 
Indonesia  
Israel 
Japan  
Korea  
Kuwait  
Malaysia 
Saudi Arabia  
Singapore 
Taiwan  
United Arab Emirates 
Missing 
5 (1.2) 
1 (0.2) 
4 (0.9) 
2 (0.5) 
5 (1.2) 
18 (4.2) 
9 (2.1) 
3 (0.7) 
1 (0.2) 
2 (0.5) 
5 (1.2) 
5 (1.2) 
1 (0.2) 
38  
 
 
 
 
 
Total = 99 (23.3%) 
Oceania Australia 
New Zealand  
93 (21.9) 
3 (0.7) 
Total = 96 (22.6%) 
Europe Austria 
Belgium 
Bulgaria  
Croatia 
Czech Republic 
Denmark 
Finland 
France 
Germany 
Greece 
Hungary 
Ireland  
Italy 
Netherlands 
Poland 
Portugal 
Serbia  
Slovakia  
Spain  
Sweden 
Switzerland  
Missing 
3 (0.7) 
9 (2.1) 
1 (0.2) 
1 (0.2) 
16 (3.8) 
1 (0.2) 
3 (0.7) 
5                  (1.2) 
6 (1.4) 
18               (4.2) 
2 (0.5) 
5 (1.2) 
15 (3.5) 
2 (0.5) 
6 (1.4) 
1 (0.2) 
1 (0.2) 
1                  (0.2) 
14                (3.3) 
11 (2.6) 
4                  (0.9) 
61 
 
 
 
 
 
 
 
 
 
Total = 186 (43.9%) 
North America Canada 
USA 
Missing 
5 (1.2) 
15 (3.5) 
15 
Total = 35 (8.3%) 
South America Brazil  
Colombia  
4 (0.9) 
4 (0.9) 
Total = 8 (1.9%) 
Years in practice 
Median (years (IQR)) 
 
12                (5 – 20.75)           
 
Number of IBD patients seen per week 
2-5 patients 
6-10 patients 
>10 patients 
 
78 (18.6) 
59 (13.9) 
286 (67.5) 
 
Practice setting 
Public  
Private 
Mixed (public + private)  
Missing 
 
291 (68.6) 
56 (13.2) 
76               (17.9) 
1                  (0.2) 
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Supplement table 6.3. Multivariate Logistic Regression Analysis of Variables Associated With the 
selection of corticosteroids as first line treatment 
 
 
 
 
 
  
Covariant considered in univariate 
analysis 
Corticosteroids 
OR (95% CI) p value 
Scenario 
• Scenario 1 
• Scenario 2 
• Scenario 3 
 
* 
 
 
 
Continent 
• Asia 
• Oceania 
• Europe  
• North America 
• South America 
 
Removed from the 
model 
 
0.645 
 
Years as gastroenterologist  
(in years) 
*  
Number of IBD patients reviewed 
per week 
• 2-5 
• 6-10 
• >10 
 
* 
 
Place of Practice  
• Public 
• Private 
• Mixed 
 
Removed from the 
model 
 
0.090 
Age limit for thiopurines  *  
Age limit for vedolizumab 3.66 (1.27 – 10.56) 0.016 
Age limit for anti- TNF *  
Age limit for Steroids 6.61 (2.70- 16.19) <0.0001 
Age limit for combination therapy *  
* Factors not statistically significant on univariate analysis 
OR – odds ratio 
CI – confidence interval 
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7.1 CONCEPTS AND CONTEXT OF THIS THESIS 
 
Over the past two decades, the advent of monoclonal biologic agents has revolutionized IBD 
treatment (115). The list of drugs available is ever growing, providing patients and treating 
physicians more therapeutic options (116). However, a significant proportion of patients do not 
respond to these drugs or lose response over time (117). The long-term adverse events of these 
therapies are not yet accurately known.  
Furthermore, these therapies come at an exceptionally high financial cost. For example, cost of 
treating a patient with azathioprine is a fraction of the cost needed to prescribe biologic 
monotherapy; azathioprine costs between 21 and 25 euros for 3 months therapy while infliximab 
and adalimumab cost between 412 and 570 euros and 427 and 629 euros per patient respectively, 
in the Netherlands(118). Therefore, with increasing incidence and increasing healthcare costs, 
affordability of these drugs is a concern in both the developing and developed world (14).  
Conventional IMs, particularly thiopurines, have been utilized in the treatment of IBD for more 
than 50 years, allowing estimation of its efficacy, safety and impact on hard clinical end points like 
surgery. Long term adverse events related to IM use, especially in the elderly, are well 
documented(106,119). Risk of intestinal surgery has decreased over the past 6 decades, 
associated with an increased earlier use of immunomodulators(120,121). However, most 
population-based studies have failed to demonstrate beneficial effect of immunomodulators in 
reducing surgical risk, due to treatment selection bias in patients with severe phenotypes or due 
to the delay in commencing the treatment(120). Additionally, two recent randomized controlled 
trials also failed to prove a beneficial effect of thiopurines (31,32). However, both these studies 
were poorly designed and were not able to assess the long-term outcomes. Both studies had 
relatively small sample size with limited follow-up and a high proportion of control subjects 
eventually required commencement of thiopurines, which may negate any benefit. In addition, 
they were designed to assess the short term impact of thiopurines, which are recognized to fail, 
be complicated by drug-induced idiosyncratic and dose-related adverse effects or not tolerated in 
up to 40% of patients (33). 
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 These results may have led to questions regarding the utility of conventional IMs in the treatment 
of IBD in the recent years. On the other hand, the use of IMs has been found to positively influence 
the outcome of patients on infliximab and decrease its immunogenicity (85). Whether IMs have 
the same effect on the less immunogenetic biologics like adalimumab is not known.  
Our understanding of thiopurine metabolism has improved over the last decade. By testing for 
TPMT gene mutations, using therapeutic drug monitoring and managing shunting with allopurinol, 
we have been able to optimize therapy and reduce adverse events. Therefore, filling the gaps in 
our knowledge about the efficacy of IMs and the contributing factors affecting their efficacy and 
their prescription will help us develop strong recommendations on the use of IMs, particularly 
thiopurines, in the treatment of IBD.  
The common aim of this doctoral program was to address some of these gaps and help to define 
the role of thiopurines in the modern treatment algorithm of IBD. Individual studies were 
conducted to assess the role of thiopurines in the long-term surgical outcome of CD and UC and 
its role as a concomitant immunomodulator with adalimumab in the treatment of CD.  A further 
study was conducted to assess its utility in elderly IBD  and outcomes related to thiopurine use in 
this increasing patient sub-group. We also assessed the physician’s knowledge, attitude and 
preferences in the use of IMs in elderly.  
 
7.2 SUMMARY OF FINDINGS 
 
Intestinal surgery is considered as a robust hard endpoint when assessing efficacy of drug 
treatments in IBD. It is hard to assess these long tern endpoints using randomised controlled 
studies. Similarly, assessing these endpoints using population-based data is also difficult due to 
inherent issues related to possible treatment selection bias and changes in practice over time.  
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These issues are clearly seen in an earlier study published from Cardiff, which did not account for 
these biases (122). Lakatos et al, reported a similar reduction in surgery associated with early 
introduction of azathioprine that was independent of the decade of diagnosis. We, for the first 
time using real life management protocols, have shown the benefit of early immunomodulator 
strategy in CD, in reducing the risk of major abdominal surgery. To eliminate drug selection bias, 
we used a strict propensity score matching.  
Using similar methodologies to eliminate possible biases, we also demonstrated significant benefit 
of early IMs post initial surgery in CD in preventing further intestinal surgeries. Despite multiple 
clinical trials demonstrating benefits of thiopurines in preventing postoperative recurrence, 
previous population-based studies have failed to demonstrate similar benefits. (23,39,123). Our 
study was the first population-based cohort study to demonstrate the reduced risk of perianal 
surgery, associated with early IM use. 
Thiopurines have been used to treat UC since the 1970’s. Despite a number of meta-analyses 
highlighting the benefits of thiopurines as maintenance of therapy for UC, most studies have failed 
to demonstrate benefits in reducing the risk of colectomy and disease progression(124).  Indirect 
evidence could be obtained from retrospective population-based studies, that have shown 
decreasing colectomy rates, while increasing rates of IM use (30,121). While reporting similar 
findings, we also demonstrated a significant reduction in the rate of colectomy and disease 
progression associated with sustained use of thiopurines within five years of UC diagnosis.  
Benefits of azathioprine and infliximab combination therapy is widely accepted and has been 
studied extensively (125). However, the same is not true regarding the utility of combination 
therapy with adalimumab. After reviewing the existing evidence, we explored the novel theory 
that immunomodulators maintained for 3 months prior to starting adalimumab positively 
influence primary response.  ADAs to adalimumab have been shown to occur as early as 2 weeks 
from starting therapy, and higher proportion of patients with ADAs were found in primary non-
responders (69). The benefits of pre-treatment IMs in reducing ADAs have been previously shown 
in murine models(70). This may be even more relevant given the slow median time to response 
(3.1 months) for thiopurines(19). 
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We demonstrated a significant increase in the primary response and lower rate of subsequent 
failure using this strategy.  Based on our findings, we would recommend that treatment with 
thiopurines should be continued at least into the first 6 months after starting adalimumab to 
reduce the risk of failure. During maintenance, combination therapy was associated with a 
decrease in the proportion of flare semesters.  
We also assessed the relationship between thiopurines stratified according to TGN levels and 
adalimumab efficacy, which has not been previously reported in literature.  Subtherapeutic TGNs 
at induction and during maintenance therapy were associated with worse clinical outcomes and 
increased risk of adalimumab failure compared with patients with therapeutic TGNs.  
Use of immunomodulators has been shown to be consistently low in elderly IBD patients in 
multiple population-based cohort studies (88,95,97,100-102). However, factors associated with 
the lower use of IMs in this age group have not been studied extensively. Particularly, the impact 
of comorbidity and polypharmacy, which are commonly found in this patient group (110), on IM 
use was not known. We, for the first time demonstrated that comorbidity, quantified using 
Charlson Comorbidity Index, to be an independent predictor of IM use, while age at diagnosis was 
not.  We also demonstrated significantly lower immunomodulator use in the elderly compared to 
younger onset patients.  
The rate of surgery was lower in elderly onset CD patients compared to younger onset. This is in 
contrast to a recent meta-analysis, which found elderly patients to have similar risk of surgical 
intervention (OR: 0.70, 95%CI: 0.40-1.22) compared to younger onset patients (113). Elderly onset 
UC patients in our study were more likely to have earlier colectomy, compared to younger onset 
patients, despite having similar risk of surgery at 10 years from diagnosis. Recent population-based 
studies have demonstrated a higher risk of colectomy in elderly UC patients, compared to the 
younger counterparts (97,101). Surgery for UC, however, is curative, and thus physicians and 
patients may prefer a more definite surgical intervention than long-term IM therapy, leading to 
the higher surgical rates in elderly UC patients.  
Early immunomodulator therapy was associated with reduced risk of surgery in both elderly and 
younger onset CD patients, but it was not associated with reduced risk of colectomy in UC patients. 
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Our findings would support the use of early IMs therapy in healthy, elderly onset CD patients with 
minimal comorbidities, but not UC patients. However, further prospective studies would be 
required to confirm the safety and efficacy in elderly CD patients.  
The study on elderly IBD, raised the possible impact of physicians’ decision-making process on the 
use of IMs in elderly IBD and also on the colectomy rate in UC patients. However, the actual impact 
of age and comorbidity on decision making has been poorly studied and demonstrated in prior 
literature. 
In chapter 6, the presence of comorbidity was found to be the single most important factor 
associated with the decision-making process by gastroenterologist, rather than the chronological 
age in our study. Our findings indicate that gastroenterologist  adhere to the recently published  
‘European Crohn’s and Colitis Organization Topical Review on IBD in the Elderly’, which 
recommends that management decisions in elderly to be made based on patients’ frailty rather 
than their chronological or biological ages(86). We also demonstrated that the gut selective anti-
integrin monoclonal antibody Vedolizumab, is the preferred treatment option in the presence of 
comorbidity. However, IMs were still the second preferred treatment option in elderly without 
comorbidity, which could be related to the gastroenterologists understanding of safety and 
efficacy of IMs, availability and regulations on the prescription of biologics.  
Interestingly, we found colectomy being recommended as the second preferred option in elderly 
UC patients with comorbidity. This may be driven by the decision to avoid long term 
immunosuppression, rather than based on the severity of the disease. Number of recent 
population-based studies have shown a higher colectomy rate in elderly UC patients, which has 
been interpreted as been due to severe disease phenotype. Our findings raise questions about 
this interpretation, as it may be simply driven by physicians’ recommendations, as opposed to 
disease severity.  
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7.3 CONCLUSION AND FUTURE DIRECTIONS 
 
Work from this thesis provides significant contribution towards the evidence supporting the use 
of IMs, particularly azathioprine in the treatment of IBD. These findings will strengthen the call for 
its continuing use in the IBD treatment paradigms for number of years to come.  
The benefits shown in reducing surgery across both CD and UC, was one of the major findings of 
this thesis. The reduction in perianal surgery risk in CD and disease progression in UC, will require 
confirmation by future studies as this has not been shown in the literature before.  
Utility of azathioprine with therapeutic drug monitoring for 3 months pre-adalimumab, should be 
recommended as standard of care to improve the primary response to these expensive drugs and 
also to reduce failure. However, the benefit of continuing use needs o to be balanced out based 
on the risks-benefit ratio of long-term combined immunosuppression(126).   
In an era of thiopurine optimization with the use of therapeutic drug monitoring, aimed at 
reducing intolerances, shunting and failure, it would be interesting to assess these outcomes in 
future population-based studies. This may well confirm a permanent place for this old friend in 
the future treatment algorithms for IBD.  
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SUMMARY
Background
Smoking demonstrates divergent effects in Crohn’s disease (CD) and ulcer-
ative colitis (UC). Smoking frequency is greater in CD and deleterious to
its disease course. Conversely, UC is primarily a disease of nonsmokers and
ex-smokers, with reports of disease amelioration in active smoking.
Aim
To determine the prevalence of smoking and its effects on disease progres-
sion and surgery in a well-characterised cohort of inflammatory bowel
diseases (IBD) patients.
Methods
Patients with smoking data of the Sydney IBD Cohort were included.
Demographic, phenotypic, medical, surgical and hospitalisation data were
analysed and reported on the basis of patient smoking status.
Results
1203 IBD patients were identified comprising 626 CD and 557 UC with 6725
and 6672 patient-years of follow-up, respectively. CD patients were more
likely to smoke than UC patients (19.2% vs. 10.2%, P < 0.001). A history of
smoking in CD was associated with an increased proportional surgery rate
(45.8% vs. 37.8%, P = 0.045), requirement for IBD-related hospitalisation
(P = 0.009) and incidence of peripheral arthritis (29.8% vs. 22.0%,
P = 0.027). Current smokers with UC demonstrated reduced corticosteroid
utilisation (24.1% vs. 37.5%, P = 0.045), yet no reduction in the rates of colec-
tomy (3.4% vs. 6.6%, P = 0.34) or hospital admission (P = 0.25) relative to
nonsmokers. Ex-smokers with UC required proportionately greater immuno-
suppressive (36.2% vs. 26.3%, P = 0.041) and corticosteroid (43.7% vs. 34.5%,
P = 0.078) therapies compared with current and never smokers.
Conclusions
This study confirms the detrimental effects of smoking in CD, yet failed to
demonstrate substantial benefit from smoking in UC. These data should
encourage all patients with IBD to quit smoking.
Aliment Pharmacol Ther 2015;42: 61–70
ª 2015 John Wiley & Sons Ltd 61
doi:10.1111/apt.13239
Alimentary Pharmacology and Therapeutics
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Original Article
Thioguanine in inflammatory bowel disease:
Long-term efficacy and safety
Mark G Ward1, Kamal V Patel1, Viraj C Kariyawasam1, Rishi Goel1,
Ben Warner1, Tim R Elliott1, Paul A Blaker1, Peter M Irving1,2,
Anthony M Marinaki3 and Jeremy D Sanderson1,2
Abstract
Background: Thioguanine (TG) is efficacious in inflammatory bowel disease (IBD), but its toxicity, particularly nodular
regenerative hyperplasia (NRH) of the liver, has limited its use. We assessed the long-term clinical outcomes and safety
of TG in patients whom were intolerant or refractory to conventional immunomodulators.
Methods: This is a retrospective, single-centre study of IBD patients treated with TG from 2001–2013. Response was defined
as clinical remission (Harvey–Bradshaw Index< 5 for Crohn’s disease (CD), Simple Clinical Colitis Activity Index< 4 for
ulcerative colitis (UC)) without corticosteroids or, if receiving anti-tumour-necrosis-factor (anti-TNF) therapy, absence of dose
escalation. We recorded TG failure, withdrawal and adverse events. Patients were monitored with biochemistry, liver biopsy
and/or magnetic resonance imaging (MRI).
Results: 54 patients (47 CD and 7 UC) whom received TG (mean dose: 27mg/d (range: 20–40mg/d)) as monotherapy (n¼ 36)
or concomitantly with anti-TNF (n¼ 18) for a median inter-quartile range of 16 (5–37) months (126 patient-years of follow-
up). 32 (59%) patients responded to TG at 6 months and 23 (43%) at 12 months. Pancreatitis did not recur amongst the 19
patients with prior thiopurine-induced pancreatitis. 16 (30%) patients ceased TG due to intolerance or toxicity (four serious);
NRH was not observed. 6-thioguanine nucleotide concentrations did not correlate with efficacy nor with toxicity.
Conclusions: TG was efficacious and well tolerated in one out of two patients who had previously failed conventional
immunomodulators. NRH did not occur.
Keywords
Crohn’s disease, thioguanine, thiopurine, toxicity, ulcerative colitis
Received: 25 February 2016; accepted: 17 July 2016
Introduction
Immunomodulation remains the first-line therapy in
inflammatory bowel disease (IBD). The conventional
thiopurines, azathioprine (AZA) and 6-mercaptopur-
ine (MP), are efficacious in maintaining steroid-
free remission in IBD.1 A substantial proportion of
patients with Crohn’s disease (CD) require treatment
with a thiopurine; however, approximately 20–30%
of these patients discontinue due to intolerance.2 A
further 30–40% withdraw treatment due to non-
response, in part because an effective therapeutic
dose measured by 6-thioguanine nucleotides (TGNs)
cannot be achieved.3 Pharmacogenetic differences in
thiopurine metabolism contribute to intolerance and
non-response.4
After ingestion, AZA is converted to MP,
which then undergoes metabolism via the purine sal-
vage pathway, to pharmacologically-active TGN.
Concurrently, competitive metabolism by reduction to
thiouric acid (via xanthine oxidase) and methylation to
1Department of Gastroenterology, Guy’s and St. Thomas’ Hospital, NHS
Foundation Trust, London, UK
2Diabetes and Nutritional Sciences Division, School of Medicine, King’s
College London, London, UK
3Purine Research Laboratory, Viapath, Guy’s and St. Thomas’ Hospital,
London, UK
Corresponding author:
JD Sanderson, Department of Gastroenterology, 1st Floor, College House,
North Wing, Saint Thomas’ Hospital, Westminster Bridge Road, London SE1
7EH, UK.
Email: jeremy.sanderson@kcl.ac.uk
United European Gastroenterology Journal
2017, Vol. 5(4) 563–570
! Author(s) 2016
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BACKGROUND: Most patients with Crohn’s disease still 
require surgery despite significant advances in medical 
therapy, surveillance, and management strategies.
OBJECTIVE: The purpose of this study was to assess 
surgical strategies and outcomes in Crohn’s disease, 
including surgical recurrence and emergency surgery.
DESIGN: This was a multicenter, retrospective review of a 
prospectively collected database.
SETTINGS: A specialist-referred cohort of patients with 
Crohn’s disease between 1970 and 2009 was studied.
PATIENTS: Included were 972 patients with Crohn’s 
disease who were referred to the Sydney Inflammatory 
Bowel Disease cohort database.
MAIN OUTCOME MEASURES: Main outcomes of interest 
were the rates of major abdominal and perianal surgery 
between decades (1970–1979, 1980–1989, 1990-1999, and 
2000-2009), indications for surgery, types of procedure 
performed, rate of elective and emergency surgery, risk of 
surgical recurrence, and predictive factors for surgery.
RESULTS: Between 1970 and 2009, the overall risks of 
surgery within 5, 10, and 15 years of diagnosis were 31.7%, 
43.3%, and 48.4%. The median time to first surgery from 
time of diagnosis was 2 years (range, 0–31 years). A total of 
6.7% of patients required emergency surgery within 5 years 
of diagnosis. In total, 8.8% of patients required emergency 
surgery within 15 years. The overall risk of surgical 
recurrence was 35.9%. The risk of major abdominal 
surgery significantly decreased between 2000 and 2009 
when compared with the 1970 to 1979 period (OR = 0.49 
(95% CI, 0.34–0.70). However, the rate of perianal surgery 
significantly increased (OR = 5.76 (95% CI, 2.54–13.06)). 
The main indications for surgery were enteric stricture or 
obstruction, perianal disease, and intra-abdominal fistulas/
abscess. Of the 972 patients over 4 decades, only 11 patients 
(1.1%) were diagnosed with colorectal cancer.
LIMITATIONS: This was a specialist-referred cohort, not a 
population-based study.
CONCLUSIONS: The rate of major abdominal surgery 
has decreased, with surgery reserved for more severe and 
complicated disease. The natural history of patients with 
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